<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LEVAQUIN - levofloxacin tablet, film coated </strong><br>RedPharm Drug Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use LEVAQUIN<span class="Sup">®</span> safely and effectively. See full prescribing information for LEVAQUIN.<br><br> LEVAQUIN<span class="Sup">®</span> (levofloxacin) Tablet, Film Coated for Oral use<br> LEVAQUIN<span class="Sup">®</span> (levofloxacin) Solution for Oral use<br> LEVAQUIN<span class="Sup">®</span> (levofloxacin) Injection, Solution, Concentrate for Intravenous use<br> LEVAQUIN<span class="Sup">®</span> (levofloxacin) Injection, Solution for Intravenous use<br> Initial U.S. Approval: 1996</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING:</span></h1>
<h1 class="Warning"> </h1>
<p class="Highlighta"><span class="Bold">Fluoroquinolones, including LEVAQUIN<span class="Sup">®</span>, are associated with an increased risk of <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span> and <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> in all ages. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants<span class="Italics"> [See<a href="#S5.1"> Warnings and Precautions (5.1)</a>]</span>.</span> </p>
<p class="Highlighta"><span class="Bold">Fluoroquinolones, including LEVAQUIN<span class="Sup">®</span>, may exacerbate <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> in persons with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. Avoid LEVAQUIN<span class="Sup">®</span> in patients with a known history of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> </span><span class="Bold Italics">[See </span><span class="Italics"><a href="#S5.2">Warnings and Precautions (5.2)</a></span><span class="Bold Italics">]</span><span class="Bold">.</span> </p>
</div></div>
<div><div><p class="Highlighta">To reduce the development of drug-resistant bacteria and maintain the effectiveness of LEVAQUIN<span class="Sup">®</span> and other antibacterial drugs, LEVAQUIN<span class="Sup">®</span> should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.  (<a href="#section-1">1</a>)</p></div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">Warnings and Precautions </p>
<ul class="Disc"><li>Exacerbation of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> (<a href="#S5.2">5.2</a>)                                                                        01/2011</li></ul>
</div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING:</span></h1>
<h1 class="Warning"> </h1>
<p class="Highlighta"><span class="Bold">Fluoroquinolones, including LEVAQUIN<span class="Sup">®</span>, are associated with an increased risk of <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span> and <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> in all ages. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants<span class="Italics"> [See<a href="#S5.1"> Warnings and Precautions (5.1)</a>]</span>.</span> </p>
<p class="Highlighta"><span class="Bold">Fluoroquinolones, including LEVAQUIN<span class="Sup">®</span>, may exacerbate <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> in persons with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. Avoid LEVAQUIN<span class="Sup">®</span> in patients with a known history of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> </span><span class="Bold Italics">[See </span><span class="Italics"><a href="#S5.2">Warnings and Precautions (5.2)</a></span><span class="Bold Italics">]</span><span class="Bold">.</span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">LEVAQUIN<span class="Sup">®</span> is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by designated, susceptible bacteria (<a href="#S1">1</a>,<a href="#S12.4"> 12.4</a>). </p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span>: nosocomial (<a href="#S1.1">1.1</a>) and community acquired (<a href="#S1.2">1.2</a>,<a href="#S1.3"> 1.3</a>)</li>
<li>Acute bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span> (<a href="#S1.4">1.4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="257905" conceptname="Mucopurulent chronic bronchitis">Acute bacterial exacerbation of chronic bronchitis</span> (<a href="#S1.5">1.5</a>)</li>
<li>Skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>: complicated (<a href="#S1.6">1.6</a>) and uncomplicated (<a href="#S1.7">1.7</a>)</li>
<li>Chronic bacterial <span class="product-label-link" type="condition" conceptid="194997" conceptname="Prostatitis">prostatitis</span> (<a href="#S1.8">1.8</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infections</span>: complicated (<a href="#S1.9">1.9</a>,<a href="#S1.10"> 1.10</a>) and uncomplicated (<a href="#S1.12">1.12</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4139915" conceptname="Acute pyelitis">Acute pyelonephritis</span> (<a href="#S1.11">1.11</a>)</li>
<li>Inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span>, post-exposure (<a href="#S1.13">1.13</a>). Not tested in humans for post-exposure prevention of inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span>; plasma concentrations are likely to predict efficacy (<a href="#S14.9">14.9</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<ul class="Disc"><li>Dosage in patients with normal renal function (<a href="#S2.1">2.1</a>)</li></ul>
<a name="ibfba0c86-961e-4c0f-8839-bd225fb907a5"></a><table>
<col align="left" valign="middle" width="50%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<thead><tr class="First Last">
<th class="Lrule" align="left" valign="top">Type of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></th>
<th class="Lrule" align="center" valign="top">Dose  Every 24 hours</th>
<th class="Lrule Rrule" align="center" valign="top">Duration (days)</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Nosocomial Pneumonia</span> (<a href="#S1.1">1.1</a>)</td>
<td class="Lrule" align="center">750 mg</td>
<td class="Lrule Rrule" align="center">7–14</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Community Acquired Pneumonia</span> (<a href="#S1.2">1.2</a>)</td>
<td class="Lrule Toprule" align="center">500 mg</td>
<td class="Lrule Rrule Toprule" align="center">7–14</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Community Acquired Pneumonia</span> (<a href="#S1.3">1.3</a>)</td>
<td class="Lrule Toprule" align="center">750 mg</td>
<td class="Lrule Rrule Toprule" align="center">5</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left">Acute Bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span> (<a href="#S1.4">1.4</a>)</td>
<td class="Lrule Toprule" align="center">750 mg</td>
<td class="Lrule Rrule Toprule" align="center">5</td>
</tr>
<tr>
<td class="Lrule" align="left"></td>
<td class="Lrule Toprule" align="center">500 mg</td>
<td class="Lrule Rrule Toprule" align="center">10–14</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="257905" conceptname="Mucopurulent chronic bronchitis">Acute Bacterial Exacerbation of Chronic Bronchitis</span> (<a href="#S1.5">1.5</a>)</td>
<td class="Lrule Toprule" align="center">500 mg</td>
<td class="Lrule Rrule Toprule" align="center">7</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left">Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> (SSSI) (<a href="#S1.6">1.6</a>)</td>
<td class="Lrule Toprule" align="center">750 mg</td>
<td class="Lrule Rrule Toprule" align="center">7–14</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left">Uncomplicated SSSI (<a href="#S1.7">1.7</a>)</td>
<td class="Lrule Toprule" align="center">500 mg</td>
<td class="Lrule Rrule Toprule" align="center">7–10</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left">Chronic Bacterial <span class="product-label-link" type="condition" conceptid="194997" conceptname="Prostatitis">Prostatitis</span> (<a href="#S1.8">1.8</a>)</td>
<td class="Lrule Toprule" align="center">500 mg</td>
<td class="Lrule Rrule Toprule" align="center">28</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left">Complicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span> (<a href="#S1.9">1.9</a>) or <span class="product-label-link" type="condition" conceptid="4139915" conceptname="Acute pyelitis">Acute Pyelonephritis</span> (<a href="#S1.11">1.11</a>)</td>
<td class="Lrule Toprule" align="center">750 mg</td>
<td class="Lrule Rrule Toprule" align="center">5</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left">Complicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span> (<a href="#S1.10">1.10</a>) or <span class="product-label-link" type="condition" conceptid="4139915" conceptname="Acute pyelitis">Acute Pyelonephritis</span> (<a href="#S1.11">1.11</a>)</td>
<td class="Lrule Toprule" align="center">250 mg</td>
<td class="Lrule Rrule Toprule" align="center">10</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left">Uncomplicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span> (<a href="#S1.12">1.12</a>)</td>
<td class="Lrule Toprule" align="center">250 mg</td>
<td class="Lrule Rrule Toprule" align="center">3</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left">Inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">Anthrax</span> (Post-Exposure) (<a href="#S1.13">1.13</a>)</td>
<td class="Lrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">Adults and Pediatric Patients &gt; 50 kg and ≥ 6 months of age</td>
<td class="Lrule" align="center">500 mg</td>
<td class="Lrule Rrule" align="center">60</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">Pediatric Patients &lt; 50 kg and ≥ 6 months of age</td>
<td class="Lrule" align="center">8 mg/kg BID (not to exceed 250 mg/dose)</td>
<td class="Lrule Rrule" align="center">60</td>
</tr>
</tbody>
</table>
<ul class="Disc">
<li>Adjust dose for creatinine clearance &lt; 50 mL/min (<a href="#S2.3">2.3</a>,<a href="#S8.6"> 8.6</a>,<a href="#S12.3"> 12.3</a>)</li>
<li>IV Injection, Single-Use or Premix: Slow IV infusion only, over 60 or 90 minutes depending on dose. Avoid rapid or bolus IV (<a href="#S2.5">2.5</a>)</li>
<li>Dilute single-use vials to 5 mg/mL prior to IV infusion (<a href="#S2.6">2.6</a>)</li>
<li>Do not mix with other medications in vial or IV line (<a href="#S2.6">2.6</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<a name="ic26f8dd6-5347-4543-8744-6c57ac091306"></a><table width="75%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<thead><tr class="First Last">
<th class="Lrule" align="left">Formulation (<a href="#S3">3</a>)</th>
<th class="Lrule Rrule" align="left">Strength</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Tablets</td>
<td class="Rrule" align="left">250 mg, 500 mg, and 750 mg</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Oral Solution</td>
<td class="Rrule" align="left">25 mg/mL</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Injection: single-use vials for dilution</td>
<td class="Rrule" align="left">500 mg in 20 mL<br>750 mg in 30 mL</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Injection: premix single-use flexible containers</td>
<td class="Rrule" align="left">250 mg in 50 mL<br>500 mg in 100 mL<br>750 mg in 150 mL</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to LEVAQUIN<span class="Sup">®</span> or other quinolones (<a href="#S4">4</a>,<a href="#S5.3"> 5.3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Risk of <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span> and <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> is increased. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroids, and in patients with kidney, heart or lung transplants. Discontinue if <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> in a tendon occurs (<a href="#S5.1">5.1</a>,<a href="#S8.5"> 8.5</a>)</li>
<li>May exacerbate <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> in persons with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. Avoid use in patients with a known history of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> (<a href="#S5.2">5.2</a>).</li>
<li><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span> and <span class="product-label-link" type="condition" conceptid="4070025" conceptname="Cutaneous hypersensitivity">allergic skin reactions</span>, serious, occasionally fatal, may occur after first dose (<a href="#S4">4</a>,<a href="#S5.3">5.3</a>)</li>
<li>Hematologic (including <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>), and renal toxicities may occur after multiple doses (<a href="#S5.4">5.4</a>)</li>
<li>Hepatotoxicity: Severe, and sometimes fatal, hepatoxicity has been reported. Discontinue immediately if signs and symptoms of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> occur (<a href="#S5.5">5.5</a>)</li>
<li>Central nervous system effects, including <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> may occur after the first dose. Use with caution in patients with known or suspected disorders that may predispose them to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold (<a href="#S5.6">5.6</a>)</li>
<li>
<span class="Italics">Clostridium difficile</span>-associated <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>: evaluate if <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurs (<a href="#S5.7">5.7</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span>: discontinue if symptoms occur in order to prevent irreversibility (<a href="#S5.8">5.8</a>)</li>
<li>Prolongation of the QT interval and isolated cases of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span> have been reported. Avoid use in patients with known prolongation, those with <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, and with other drugs that prolong the QT interval (<a href="#S5.9">5.9</a>,<a href="#S8.5"> 8.5</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common reactions (≥3%) were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (<a href="#S6.2">6.2</a>).  </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Ortho-McNeil-Janssen Scientific Affairs Customer Communications Center at 1-800-526-7736 or FDA at 1-800-FDA-1088 or </span><span class="Italics Underline">www.fda.gov/medwatch</span><span class="Bold">.</span> </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<a name="i5d95d771-6b00-4f01-8e9e-74cb90bfe3ca"></a><table width="75%">
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="75%">
<thead><tr class="First Last">
<th class="Lrule" align="left">Interacting Drug</th>
<th class="Lrule Rrule" align="left">Interaction</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Multivalent cation-containing products including antacids, metal cations or didanosine</td>
<td class="Rrule" align="left">Absorption of levofloxacin is decreased when the tablet or oral solution formulation is taken within 2 hours of these products. Do not co-administer the intravenous formulation in the same IV line with a multivalent cation, e.g., magnesium (<a href="#S2.4">2.4</a>, <a href="#S7.1">7.1</a>)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Warfarin</td>
<td class="Rrule" align="left">Effect may be enhanced. Monitor <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, INR, watch for <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (<a href="#S7.2">7.2</a>)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Antidiabetic agents</td>
<td class="Rrule" align="left">Carefully monitor blood glucose (<a href="#S5.11">5.11</a>, <a href="#S7.3">7.3</a>)</td>
</tr>
</tbody>
</table>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>
<span class="Bold">Geriatrics: </span>Severe hepatotoxicity has been reported. The majority of reports describe patients 65 years of age or older (<a href="#S5.5">5.5</a>,<a href="#S8.5"> 8.5</a>,<a href="#S17"> 17</a>). May have increased risk of tendinopathy (including rupture), especially with concomitant corticosteroid use (<a href="#S5.1">5.1</a>,<a href="#S8.5"> 8.5</a>,<a href="#S17"> 17</a>). May be more susceptible to prolongation of the QT interval. (<a href="#S5.9">5.9</a>,<a href="#S8.5"> 8.5</a>,<a href="#S17"> 17</a>). </li>
<li>
<span class="Bold">Pediatrics: </span><span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">Musculoskeletal disorders</span> (<span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, tendinopathy, and gait abnormality) seen in more LEVAQUIN<span class="Sup">®</span>-treated patients than in comparator. Shown to cause <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> and <span class="product-label-link" type="condition" conceptid="433565" conceptname="Juvenile osteochondrosis of spine">osteochondrosis</span> in juvenile animals (<a href="#S5.10">5.10</a>,<a href="#S8.4"> 8.4</a>,<a href="#S13.2"> 13.2</a>). Safety in pediatric patients treated for more than 14 days has not been studied. Risk-benefit appropriate only for the treatment of inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> (post-exposure) (<a href="#S1.13">1.13</a>,<a href="#S2.2"> 2.2</a>,<a href="#S8.4"> 8.4</a>,<a href="#S14.9"> 14.9</a>)</li>
</ul></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div><div>
<div></div>
<div></div>
<div></div>
</div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 6/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Emphasis">WARNING:</span></a></h1>
<h1><a href="#section-2" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-2.2" class="toc">1.1 <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Nosocomial Pneumonia</span></a></h2>
<h2><a href="#section-2.3" class="toc">1.2 Community-Acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span>: 7–14 day Treatment Regimen</a></h2>
<h2><a href="#section-2.4" class="toc">1.3 Community-Acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span>: 5-day Treatment Regimen</a></h2>
<h2><a href="#section-2.5" class="toc">1.4 Acute Bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span>: 5-day and 10–14 day Treatment Regimens</a></h2>
<h2><a href="#section-2.6" class="toc">1.5 <span class="product-label-link" type="condition" conceptid="257905" conceptname="Mucopurulent chronic bronchitis">Acute Bacterial Exacerbation of Chronic Bronchitis</span></a></h2>
<h2><a href="#section-2.7" class="toc">1.6 Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></h2>
<h2><a href="#section-2.8" class="toc">1.7 Uncomplicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></h2>
<h2><a href="#section-2.9" class="toc">1.8 Chronic Bacterial <span class="product-label-link" type="condition" conceptid="194997" conceptname="Prostatitis">Prostatitis</span></a></h2>
<h2><a href="#section-2.10" class="toc">1.9 Complicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span>: 5-day Treatment Regimen</a></h2>
<h2><a href="#section-2.11" class="toc">1.10 Complicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span>: 10-day Treatment Regimen</a></h2>
<h2><a href="#section-2.12" class="toc">1.11 <span class="product-label-link" type="condition" conceptid="4139915" conceptname="Acute pyelitis">Acute Pyelonephritis</span>: 5 or 10-day Treatment Regimen</a></h2>
<h2><a href="#section-2.13" class="toc">1.12 Uncomplicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span></a></h2>
<h2><a href="#section-2.14" class="toc">1.13 Inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">Anthrax</span> (Post-Exposure)</a></h2>
<h1><a href="#section-3" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-3.1" class="toc">2.1 Dosage in Adult Patients with Normal Renal Function</a></h2>
<h2><a href="#section-3.2" class="toc">2.2 Dosage in Pediatric Patients</a></h2>
<h2><a href="#section-3.3" class="toc">2.3 Dosage Adjustment in Adults with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-3.4" class="toc">2.4 Drug Interaction With Chelation Agents: Antacids, Sucralfate, Metal Cations, Multivitamins</a></h2>
<h2><a href="#section-3.5" class="toc">2.5 Administration Instructions</a></h2>
<h2><a href="#section-3.6" class="toc">2.6 Preparation of Intravenous Product</a></h2>
<h1><a href="#section-4" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-5" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-6" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">5.1 Tendinopathy and <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">Tendon Rupture</span></a></h2>
<h2><a href="#section-6.2" class="toc">5.2 Exacerbation of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">Myasthenia Gravis</span></a></h2>
<h2><a href="#section-6.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h2><a href="#section-6.4" class="toc">5.4 Other Serious and Sometimes Fatal Reactions</a></h2>
<h2><a href="#section-6.5" class="toc">5.5 Hepatotoxicity</a></h2>
<h2><a href="#section-6.6" class="toc">5.6 Central Nervous System Effects</a></h2>
<h2><a href="#section-6.7" class="toc">5.7<span class="Italics"> Clostridium difficile</span>-Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></a></h2>
<h2><a href="#section-6.8" class="toc">5.8 <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral Neuropathy</span></a></h2>
<h2><a href="#section-6.9" class="toc">5.9 Prolongation of the QT Interval</a></h2>
<h2><a href="#section-6.10" class="toc">5.10 <span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">Musculoskeletal Disorders</span> in Pediatric Patients and Arthropathic Effects in Animals</a></h2>
<h2><a href="#section-6.11" class="toc">5.11 Blood Glucose Disturbances</a></h2>
<h2><a href="#section-6.12" class="toc">5.12 <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span>/<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Phototoxicity</span></a></h2>
<h2><a href="#section-6.13" class="toc">5.13 Development of Drug Resistant Bacteria</a></h2>
<h1><a href="#section-7" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">6.1 Serious and Otherwise Important Adverse Reactions</a></h2>
<h2><a href="#section-7.2" class="toc">6.2 Clinical Trial Experience</a></h2>
<h2><a href="#section-7.3" class="toc">6.3 Postmarketing Experience</a></h2>
<h1><a href="#section-8" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-8.1" class="toc">7.1 Chelation Agents: Antacids, Sucralfate, Metal Cations, Multivitamins</a></h2>
<h2><a href="#section-8.2" class="toc">7.2 Warfarin</a></h2>
<h2><a href="#section-8.3" class="toc">7.3 Antidiabetic Agents</a></h2>
<h2><a href="#section-8.4" class="toc">7.4 Non-Steroidal Anti-Inflammatory Drugs</a></h2>
<h2><a href="#section-8.5" class="toc">7.5 Theophylline</a></h2>
<h2><a href="#section-8.6" class="toc">7.6 Cyclosporine</a></h2>
<h2><a href="#section-8.7" class="toc">7.7 Digoxin</a></h2>
<h2><a href="#section-8.8" class="toc">7.8 Probenecid and Cimetidine</a></h2>
<h2><a href="#section-8.9" class="toc">7.9 Interactions with Laboratory or Diagnostic Testing</a></h2>
<h1><a href="#section-9" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-9.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-9.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-9.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-9.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-9.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-9.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-12.3" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-13.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-14.1" class="toc">14.1 <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Nosocomial Pneumonia</span></a></h2>
<h2><a href="#section-14.2" class="toc">14.2 Community-Acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span>: 7–14 day Treatment Regimen</a></h2>
<h2><a href="#section-14.3" class="toc">14.3 Community-Acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span>: 5-Day Treatment Regimen</a></h2>
<h2><a href="#section-14.4" class="toc">14.4 Acute Bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span>: 5-day and 10–14 day Treatment Regimens</a></h2>
<h2><a href="#section-14.5" class="toc">14.5 Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></h2>
<h2><a href="#section-14.6" class="toc">14.6 Chronic Bacterial <span class="product-label-link" type="condition" conceptid="194997" conceptname="Prostatitis">Prostatitis</span></a></h2>
<h2><a href="#section-14.7" class="toc">14.7 Complicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span> and <span class="product-label-link" type="condition" conceptid="4139915" conceptname="Acute pyelitis">Acute Pyelonephritis</span>: 5-day Treatment Regimen</a></h2>
<h2><a href="#section-14.8" class="toc">14.8 Complicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span> and <span class="product-label-link" type="condition" conceptid="4139915" conceptname="Acute pyelitis">Acute Pyelonephritis</span>: 10-day Treatment Regimen</a></h2>
<h2><a href="#section-14.9" class="toc">14.9 Inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">Anthrax</span> (Post-Exposure)</a></h2>
<h1><a href="#section-15" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-16" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-16.1" class="toc">16.1 LEVAQUIN<span class="Sup">®</span> Tablets</a></h2>
<h2><a href="#section-16.2" class="toc">16.2 LEVAQUIN® Oral Solution</a></h2>
<h2><a href="#section-16.3" class="toc">16.3 LEVAQUIN® Injection, Single-Use Vials</a></h2>
<h2><a href="#section-16.4" class="toc">16.4 LEVAQUIN® Injection Pre-Mixed Solution, Single-Use in Flexible Container</a></h2>
<h1><a href="#section-17" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-17.1" class="toc">17.1 Antibacterial Resistance</a></h2>
<h2><a href="#section-17.2" class="toc">17.2 Administration with Food, Fluids, and Concomitant Medications</a></h2>
<h2><a href="#section-17.3" class="toc">17.3 Serious and Potentially Serious Adverse Reactions</a></h2>
<h2><a href="#section-17.4" class="toc">17.4 Drug Interactions with Insulin, Oral Hypoglycemic Agents, and Warfarin</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<h1><span class="Emphasis">WARNING:</span></h1>
<p class="First"><span class="Bold">Fluoroquinolones, including LEVAQUIN<span class="Sup">®</span>, are associated with an increased risk of <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span> and <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> in all ages. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants<span class="Italics"> [See<a href="#S5.1"> Warnings and Precautions (5.1)</a>]</span>.</span></p>
<p style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="XmChange"><span class="Bold">Fluoroquinolones, including LEVAQUIN<span class="Sup">®</span>, may exacerbate <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> in persons with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. Avoid LEVAQUIN<span class="Sup">®</span> in patients with a known history of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> </span><span class="Italics"><span class="Bold">[See </span><a href="#S5.2">Warnings and Precautions (5.2)</a></span><span class="Bold"><span class="Italics">]</span>.</span></span></p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-2"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of LEVAQUIN<span class="Sup">®</span> and other antibacterial drugs, LEVAQUIN<span class="Sup">®</span> should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
<p>LEVAQUIN<span class="Sup">®</span> Tablets/Injection and Oral Solution are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated microorganisms in the conditions listed in this section. LEVAQUIN<span class="Sup">®</span> Injection is indicated when intravenous administration offers a route of administration advantageous to the patient (e.g., patient cannot tolerate an oral dosage form).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1"></a><p></p>
<p class="First"><span class="Bold">Culture and susceptibility testing</span></p>
<p>Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and to determine their susceptibility to levofloxacin<span class="Italics"> [see<a href="#S12.4"> Clinical Pharmacology (12.4)</a>]</span>. Therapy with LEVAQUIN<span class="Sup">®</span> may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected.</p>
<p>As with other drugs in this class, some <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of<span class="Italics"> Pseudomonas aeruginosa </span>may develop resistance fairly rapidly during treatment with LEVAQUIN<span class="Sup">®</span>. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of <span class="product-label-link" type="condition" conceptid="4207042" conceptname="Viral resistance">bacterial resistance</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.1"></a><a name="section-2.2"></a><p></p>
<h2>1.1 <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Nosocomial Pneumonia</span></h2>
<p class="First">LEVAQUIN<span class="Sup">®</span> is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">nosocomial pneumonia</span> due to methicillin-susceptible<span class="Italics"> Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, </span>or<span class="Italics"> Streptococcus pneumoniae</span>. Adjunctive therapy should be used as clinically indicated. Where<span class="Italics"> Pseudomonas aeruginosa </span>is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended<span class="Italics"> [see<a href="#S14.1"> Clinical Studies (14.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.2"></a><a name="section-2.3"></a><p></p>
<h2>1.2 Community-Acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span>: 7–14 day Treatment Regimen</h2>
<p class="First">LEVAQUIN<span class="Sup">®</span> is indicated for the treatment of community-acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> due to methicillin-susceptible<span class="Italics"> Staphylococcus aureus, Streptococcus pneumoniae </span>(including multi-drug-resistant<span class="Italics"> Streptococcus pneumoniae </span>[MDRSP]),<span class="Italics"> Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, </span>or<span class="Italics"> Mycoplasma pneumoniae [see<a href="#S2.1"> Dosage and Administration (2.1) </a>and<a href="#S14.2"> Clinical Studies (14.2)</a>]</span>.</p>
<p>MDRSP isolates are <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2<span class="Sup">nd</span> generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.3"></a><a name="section-2.4"></a><p></p>
<h2>1.3 Community-Acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span>: 5-day Treatment Regimen</h2>
<p class="First">LEVAQUIN<span class="Sup">®</span> is indicated for the treatment of community-acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> due to<span class="Italics"> Streptococcus pneumoniae </span>(excluding multi-drug-resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> [MDRSP]),<span class="Italics"> Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, </span>or<span class="Italics"> Chlamydophila pneumoniae [see<a href="#S2.1"> Dosage and Administration (2.1) </a>and<a href="#S14.3"> Clinical Studies (14.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.4"></a><a name="section-2.5"></a><p></p>
<h2>1.4 Acute Bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span>: 5-day and 10–14 day Treatment Regimens</h2>
<p class="First">LEVAQUIN<span class="Sup">®</span> is indicated for the treatment of acute bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span> due to<span class="Italics"> Streptococcus pneumoniae</span>,<span class="Italics"> Haemophilus influenzae, </span>or<span class="Italics"> Moraxella catarrhalis [see<a href="#S14.4"> Clinical Studies (14.4)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.5"></a><a name="section-2.6"></a><p></p>
<h2>1.5 <span class="product-label-link" type="condition" conceptid="257905" conceptname="Mucopurulent chronic bronchitis">Acute Bacterial Exacerbation of Chronic Bronchitis</span></h2>
<p class="First">LEVAQUIN<span class="Sup">®</span> is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="257905" conceptname="Mucopurulent chronic bronchitis">acute bacterial exacerbation of chronic bronchitis</span> due to methicillin-susceptible<span class="Italics"> Staphylococcus aureus</span>,<span class="Italics"> Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, </span>or<span class="Italics"> Moraxella catarrhalis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.6"></a><a name="section-2.7"></a><p></p>
<h2>1.6 Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">LEVAQUIN<span class="Sup">®</span> is indicated for the treatment of complicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to methicillin-susceptible<span class="Italics"> Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, </span>or<span class="Italics"> Proteus mirabilis [see<a href="#S14.5"> Clinical Studies (14.5)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.7"></a><a name="section-2.8"></a><p></p>
<h2>1.7 Uncomplicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">LEVAQUIN<span class="Sup">®</span> is indicated for the treatment of uncomplicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (mild to moderate) including <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscesses</span>, <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>, <span class="product-label-link" type="condition" conceptid="4220002" conceptname="Furuncle">furuncles</span>, <span class="product-label-link" type="condition" conceptid="140480" conceptname="Impetigo">impetigo</span>, <span class="product-label-link" type="condition" conceptid="133547" conceptname="Pyoderma">pyoderma</span>, <span class="product-label-link" type="condition" conceptid="4153877" conceptname="Post-traumatic wound infection">wound infections</span>, due to methicillin-susceptible<span class="Italics"> Staphylococcus aureus</span>, or<span class="Italics"> Streptococcus pyogenes</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.8"></a><a name="section-2.9"></a><p></p>
<h2>1.8 Chronic Bacterial <span class="product-label-link" type="condition" conceptid="194997" conceptname="Prostatitis">Prostatitis</span></h2>
<p class="First">LEVAQUIN<span class="Sup">®</span> is indicated for the treatment of chronic bacterial <span class="product-label-link" type="condition" conceptid="194997" conceptname="Prostatitis">prostatitis</span> due to<span class="Italics"> Escherichia coli, Enterococcus faecalis, </span>or methicillin-susceptible<span class="Italics"> Staphylococcus epidermidis [see<a href="#S14.6"> Clinical Studies (14.6)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.9"></a><a name="section-2.10"></a><p></p>
<h2>1.9 Complicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span>: 5-day Treatment Regimen</h2>
<p class="First">LEVAQUIN<span class="Sup">®</span> is indicated for the treatment of complicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> due to<span class="Italics"> Escherichia coli, Klebsiella pneumoniae, </span>or<span class="Italics"> Proteus mirabilis [see<a href="#S14.7"> Clinical Studies (14.7)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.10"></a><a name="section-2.11"></a><p></p>
<h2>1.10 Complicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span>: 10-day Treatment Regimen</h2>
<p class="First">LEVAQUIN<span class="Sup">®</span> is indicated for the treatment of complicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> (mild to moderate) due to<span class="Italics"> Enterococcus faecalis</span>,<span class="Italics"> Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, </span>or<span class="Italics"> Pseudomonas aeruginosa [see<a href="#S14.8"> Clinical Studies (14.8)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.11"></a><a name="section-2.12"></a><p></p>
<h2>1.11 <span class="product-label-link" type="condition" conceptid="4139915" conceptname="Acute pyelitis">Acute Pyelonephritis</span>: 5 or 10-day Treatment Regimen</h2>
<p class="First">LEVAQUIN<span class="Sup">®</span> is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4139915" conceptname="Acute pyelitis">acute pyelonephritis</span> caused by<span class="Italics"> Escherichia coli</span>, including cases with concurrent <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span><span class="Italics"> [see <a href="#S14.7">Clinical Studies (14.7</a>,<a href="#S14.8"> 14.8)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.12"></a><a name="section-2.13"></a><p></p>
<h2>1.12 Uncomplicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span></h2>
<p class="First">LEVAQUIN<span class="Sup">®</span> is indicated for the treatment of uncomplicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> (mild to moderate) due to<span class="Italics"> Escherichia coli, Klebsiella pneumoniae, </span>or<span class="Italics"> Staphylococcus saprophyticus</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.13"></a><a name="section-2.14"></a><p></p>
<h2>1.13 Inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">Anthrax</span> (Post-Exposure)</h2>
<p class="First">LEVAQUIN<span class="Sup">®</span> is indicated for inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized<span class="Italics"> Bacillus anthracis. </span>The effectiveness of LEVAQUIN<span class="Sup">®</span> is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. LEVAQUIN<span class="Sup">®</span> has not been tested in humans for the post-exposure prevention of inhalation <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span>. The safety of LEVAQUIN<span class="Sup">®</span> in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged LEVAQUIN<span class="Sup">®</span> therapy should only be used when the benefit outweighs the risk<span class="Italics"> [see <a href="#S2.1"> Dosage and Administration (2.1</a>,<a href="#S2.2"> 2.2)</a> and<a href="#S14.9"> Clinical Studies (14.9)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-3"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-3.1"></a><p></p>
<h2>2.1 Dosage in Adult Patients with Normal Renal Function</h2>
<p class="First">The usual dose of LEVAQUIN<span class="Sup">®</span> Tablets or Oral Solution is 250 mg, 500 mg, or 750 mg administered orally every 24 hours, as indicated by <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and described in Table 1. The usual dose of LEVAQUIN<span class="Sup">®</span> Injection is 250 mg or 500 mg administered by slow infusion over 60 minutes every 24 hours or 750 mg administered by slow infusion over 90 minutes every 24 hours, as indicated by <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and described in Table 1.</p>
<p>These recommendations apply to patients with creatinine clearance ≥ 50 mL/min. For patients with creatinine clearance &lt;50 mL/min, adjustments to the dosing regimen are required<span class="Italics"> [see<a href="#S2.3"> Dosage and Administration (2.3)</a>]</span>.</p>
<a name="i906613b7-ea43-474f-8fdb-fb8fd65455d4"></a><table width="100%">
<caption><span>Table 1: Dosage in Adult Patients with Normal Renal Function (creatinine clearance ≥ 50 mL/min)</span></caption>
<col align="left" valign="top" width="45%">
<col align="center" valign="top" width="40%">
<col align="center" valign="top" width="15%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Type of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
<th class="Rrule" align="center">Dosed Every 24 hours</th>
<th class="Rrule" align="center">Duration (days)<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Due to the designated pathogens <span class="Italics">[see <a href="#S1">Indications and Usage (1)</a>]</span>.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Sequential therapy (intravenous to oral) may be instituted at the discretion of the physician.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>Due to methicillin-susceptible <span class="Italics">Staphylococcus aureus, Streptococcus pneumoniae</span> (including multi-drug-resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> [MDRSP]), <span class="Italics">Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, </span>or <span class="Italics">Mycoplasma pneumoniae [see <a href="#S1.2">Indications and Usage (1.2)</a>].  </span>
</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">§</a></dt>
<dd>Due to <span class="Italics">Streptococcus pneumoniae</span> (excluding multi-drug-resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> [MDRSP]), <span class="Italics">Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, </span>or<span class="Italics"> Chlamydophila pneumoniae [see <a href="#S1.3">Indications and Usage (1.3)</a>].</span>
</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">¶</a></dt>
<dd>This regimen is indicated for cUTI due to <span class="Italics">Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis </span>and AP due to <span class="Italics">E. coli,</span> including cases with concurrent <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>.</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">#</a></dt>
<dd>This regimen is indicated for cUTI due to <span class="Italics">Enterococcus faecalis, Enterococcus cloacae, Escherichia coli</span>, <span class="Italics">Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa</span>; and for AP due to <span class="Italics">E. coli.</span>
</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">Þ</a></dt>
<dd>Drug administration should begin as soon as possible after suspected or confirmed exposure to aerosolized <span class="Italics">B. anthracis</span>. This indication is based on a surrogate endpoint. Levofloxacin plasma concentrations achieved in humans are reasonably likely to predict clinical benefit <span class="Italics">[see <a href="#S14.9">Clinical Studies (14.9)</a>]</span>.</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">ß</a></dt>
<dd>The safety of LEVAQUIN<span class="Sup">®</span> in adults for durations of therapy beyond 28 days or in pediatric patients for durations beyond 14 days has not been studied. An increased incidence of musculoskeletal adverse events compared to controls has been observed in pediatric patients <span class="Italics">[see  <a href="#S5.10">Warnings and Precautions (5.10)</a>, <a href="#S8.4">Use in Specific Populations (8.4)</a>, and <a href="#S14.9">Clinical Studies (14.9)</a>].</span> Prolonged LEVAQUIN<span class="Sup">®</span> therapy should only be used when the benefit outweighs the risk.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Nosocomial Pneumonia</span></td>
<td class="Rrule" align="center">750 mg</td>
<td class="Rrule" align="center">7–14</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Community Acquired Pneumonia</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">500 mg</td>
<td class="Rrule" align="center">7–14</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Community Acquired Pneumonia</span><a name="footnote-reference-4" href="#footnote-4" class="Sup">§</a>
</td>
<td class="Rrule" align="center">750 mg</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="2">Acute Bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td class="Rrule" align="center">750 mg</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="center">500 mg</td>
<td class="Rrule" align="center">10–14</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="257905" conceptname="Mucopurulent chronic bronchitis">Acute Bacterial Exacerbation of Chronic Bronchitis</span></td>
<td class="Rrule" align="center">500 mg </td>
<td class="Rrule" align="center">7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> (SSSI)</td>
<td class="Rrule" align="center">750 mg</td>
<td class="Rrule" align="center">7–14</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Uncomplicated SSSI</td>
<td class="Rrule" align="center">500 mg</td>
<td class="Rrule" align="center">7–10</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Chronic Bacterial <span class="product-label-link" type="condition" conceptid="194997" conceptname="Prostatitis">Prostatitis</span></td>
<td class="Rrule" align="center">500 mg</td>
<td class="Rrule" align="center">28</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Complicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span> (cUTI) or <span class="product-label-link" type="condition" conceptid="4139915" conceptname="Acute pyelitis">Acute Pyelonephritis</span> (AP)<a name="footnote-reference-5" href="#footnote-5" class="Sup">¶</a>
</td>
<td class="Rrule" align="center">750 mg</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Complicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span> (cUTI) or <span class="product-label-link" type="condition" conceptid="4139915" conceptname="Acute pyelitis">Acute Pyelonephritis</span> (AP)<a name="footnote-reference-6" href="#footnote-6" class="Sup">#</a>
</td>
<td class="Rrule" align="center">250 mg</td>
<td class="Rrule" align="center">10</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Uncomplicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span></td>
<td class="Rrule" align="center">250 mg</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">Anthrax</span> (Post-Exposure), adult and pediatric patients &gt; 50 kg and ≥ 6 months of age<a name="footnote-reference-7" href="#footnote-7" class="Sup">Þ</a><span class="Sup">,</span><a name="footnote-reference-8" href="#footnote-8" class="Sup">ß</a>
</td>
<td class="Rrule" align="center" valign="middle">500 mg</td>
<td class="Rrule" align="center" valign="middle">60<a href="#footnote-8" class="Sup">ß</a>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left" valign="middle">Pediatric patients &lt; 50 kg and ≥ 6 months of age<a href="#footnote-7" class="Sup">Þ</a><span class="Sup">,</span><a href="#footnote-8" class="Sup">ß</a>
</td>
<td class="Rrule" align="center" valign="middle">see <a href="#table2">Table 2</a> below (<a href="#S2.2">2.2</a>)</td>
<td class="Rrule" align="center" valign="middle">60<a href="#footnote-8" class="Sup">ß</a>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-3.2"></a><p></p>
<h2>2.2 Dosage in Pediatric Patients</h2>
<p class="First">The dosage in pediatric patients ≥ 6 months of age is described below in Table 2.</p>
<a name="table2"></a><table width="100%">
<caption><span>Table 2: Dosage in Pediatric Patients ≥ 6 months of age</span></caption>
<col align="left" valign="middle" width="30%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="30%">
<thead><tr class="First Last">
<th class="Lrule" align="left">Type of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span><a name="footnote-reference-9" href="#footnote-9" class="Sup">*</a>
</th>
<th class="Lrule" align="center">Dose</th>
<th class="Lrule" align="center">Freq. Once every</th>
<th class="Lrule Rrule" align="center">Duration<a name="footnote-reference-10" href="#footnote-10" class="Sup">†</a>
</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-9" href="#footnote-reference-9">*</a></dt>
<dd>Due to <span class="Italics">Bacillus anthracis [see  <a href="#S1.13">Indications and Usage (1.13)</a>]</span>
</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">†</a></dt>
<dd>Sequential therapy (intravenous to oral) may be instituted at the discretion of the physician.</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">‡</a></dt>
<dd>Drug administration should begin as soon as possible after suspected or confirmed exposure to aerosolized <span class="Italics">B. anthracis</span>. This indication is based on a surrogate endpoint. Levofloxacin plasma concentrations achieved in humans are reasonably likely to predict clinical benefit <span class="Italics">[see  <a href="#S14.9">Clinical Studies (14.9)</a>]</span>
</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">§</a></dt>
<dd>The safety of LEVAQUIN<span class="Sup">®</span> in pediatric patients for durations of therapy beyond 14 days has not been studied. An increased incidence of musculoskeletal adverse events compared to controls has been observed in pediatric patients <span class="Italics">[see <a href="#S5.10">Warnings and Precautions (5.10)</a>,  <a href="#S8.4">Use in Specific Populations (8.4)</a>,  and <a href="#S14.9">Clinical Studies (14.9)</a>]</span>. Prolonged LEVAQUIN<span class="Sup">®</span> therapy should only be used when the benefit outweighs the risk.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="left">Inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">Anthrax</span> (post-exposure)<a name="footnote-reference-11" href="#footnote-11" class="Sup">‡</a><span class="Sup">,</span><a name="footnote-reference-12" href="#footnote-12" class="Sup">§</a>
</td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Toprule" align="left">Pediatric patients &gt; 50 kg and ≥ 6 months of age</td>
<td class="Lrule Toprule" align="center">500 mg</td>
<td class="Lrule Toprule" align="center">24 hr</td>
<td class="Lrule Rrule Toprule" align="center">60 days<a href="#footnote-12" class="Sup">§</a>
</td>
</tr>
<tr class="Last">
<td class="Lrule Toprule" align="left">Pediatric patients &lt; 50 kg and ≥ 6 months of age</td>
<td class="Lrule Toprule" align="center">8 mg/kg<br>(not to exceed 250 mg per dose)</td>
<td class="Lrule Toprule" align="center">12 hr</td>
<td class="Lrule Rrule Toprule" align="center">60 days<a href="#footnote-12" class="Sup">§</a>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-3.3"></a><p></p>
<h2>2.3 Dosage Adjustment in Adults with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Administer LEVAQUIN<span class="Sup">®</span> with caution in the presence of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>. Careful clinical observation and appropriate laboratory studies should be performed prior to and during therapy since elimination of levofloxacin may be reduced.</p>
<p>No adjustment is necessary for patients with a creatinine clearance ≥ 50 mL/min.</p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (creatinine clearance &lt;50 mL/min), adjustment of the dosage regimen is necessary to avoid the accumulation of levofloxacin due to decreased clearance<span class="Italics"> [see<a href="#S8.6"> Use in Specific Populations (8.6)</a>]</span>.</p>
<p>Table 3 shows how to adjust dose based on creatinine clearance.</p>
<a name="iaa0e5be9-2b82-454d-8f52-06095d38e2cf"></a><table width="100%">
<caption><span>Table 3: Dosage Adjustment in Adult Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> (creatinine clearance &lt;50 mL/min)</span></caption>
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Dosage in Normal Renal Function Every 24 hours</th>
<th class="Rrule" align="left">Creatinine Clearance<br>20 to 49 mL/min</th>
<th class="Rrule" align="left">Creatinine Clearance<br>10 to 19 mL/min</th>
<th class="Rrule" align="left">Hemodialysis or Chronic Ambulatory Peritoneal Dialysis (CAPD)</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">750 mg</td>
<td class="Rrule" align="left">750 mg every 48 hours</td>
<td class="Rrule" align="left">750 mg initial dose, then 500 mg every 48 hours</td>
<td class="Rrule" align="left">750 mg initial dose, then 500 mg every 48 hours</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">500 mg</td>
<td class="Rrule" align="left">500 mg initial dose, then 250 mg every 24 hours</td>
<td class="Rrule" align="left">500 mg initial dose, then 250 mg every 48 hours</td>
<td class="Rrule" align="left">500 mg initial dose, then 250 mg every 48 hours</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">250 mg</td>
<td class="Rrule" align="left">No dosage adjustment required</td>
<td class="Rrule" align="left">250 mg every 48 hours. If treating uncomplicated UTI, then no dosage adjustment is required</td>
<td class="Rrule" align="left">No information on dosing adjustment is available</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.4"></a><a name="section-3.4"></a><p></p>
<h2>2.4 Drug Interaction With Chelation Agents: Antacids, Sucralfate, Metal Cations, Multivitamins</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.4.1"></a><p></p>
<p class="First"><span class="Bold">LEVAQUIN<span class="Sup">®</span> Tablets and Oral Solution</span></p>
<p>LEVAQUIN<span class="Sup">®</span> Tablets and Oral Solution should be administered at least two hours before or two hours after antacids containing magnesium, aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc or didanosine chewable/buffered tablets or the pediatric powder for oral solution<span class="Italics"> [see<a href="#S7.1"> Drug Interactions (7.1) </a>and<a href="#S17.2"> Patient Counseling Information (17.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.4.2"></a><p></p>
<p class="First"><span class="Bold">LEVAQUIN<span class="Sup">®</span> Injection</span></p>
<p>LEVAQUIN<span class="Sup">®</span> Injection should not be co-administered with any solution containing multivalent cations, e.g., magnesium, through the same intravenous line<span class="Italics"> [see<a href="#S2.6"> Dosage and Administration (2.6)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.5"></a><a name="section-3.5"></a><p></p>
<h2>2.5 Administration Instructions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.5.1"></a><p></p>
<p class="First"><span class="Bold">Food and LEVAQUIN<span class="Sup">®</span> Tablets and Oral Solution</span></p>
<p>LEVAQUIN<span class="Sup">®</span> Tablets can be administered without regard to food. It is recommended that LEVAQUIN<span class="Sup">®</span> Oral Solution be taken 1 hour before or 2 hours after eating.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.5.2"></a><p></p>
<p class="First"><span class="Bold">LEVAQUIN<span class="Sup">®</span> Injection</span></p>
<p>Caution: Rapid or bolus intravenous infusion of LEVAQUIN<span class="Sup">®</span> has been associated with <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and must be avoided. LEVAQUIN<span class="Sup">®</span> Injection should be infused intravenously slowly over a period of not less than 60 or 90 minutes, depending on the dosage. LEVAQUIN<span class="Sup">®</span> Injection should be administered only by intravenous infusion. It is not for intramuscular, intrathecal, intraperitoneal, or subcutaneous administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.5.3"></a><p></p>
<p class="First"><span class="Bold">Hydration for Patients Receiving LEVAQUIN<span class="Sup">®</span> Tablets, Oral Solution, and Injection</span></p>
<p>Adequate hydration of patients receiving oral or intravenous LEVAQUIN<span class="Sup">®</span> should be maintained to prevent the formation of highly concentrated urine. <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">Crystalluria</span> and <span class="product-label-link" type="condition" conceptid="442282" conceptname="Urinary casts">cylindruria</span> have been reported with quinolones<span class="Italics"> [see<a href="#S6.1"> Adverse Reactions (6.1) </a></span>and<span class="Italics"><a href="#S17.2"> Patient Counseling Information (17.2)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.6"></a><a name="section-3.6"></a><p></p>
<h2>2.6 Preparation of Intravenous Product</h2>
<p class="First">Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
<p>Because only limited data are available on the compatibility of LEVAQUIN<span class="Sup">®</span> Injection with other intravenous substances, additives or other medications should not be added to LEVAQUIN<span class="Sup">®</span> Injection Premix in Single-Use Flexible Containers and LEVAQUIN<span class="Sup">®</span> Injection in Single-Use Vials, or infused simultaneously through the same intravenous line. If the same intravenous line is used for sequential infusion of several different drugs, the line should be <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span> before and after infusion of LEVAQUIN<span class="Sup">®</span> Injection with an infusion solution compatible with LEVAQUIN<span class="Sup">®</span> Injection and with any other drug(s) administered via this common line.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.6.1"></a><p></p>
<p class="First"><span class="Bold">LEVAQUIN<span class="Sup">®</span> Injection in Single-Use Vials</span></p>
<p>Single-use vials require dilution prior to administration.</p>
<p>LEVAQUIN<span class="Sup">®</span> Injection is supplied in single-use vials containing a concentrated levofloxacin solution with the equivalent of 500 mg (20 mL vial) and 750 mg (30 mL vial) of levofloxacin in Water for Injection, USP. The 20 mL and 30 mL vials each contain 25 mg of levofloxacin/mL. These LEVAQUIN<span class="Sup">®</span> Injection single-use vials must be further diluted with an appropriate solution prior to intravenous administration<span class="Italics"> [see<a href="#table4"> Table 4</a>]</span>. The concentration of the resulting diluted solution should be 5 mg/mL prior to administration.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.6.1.1"></a><p></p>
<p class="First"><span class="Underline">Compatible Intravenous Solutions</span>: Any of the following intravenous solutions may be used to prepare a 5 mg/mL levofloxacin solution with the approximate pH values:</p>
<a name="table4"></a><table width="70%">
<caption><span>Table 4: Compatible Intravenous Solutions</span></caption>
<col align="left" valign="middle" width="50%">
<col align="center" valign="top" width="50%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Intravenous Fluids</th>
<th class="Rrule" align="center">Final pH of LEVAQUIN<span class="Sup">®</span> Solution</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">0.9% Sodium Chloride Injection, USP</td>
<td class="Rrule" align="center">4.71</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">5% Dextrose Injection, USP</td>
<td class="Rrule" align="center">4.58</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">5% Dextrose/0.9% NaCl Injection</td>
<td class="Rrule" align="center">4.62</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">5% Dextrose in Lactated Ringers</td>
<td class="Rrule" align="center">4.92</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Plasma-Lyte<span class="Sup">®</span> 56/5% Dextrose Injection</td>
<td class="Rrule" align="center">5.03</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">5% Dextrose, 0.45% Sodium Chloride, and 0.15% Potassium Chloride Injection</td>
<td class="Rrule" align="center">4.61</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Sodium Lactate Injection (M/6)</td>
<td class="Rrule" align="center">5.54</td>
</tr>
</tbody>
</table>
<p>Since no preservative or bacteriostatic agent is present in this product, aseptic technique must be used in preparation of the final intravenous solution. Since the vials are for single-use only, any unused portion remaining in the vial should be discarded. When used to prepare two 250 mg doses from the 20 mL vial containing 500 mg of levofloxacin, the full content of the vial should be withdrawn at once using a single-entry procedure, and a second dose should be prepared and stored for subsequent use<span class="Italics"> [see<a href="#stabilityoflevaquin"> Stability of LEVAQUIN</a><span class="Sup">®</span><a href="#stabilityoflevaquin"> Injection Following Dilution</a>]</span>.</p>
<p>Prepare the desired dosage of levofloxacin according to Table 5:</p>
<a name="i43a6ea57-86b7-4c42-8949-5deb0cf7e06f"></a><table width="100%">
<caption><span>Table 5: Preparation of LEVAQUIN<span class="Sup">®</span> Intravenous Solution</span></caption>
<col align="left" valign="top" width="26%">
<col align="center" valign="top" width="34%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Desired Dosage Strength</th>
<th class="Rrule" align="center">From Appropriate Vial,<br>Withdraw Volume</th>
<th class="Rrule" align="center">Volume of Diluent</th>
<th class="Rrule" align="center">Infusion Time</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">250 mg</td>
<td class="Rrule" align="center">10 mL (20 mL Vial)</td>
<td class="Rrule" align="center">40 mL</td>
<td class="Rrule" align="center">60 min</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">500 mg</td>
<td class="Rrule" align="center">20 mL (20 mL Vial)</td>
<td class="Rrule" align="center">80 mL</td>
<td class="Rrule" align="center">60 min</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">750 mg</td>
<td class="Rrule" align="center">30 mL (30 mL Vial)</td>
<td class="Rrule" align="center">120 mL</td>
<td class="Rrule" align="center">90 min</td>
</tr>
</tbody>
</table>
<p>For example, to prepare a 500 mg dose using the 20 mL vial (25 mg/mL), withdraw 20 mL and dilute with a compatible intravenous solution to a total volume of 100 mL.</p>
<p>This intravenous drug product should be inspected visually for particulate matter prior to administration. Samples containing visible particles should be discarded.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="stabilityoflevaquin"></a><a name="section-3.6.1.2"></a><p></p>
<p class="First"><span class="Underline">Stability of LEVAQUIN<span class="Sup">®</span> Injection Following Dilution</span>: LEVAQUIN<span class="Sup">®</span> Injection, when diluted in a compatible intravenous fluid to a concentration of 5 mg/mL, is stable for 72 hours when stored at or below 25°C (77°F) and for 14 days when stored under refrigeration at 5°C (41°F) in plastic intravenous containers. Solutions that are diluted in a compatible intravenous solution and frozen in glass bottles or plastic intravenous containers are stable for 6 months when stored at - 20°C (- 4°F). Thaw frozen solutions at room temperature 25°C (77°F) or in a refrigerator 8°C (46°F). Do not force thaw by microwave irradiation or water bath immersion. Do not refreeze after initial thawing.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.6.2"></a><p></p>
<p class="First"><span class="Bold">LEVAQUIN<span class="Sup">®</span> Injection Premix in Single-Use Flexible Containers (5 mg/mL)</span></p>
<p>LEVAQUIN<span class="Sup">®</span> Injection is also supplied in flexible containers within a foil overwrap. These contain a premixed, ready to use levofloxacin solution in 5% dextrose (D5W) for single-use. The 100 mL premixed flexible containers contain either 250 mg/50 mL or 500 mg/100 mL of levofloxacin solution. The 150 mL flexible container contains 750 mg/150 mL of levofloxacin solution. The concentration of each container is 5 mg/mL. No further dilution of these preparations is necessary. Because the premix flexible containers are for single-use only, any unused portion should be discarded.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.6.2.1"></a><p></p>
<p class="First"><span class="Underline">Instructions for the Use of LEVAQUIN<span class="Sup">®</span> Injection Premix in Flexible Containers:</span></p>
<ol class="Arabic">
<li>Tear outer wrap at the notch and remove solution container.</li>
<li>Check the container for minute leaks by squeezing the inner bag firmly. If leaks are found, or if the seal is not intact, discard the solution, as the <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> may be compromised.</li>
<li>Do not use if the solution is cloudy or a precipitate is present.</li>
<li>Use sterile equipment.</li>
<li>
<span class="Bold">WARNING: Do not use flexible containers in series connections. </span>Such use could result in <span class="product-label-link" type="condition" conceptid="4156949" conceptname="Air embolism">air embolism</span> due to residual air being drawn from the primary container before administration of the fluid from the secondary container is complete. </li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.6.2.2"></a><p></p>
<p class="First"><span class="Underline">Preparation for Administration</span>:</p>
<ol class="Arabic">
<li>Close flow control clamp of administration set.</li>
<li>Remove cover from port at bottom of container.</li>
<li>Insert piercing pin of administration set into port with a twisting motion until the pin is firmly seated.<span class="Bold"> NOTE: See full directions on administration set carton.</span>
</li>
<li>Suspend container from hanger.</li>
<li>Squeeze and release drip chamber to establish proper fluid level in chamber during infusion of LEVAQUIN<span class="Sup">®</span> Injection Premix in Flexible Containers.</li>
<li>Open flow control clamp to expel air from set. Close clamp.</li>
<li>Regulate rate of administration with flow control clamp.</li>
</ol>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-4"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">TABLETS, Film-coated, capsule-shaped</p>
<ul class="Disc">
<li>250 mg terra cotta pink tablets, imprinted with "250" on one side and "LEVAQUIN" on the other</li>
<li>500 mg peach tablets, imprinted with "500" on one side and "LEVAQUIN" on the other</li>
<li>750 mg white tablets, imprinted with "750" on one side and "LEVAQUIN" on the other</li>
</ul>
<p>ORAL SOLUTION, 25mg/mL, clear yellow to clear greenish-yellow color</p>
<p>INJECTION, Single-Use Vials of concentrated solution for dilution for intravenous infusion, clear yellow to clear greenish-yellow in appearance</p>
<ul class="Disc">
<li>20 mL vial of 25 mg/mL levofloxacin solution, equivalent to 500 mg of levofloxacin</li>
<li>30 mL vial of 25 mg/mL levofloxacin solution, equivalent to 750 mg of levofloxacin</li>
</ul>
<p>INJECTION (5 mg/mL in 5% Dextrose) Premix in Single-Use Flexible Containers, for intravenous infusion</p>
<ul class="Disc">
<li>100 mL container, fill volume 50 mL (equivalent to 250 mg levofloxacin)</li>
<li>100 mL container, fill volume 100 mL (equivalent to 500 mg levofloxacin)</li>
<li>150 mL container, fill volume 150 mL (equivalent to 750 mg levofloxacin)</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-5"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">LEVAQUIN<span class="Sup">®</span> is contraindicated in persons with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to levofloxacin, or other quinolone antibacterials<span class="Italics"> [see<a href="#S5.3"> Warnings and Precautions (5.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-6"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-6.1"></a><p></p>
<h2>5.1 Tendinopathy and <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">Tendon Rupture</span></h2>
<p class="First">Fluoroquinolones, including LEVAQUIN<span class="Sup">®</span>, are associated with an increased risk of <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span> and <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> in all ages. This adverse reaction most frequently involves the Achilles tendon, and rupture of the Achilles tendon may require surgical repair. <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">Tendinitis</span> and <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> in the rotator cuff (the shoulder), the hand, the biceps, the thumb, and other tendon sites have also been reported. The risk of developing fluoroquinolone-associated <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span> and <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> is further increased in older patients usually over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. Factors, in addition to age and corticosteroid use, that may independently increase the risk of <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> include strenuous physical activity, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, and previous <span class="product-label-link" type="condition" conceptid="442264" conceptname="Disorder of tendon">tendon disorders</span> such as <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>. <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">Tendinitis</span> and <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> have been reported in patients taking fluoroquinolones who do not have the above risk factors. <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">Tendon rupture</span> can occur during or after completion of therapy; cases occurring up to several months after completion of therapy have been reported. LEVAQUIN<span class="Sup">®</span> should be discontinued if the patient experiences <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> or rupture of a tendon. Patients should be advised to rest at the first sign of <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span> or <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span>, and to contact their healthcare provider regarding changing to a non-quinolone antimicrobial drug.<span class="Italics"> [see<a href="#S6.3"> Adverse Reactions (6.3)</a>;<a href="#S17.3"> Patient Counseling Information (17.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-6.2"></a><p></p>
<h2>5.2 Exacerbation of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">Myasthenia Gravis</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Fluoroquinolones, including LEVAQUIN<span class="Sup">®</span>, have neuromuscular blocking activity and may exacerbate <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> in persons with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. Postmarketing serious adverse events, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> and requirement for ventilatory support, have been associated with fluoroquinolone use in persons with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. Avoid LEVAQUIN<span class="Sup">®</span> in patients with a known history of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span><span class="Italics"> [see</span><a href="#S6.3"> Adverse Reactions (6.3)</a><span class="Italics">;<a href="#S17.3"> Patient Counseling Information (17.3)</a>].</span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-6.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First">Serious and occasionally fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> and/or <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> have been reported in patients receiving therapy with fluoroquinolones, including LEVAQUIN<span class="Sup">®</span>. These reactions often occur following the first dose. Some reactions have been accompanied by <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>/<span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> (including tongue, laryngeal, throat, or facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>/<span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>), airway obstruction (including <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, and acute <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>), <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, and other serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>. LEVAQUIN<span class="Sup">®</span> should be discontinued immediately at the first appearance of a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or any other sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>. Serious acute <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> may require treatment with epinephrine and other resuscitative measures, including oxygen, intravenous fluids, antihistamines, corticosteroids, pressor amines, and airway management, as clinically indicated<span class="Italics"> [see<a href="#S6"> Adverse Reactions (6)</a>;<a href="#S17.3"> Patient Counseling Information (17.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-6.4"></a><p></p>
<h2>5.4 Other Serious and Sometimes Fatal Reactions</h2>
<p class="First">Other serious and sometimes fatal events, some due to <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, and some due to uncertain etiology, have been reported rarely in patients receiving therapy with fluoroquinolones, including LEVAQUIN<span class="Sup">®</span>. These events may be severe and generally occur following the administration of multiple doses. Clinical manifestations may include one or more of the following:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, or severe dermatologic reactions (e.g., <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span>);</li>
<li><span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>; <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>; <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>; <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>;</li>
<li>allergic <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>;</li>
<li>interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>; <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal insufficiency</span> or failure;</li>
<li><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>; <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>; acute <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span> or failure;</li>
<li><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, including hemolytic and aplastic; <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, including <span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">thrombotic thrombocytopenic purpura</span>; <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>; <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>; <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>; and/or other hematologic abnormalities.</li>
</ul>
<p>The drug should be discontinued immediately at the first appearance of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, or any other sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> and supportive measures instituted<span class="Italics"> [see<a href="#S6"> Adverse Reactions (6)</a>;<a href="#S17.3"> Patient Counseling Information (17.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-6.5"></a><p></p>
<h2>5.5 Hepatotoxicity</h2>
<p class="First">Post-marketing reports of severe hepatotoxicity (including acute <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and fatal events) have been received for patients treated with LEVAQUIN<span class="Sup">®.</span> No evidence of serious drug-associated hepatotoxicity was detected in clinical trials of over 7,000 patients. Severe hepatotoxicity generally occurred within 14 days of initiation of therapy and most cases occurred within 6 days. Most cases of severe hepatotoxicity were not associated with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span><span class="Italics"> [see<a href="#S5.4"> Warnings and Precautions (5.4)</a>]</span>. The majority of fatal hepatotoxicity reports occurred in patients 65 years of age or older and most were not associated with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>. LEVAQUIN<span class="Sup">®</span> should be discontinued immediately if the patient develops signs and symptoms of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span><span class="Italics"> [see<a href="#S6"> Adverse Reactions (6)</a>;<a href="#S17.3"> Patient Counseling Information (17.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-6.6"></a><p></p>
<h2>5.6 Central Nervous System Effects</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> and toxic psychoses have been reported in patients receiving fluoroquinolones, including LEVAQUIN<span class="Sup">®</span>. Fluoroquinolones may also cause <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span> and central nervous system stimulation which may lead to <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="432590" conceptname="Delusional disorder">paranoia</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, and, rarely, suicidal thoughts or acts. These reactions may occur following the first dose. If these reactions occur in patients receiving LEVAQUIN<span class="Sup">®</span>, the drug should be discontinued and appropriate measures instituted. As with other fluoroquinolones, LEVAQUIN<span class="Sup">®</span> should be used with caution in patients with a known or suspected central nervous system (CNS) disorder that may predispose them to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold (e.g., severe <span class="product-label-link" type="condition" conceptid="4278243" conceptname="Cerebral arteriosclerosis">cerebral arteriosclerosis</span>, <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>) or in the presence of other risk factors that may predispose them to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold (e.g., certain drug therapy, renal dysfunction.)<span class="Italics"> [see<a href="#S6"> Adverse Reactions (6)</a></span>;<span class="Italics"><a href="#S7.4"> Drug Interactions (7.4</a>,<a href="#S7.5"> 7.5)</a></span>;<span class="Italics"><a href="#S17.3"> Patient Counseling Information (17.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-6.7"></a><p></p>
<h2>5.7<span class="Italics"> Clostridium difficile</span>-Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></h2>
<p class="First"><span class="Italics">Clostridium difficile</span>-associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including LEVAQUIN<span class="Sup">®</span>, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of<span class="Italics"> C. difficile</span>.</p>
<p><span class="Italics">C. difficile </span>produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of<span class="Italics"> C. difficile </span>cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against<span class="Italics"> C. difficile </span>may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of<span class="Italics"> C. difficile, </span>and surgical evaluation should be instituted as clinically indicated<span class="Italics"> [see<a href="#S6.2"> Adverse Reactions (6.2)</a>,<a href="#S17.3"> Patient Counseling Information (17.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.8"></a><a name="section-6.8"></a><p></p>
<h2>5.8 <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral Neuropathy</span></h2>
<p class="First">Rare cases of sensory or sensorimotor axonal <span class="product-label-link" type="condition" conceptid="4174262" conceptname="Polyneuropathy">polyneuropathy</span> affecting small and/or large axons resulting in <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesias</span>, <span class="product-label-link" type="condition" conceptid="4150134" conceptname="Dysesthesia">dysesthesias</span> and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> have been reported in patients receiving fluoroquinolones, including LEVAQUIN<span class="Sup">®</span>. LEVAQUIN<span class="Sup">®</span> should be discontinued if the patient experiences symptoms of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> including <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, burning, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, and/or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or other alterations of sensation including light touch, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, temperature, position sense, and vibratory sensation in order to prevent the development of an irreversible condition<span class="Italics"> [see<a href="#S6"> Adverse Reactions (6)</a>,<a href="#S17.3"> Patient Counseling Information (17.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.9"></a><a name="section-6.9"></a><p></p>
<h2>5.9 Prolongation of the QT Interval</h2>
<p class="First">Some fluoroquinolones, including LEVAQUIN<span class="Sup">®</span>, have been associated with prolongation of the QT interval on the electrocardiogram and infrequent cases of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>. Rare cases of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span> have been spontaneously reported during postmarketing surveillance in patients receiving fluoroquinolones, including LEVAQUIN<span class="Sup">®</span>. LEVAQUIN<span class="Sup">®</span> should be avoided in patients with known prolongation of the QT interval, patients with uncorrected <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, and patients receiving Class IA (quinidine, procainamide), or Class III (amiodarone, sotalol) antiarrhythmic agents. Elderly patients may be more susceptible to drug-associated effects on the QT interval<span class="Italics"> [see<a href="#S6.3"> Adverse Reactions (6.3)</a>,<a href="#S8.5"> Use in Specific Populations (8.5)</a>, and<a href="#S17.3"> Patient Counseling Information (17.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.10"></a><a name="section-6.10"></a><p></p>
<h2>5.10 <span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">Musculoskeletal Disorders</span> in Pediatric Patients and Arthropathic Effects in Animals</h2>
<p class="First">LEVAQUIN<span class="Sup">®</span> is indicated in pediatric patients (≥6 months of age) only for the prevention of inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> (post-exposure)<span class="Italics"> [see<a href="#S1.13"> Indications and Usage (1.13)</a>]</span>. An increased incidence of <span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">musculoskeletal disorders</span> (<span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, tendinopathy, and gait abnormality) compared to controls has been observed in pediatric patients receiving LEVAQUIN<span class="Sup">®</span><span class="Italics">[see<a href="#S8.4"> Use in Specific Populations (8.4)</a>]</span>.</p>
<p>In immature rats and dogs, the oral and intravenous administration of levofloxacin resulted in increased <span class="product-label-link" type="condition" conceptid="433565" conceptname="Juvenile osteochondrosis of spine">osteochondrosis</span>. Histopathological examination of the weight-bearing joints of immature dogs dosed with levofloxacin revealed persistent lesions of the cartilage. Other fluoroquinolones also produce similar erosions in the weight-bearing joints and other signs of <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> in immature animals of various species<span class="Italics"> [see<a href="#S13.2"> Animal Toxicology and/or Pharmacology (13.2)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.11"></a><a name="section-6.11"></a><p></p>
<h2>5.11 Blood Glucose Disturbances</h2>
<p class="First">As with other fluoroquinolones, disturbances of blood glucose, including symptomatic hyper- and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, have been reported with LEVAQUIN<span class="Sup">®</span>, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., glyburide) or with insulin. In these patients, careful monitoring of blood glucose is recommended. If a <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemic reaction</span> occurs in a patient being treated with LEVAQUIN<span class="Sup">®</span>, LEVAQUIN<span class="Sup">®</span> should be discontinued and appropriate therapy should be initiated immediately<span class="Italics"> [see<a href="#S6.2"> Adverse Reactions (6.2)</a>;<a href="#S7.3"> Drug Interactions (7.3)</a>;<a href="#S17.4"> Patient Counseling Information (17.4)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.12"></a><a name="section-6.12"></a><p></p>
<h2>5.12 <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span>/<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Phototoxicity</span></h2>
<p class="First">Moderate to severe <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>/<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">phototoxicity</span> reactions, the latter of which may manifest as exaggerated sunburn reactions (e.g., burning, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, exudation, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>) involving areas exposed to light (typically the face, "V" area of the neck, extensor surfaces of the forearms, dorsa of the hands), can be associated with the use of fluoroquinolones after sun or UV light exposure. Therefore, excessive exposure to these sources of light should be avoided. Drug therapy should be discontinued if <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>/<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">phototoxicity</span> occurs<span class="Italics"> [see<a href="#S6.3"> Adverse Reactions (6.3)</a>;<a href="#S17.3"> Patient Counseling Information (17.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.13"></a><a name="section-6.13"></a><p></p>
<h2>5.13 Development of Drug Resistant Bacteria</h2>
<p class="First">Prescribing LEVAQUIN<span class="Sup">®</span> in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria<span class="Italics"> [see<a href="#S17.1"> Patient Counseling Information (17.1)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-7"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-7.1"></a><p></p>
<h2>6.1 Serious and Otherwise Important Adverse Reactions</h2>
<p class="First">The following serious and otherwise important adverse drug reactions are discussed in greater detail in other sections of labeling:</p>
<ul class="Disc">
<li>Tendon Effects<span class="Italics"> [see<a href="#S5.1"> Warnings and Precautions (5.1)</a>]</span>
</li>
<li>Exacerbation of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">Myasthenia Gravis</span><span class="Italics"> [see<a href="#S5.2"> Warnings and Precautions (5.2)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span><span class="Italics"> [see<a href="#S5.3"> Warnings and Precautions (5.3)</a>]</span>
</li>
<li>Other Serious and Sometimes Fatal Reactions<span class="Italics"> [see<a href="#S5.4"> Warnings and Precautions (5.4)</a>]</span>
</li>
<li>Hepatotoxicity<span class="Italics"> [see<a href="#S5.5"> Warnings and Precautions (5.5)</a>]</span>
</li>
<li>Central Nervous System Effects<span class="Italics"> [see<a href="#S5.6"> Warnings and Precautions (5.6)</a>]</span>
</li>
<li>
<span class="Italics">Clostridium difficile</span>-Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span><span class="Italics"> [see<a href="#S5.7"> Warnings and Precautions (5.7)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral Neuropathy</span><span class="Italics"> [see<a href="#S5.8"> Warnings and Precautions (5.8)</a>]</span>
</li>
<li>Prolongation of the QT Interval<span class="Italics"> [see<a href="#S5.9"> Warnings and Precautions (5.9)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">Musculoskeletal Disorders</span> in Pediatric Patients<span class="Italics"> [see<a href="#S5.10"> Warnings and Precautions (5.10)</a>]</span>
</li>
<li>Blood Glucose Disturbances<span class="Italics"> [see<a href="#S5.11"> Warnings and Precautions (5.11)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span>/<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Phototoxicity</span><span class="Italics"> [see<a href="#S5.12"> Warnings and Precautions (5.12)</a>]</span>
</li>
<li>Development of Drug Resistant Bacteria<span class="Italics"> [see<a href="#S5.13"> Warnings and Precautions (5.13)</a>]</span>
</li>
</ul>
<p><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> has been associated with rapid or bolus intravenous infusion of LEVAQUIN<span class="Sup">®</span>. LEVAQUIN<span class="Sup">®</span> should be infused slowly over 60 to 90 minutes, depending on dosage<span class="Italics"> [see<a href="#S2.5"> Dosage and Administration (2.5)</a>].</span></p>
<p><span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">Crystalluria</span> and <span class="product-label-link" type="condition" conceptid="442282" conceptname="Urinary casts">cylindruria</span> have been reported with quinolones, including LEVAQUIN<span class="Sup">®</span>. Therefore, adequate hydration of patients receiving LEVAQUIN<span class="Sup">®</span> should be maintained to prevent the formation of a highly concentrated urine<span class="Italics"> [see<a href="#S2.5"> Dosage and Administration (2.5)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-7.2"></a><p></p>
<h2>6.2 Clinical Trial Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The data described below reflect exposure to LEVAQUIN<span class="Sup">®</span> in 7537 patients in 29 pooled Phase 3 clinical trials. The population studied had a mean age of 50 years (approximately 74% of the population was &lt; 65 years of age), 50% were male, 71% were Caucasian, 19% were Black. Patients were treated with LEVAQUIN<span class="Sup">®</span> for a wide variety of infectious diseases<span class="Italics"> [see<a href="#S1"> Indications and Usage (1)</a>]</span>. Patients received LEVAQUIN<span class="Sup">®</span> doses of 750 mg once daily, 250 mg once daily, or 500 mg once or twice daily. Treatment duration was usually 3–14 days, and the mean number of days on therapy was 10 days.</p>
<p>The overall incidence, type and distribution of adverse reactions was similar in patients receiving LEVAQUIN<span class="Sup">®</span> doses of 750 mg once daily, 250 mg once daily, and 500 mg once or twice daily. Discontinuation of LEVAQUIN<span class="Sup">®</span> due to adverse drug reactions occurred in 4.3% of patients overall, 3.8% of patients treated with the 250 mg and 500 mg doses and 5.4% of patients treated with the 750 mg dose. The most common adverse drug reactions leading to discontinuation with the 250 and 500 mg doses were gastrointestinal (1.4%), primarily <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (0.6%); <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (0.4%); <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (0.3%); and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (0.2%). The most common adverse drug reactions leading to discontinuation with the 750 mg dose were gastrointestinal (1.2%), primarily <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (0.6%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (0.5%); <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (0.3%); and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (0.3%).</p>
<p>Adverse reactions occurring in ≥1% of LEVAQUIN<span class="Sup">®</span>-treated patients and less common adverse reactions, occurring in 0.1 to &lt;1% of LEVAQUIN<span class="Sup">®</span>-treated patients, are shown in Table 6 and Table 7, respectively. The most common adverse drug reactions (≥3%) are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.</p>
<a name="i5c72b02f-1d2d-4ee5-80a7-b99dd7572d08"></a><table width="90%">
<caption><span>Table 6:  Common (≥1%) Adverse Reactions Reported in Clinical Trials with  LEVAQUIN<span class="Sup">®</span></span></caption>
<col align="left" valign="top" width="35%">
<col align="left" valign="top" width="50%">
<col align="center" valign="top" width="15%">
<thead><tr class="First Last">
<th class="Lrule" align="left">System/Organ  Class</th>
<th class="Lrule" align="left">Adverse  Reaction</th>
<th class="Lrule Rrule" align="center">%<br>(N=7537)</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-13" href="#footnote-reference-13">*</a></dt>
<dd>N=7274</dd>
<dt><a name="footnote-14" href="#footnote-reference-14">†</a></dt>
<dd>N=3758 (women)</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span></td>
<td class="Lrule Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="Bold">Psychiatric Disorders</span></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span><a name="footnote-reference-13" href="#footnote-13" class="Sup">*</a><span class="Italics"> [see <a href="#S5.6">Warnings and Precautions (5.6)</a>]</span><br>
</td>
<td class="Lrule Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td>
<td class="Lrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span><br><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> <span class="Italics">[see  <a href="#S5.6">Warnings and Precautions (5.6)</a>] </span>
</td>
<td class="Lrule Rrule" align="center" valign="middle">6<br>3</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="Bold">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>
</td>
<td class="Lrule Rrule" align="center">1</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" rowspan="6"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></td>
<td class="Lrule Rrule" align="center">7</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></td>
<td class="Lrule Rrule" align="center">5</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></td>
<td class="Lrule Rrule" align="center">3</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span></td>
<td class="Lrule Rrule" align="center">2</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></td>
<td class="Lrule Rrule" align="center"> 2</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span></td>
<td class="Lrule Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="Bold">Skin and Subcutaneous Tissue Disorders   </span></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span><br><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></td>
<td class="Lrule Rrule" align="center">2<br>1</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="Bold">Reproductive System and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span> </span></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span></td>
<td class="Lrule Rrule" align="center" valign="middle">1<a name="footnote-reference-14" href="#footnote-14" class="Sup">†</a>
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" rowspan="3"><span class="Bold">General Disorders and Administration Site Conditions</span></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span></td>
<td class="Lrule Rrule" align="center">1</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reaction</span></td>
<td class="Lrule Rrule" align="center">1</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span></td>
<td class="Lrule Rrule" align="center">1</td>
</tr>
</tbody>
</table>
<a name="i259f71ac-79e4-407d-88c7-7399fd0cf724"></a><table width="87%">
<caption><span>Table 7: Less Common (0.1 to 1%) Adverse  Reactions Reported in Clinical Trials with LEVAQUIN<span class="Sup">®</span> (N=7537)</span></caption>
<col align="left" valign="top" width="40%">
<col align="left" valign="top" width="60%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">System/Organ Class</th>
<th class="Rrule" align="left">Adverse Reaction</th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-15" href="#footnote-reference-15">*</a></dt>
<dd>N = 7274</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span></td>
<td class="Rrule" align="left">genital <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Blood and Lymphatic System Disorders</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span><br><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span><br><span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span> <br><span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>]  </span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span></span><br>
</td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> <span class="Italics">[see  <a href="#S5.3">Warnings and Precautions (5.3,</a><a href="#S5.4">5.4)</a>]</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Metabolism and Nutrition Disorders </span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span><br><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span><br><span class="Italics">[see <a href="#S5.11">Warnings and Precautions (5.11)</a>]</span><br><br><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Psychiatric Disorders</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span><br><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span><br><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span><br><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span><br><span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span><br><span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmare</span><a name="footnote-reference-15" href="#footnote-15" class="Sup">*</a><br><span class="Italics">[see  <a href="#S5.6">Warnings and Precautions (5.6)</a>]</span><br><br><span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorder</span><a href="#footnote-15" class="Sup">*</a><br><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span><br>abnormal dreaming<a href="#footnote-15" class="Sup">*</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span><br><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span><br><span class="Italics">[see  <a href="#S5.6">Warnings and Precautions (5.6)</a>]</span><br><br><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> <span class="Italics">[see  <a href="#S5.8">Warnings and Precautions (5.8)</a>]</span><br><span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span><br><span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span><br><span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesias</span><br><span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">abnormal gait</span><br><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span><a href="#footnote-15" class="Sup">*</a><br><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span></td>
<td class="Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span></span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> <br><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span><br><span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span><br><span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span></span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span> </span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span><br><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span><br><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span><br><span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span><br><span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span><br><span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span><br>pseudomembraneous/ <span class="Italics">C. difficile</span> <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> <span class="Italics">[see  <a href="#S5.7">Warnings and Precautions (5.7)</a>]</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Hepatobiliary Disorders</span></td>
<td class="Rrule" align="left">abnormal hepatic function <br>increased hepatic enzymes<br>increased alkaline phosphatase</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Skin and Subcutaneous Tissue Disorders</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span><br><span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span><br><span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]  </span><br><br><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span><br><span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">skeletal pain</span></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="Bold">Renal and Urinary Disorders</span></td>
<td class="Rrule" align="left" valign="middle">abnormal renal function<br><span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> <span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>]  </span>
</td>
</tr>
</tbody>
</table>
<p>In clinical trials using multiple-dose therapy, ophthalmologic abnormalities, including <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span> and multiple punctate <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">lenticular opacities</span>, have been noted in patients undergoing treatment with quinolones, including LEVAQUIN<span class="Sup">®</span>. The relationship of the drugs to these events is not presently established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.3"></a><a name="section-7.3"></a><p></p>
<h2>6.3 Postmarketing Experience</h2>
<p class="First">Table 8 lists adverse reactions that have been identified during post-approval use of LEVAQUIN<span class="Sup">®</span>. Because these reactions are reported voluntarily from a population of uncertain size, reliably estimating their frequency or establishing a causal relationship to drug exposure is not always possible.</p>
<a name="ie1991abb-a0ce-4b98-85af-4371c2ed4c26"></a><table width="85%">
<caption><span>Table 8: Postmarketing Reports Of Adverse Drug Reactions</span></caption>
<col align="left" valign="top" width="40%">
<col align="left" valign="top" width="60%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">System/Organ Class</th>
<th class="Rrule" align="left">Adverse Reaction</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">Blood and Lymphatic System Disorders </span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span><br> <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span><br> <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span><br> <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span><br><span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>]</span><br><br> <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span></span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, sometimes fatal including:<br>   anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span><br>   <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span><br>   <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span><br>   <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span><br><span class="Italics">[see  <a href="#S5.3">Warnings and Precautions (5.3</a>,<a href="#S5.4">5.4)</a>]</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Psychiatric Disorders</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span><br> <span class="product-label-link" type="condition" conceptid="432590" conceptname="Delusional disorder">paranoia</span><br> isolated reports of <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span> and <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span><br><span class="Italics">[see  <a href="#S5.6">Warnings and Precautions (5.6)</a>]</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span><br>
</td>
<td class="Rrule" align="left">exacerbation of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span><span class="Italics"> [see<a href="#S5.2"> Warnings and Precautions (5.2)</a>]</span><br><span class="product-label-link" type="condition" conceptid="4185711" conceptname="Loss of sense of smell">anosmia</span><br> <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">ageusia</span><br> <span class="product-label-link" type="condition" conceptid="444223" conceptname="Sense of smell altered">parosmia</span><br> <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span><br> <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> <span class="Italics">[see <a href="#S5.8">Warnings and Precautions (5.8)</a>]</span><br> isolated reports of <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span><br> <span class="product-label-link" type="condition" conceptid="4168553" conceptname="Electroencephalogram abnormal">abnormal electroencephalogram</span> (EEG)<br><span class="product-label-link" type="condition" conceptid="432730" conceptname="Difficulty speaking">dysphonia</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span>  </span></td>
<td class="Rrule" align="left">vision disturbance, including <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span><br> <span class="product-label-link" type="condition" conceptid="376402" conceptname="Low vision, one eye">visual acuity reduced</span><br> <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">vision blurred</span><br> <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">scotoma</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Ear and Labyrinth Disorders</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hypoacusis</span><br> <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span></span></td>
<td class="Rrule" align="left">isolated reports of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span><br> <span class="product-label-link" type="condition" conceptid="4008859" conceptname="Prolonged QT interval">electrocardiogram QT prolonged</span><br><span class="Italics">[see <a href="#S5.9">Warnings and Precautions (5.9)</a>]</span><br><br> <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span></span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span></td>
<td class="Rrule" align="left">isolated reports of allergic <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> <span class="Italics">[see  <a href="#S5.4">Warnings and Precautions (5.4)</a>]</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Hepatobiliary Disorders</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> (including fatal cases)<br> <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span><br> <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span><br><span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4</a>),<a href="#S5.5">(5.5)</a>]</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Skin and Subcutaneous Tissue Disorders</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">bullous eruptions</span> to include:<br>   <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span><br>   <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span><br>   <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span><br><span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>]</span><br><br> <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>/<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">phototoxicity</span> reaction <span class="Italics">[see <a href="#S5.12">Warnings and Precautions (5.12)</a>]</span><br> <span class="product-label-link" type="condition" conceptid="196431" conceptname="Hypersensitivity angiitis">leukocytoclastic vasculitis</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span> </span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span><br> <span class="product-label-link" type="condition" conceptid="4048093" conceptname="Hamstring injury">muscle injury</span>, including rupture<br> <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Renal and Urinary Disorders</span></td>
<td class="Rrule" align="left">interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> <span class="Italics">[see  <a href="#S5.4">Warnings and Precautions (5.4)</a>]</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">General Disorders and Administration Site Conditions</span></td>
<td class="Rrule" align="left">multi-organ failure<br> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="Bold">Investigations  </span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4260197" conceptname="Prothrombin time increased">prothrombin time prolonged</span><br> international normalized ratio prolonged<br> muscle enzymes increased<br>
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-8"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-8.1"></a><p></p>
<h2>7.1 Chelation Agents: Antacids, Sucralfate, Metal Cations, Multivitamins</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Bold">LEVAQUIN<span class="Sup">®</span> Tablets and Oral Solution</span></p>
<p>While the chelation by divalent cations is less marked than with other fluoroquinolones, concurrent administration of LEVAQUIN<span class="Sup">®</span> Tablets and Oral Solution with antacids containing magnesium, or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc may interfere with the gastrointestinal absorption of levofloxacin, resulting in systemic levels considerably lower than desired. Tablets with antacids containing magnesium, aluminum, as well as sucralfate, metal cations such as iron, and multivitamins preparations with zinc or didanosine may substantially interfere with the gastrointestinal absorption of levofloxacin, resulting in systemic levels considerably lower than desired. These agents should be taken at least two hours before or two hours after oral LEVAQUIN<span class="Sup">®</span> administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.2"></a><p></p>
<p class="First"><span class="Bold">LEVAQUIN<span class="Sup">®</span> Injection</span></p>
<p>There are no data concerning an interaction of intravenous fluoroquinolones with oral antacids, sucralfate, multivitamins, didanosine, or metal cations. However, no fluoroquinolone should be co-administered with any solution containing multivalent cations, e.g., magnesium, through the same intravenous line<span class="Italics"> [see<a href="#S2.5"> Dosage and Administration (2.5)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-8.2"></a><p></p>
<h2>7.2 Warfarin</h2>
<p class="First">No significant effect of LEVAQUIN<span class="Sup">®</span> on the peak plasma concentrations, AUC, and other disposition parameters for R- and S- warfarin was detected in a clinical study involving healthy volunteers. Similarly, no apparent effect of warfarin on levofloxacin absorption and disposition was observed. However, there have been reports during the postmarketing experience in patients that LEVAQUIN<span class="Sup">®</span> enhances the effects of warfarin. Elevations of the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time in the setting of concurrent warfarin and LEVAQUIN<span class="Sup">®</span> use have been associated with episodes of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> time, International Normalized Ratio (INR), or other suitable anticoagulation tests should be closely monitored if LEVAQUIN<span class="Sup">®</span> is administered concomitantly with warfarin. Patients should also be monitored for evidence of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span><span class="Italics"> [see<a href="#S6.3"> Adverse Reactions (6.3)</a>;<a href="#S17.4"> Patient Counseling Information (17.4)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-8.3"></a><p></p>
<h2>7.3 Antidiabetic Agents</h2>
<p class="First">Disturbances of blood glucose, including <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, have been reported in patients treated concomitantly with fluoroquinolones and an antidiabetic agent. Therefore, careful monitoring of blood glucose is recommended when these agents are co-administered<span class="Italics"> [see<a href="#S5.11"> Warnings and Precautions (5.11)</a>;<a href="#S6.2"> Adverse Reactions (6.2)</a>,<a href="#S17.4"> Patient Counseling Information (17.4)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.4"></a><a name="section-8.4"></a><p></p>
<h2>7.4 Non-Steroidal Anti-Inflammatory Drugs</h2>
<p class="First">The concomitant administration of a non-steroidal anti-inflammatory drug with a fluoroquinolone, including LEVAQUIN<span class="Sup">®</span>, may increase the risk of CNS stimulation and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive seizures</span><span class="Italics"> [see<a href="#S5.6"> Warnings and Precautions (5.6)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.5"></a><a name="section-8.5"></a><p></p>
<h2>7.5 Theophylline</h2>
<p class="First">No significant effect of LEVAQUIN<span class="Sup">®</span> on the plasma concentrations, AUC, and other disposition parameters for theophylline was detected in a clinical study involving healthy volunteers. Similarly, no apparent effect of theophylline on levofloxacin absorption and disposition was observed. However, concomitant administration of other fluoroquinolones with theophylline has resulted in prolonged elimination half-life, elevated serum theophylline levels, and a subsequent increase in the risk of theophylline-related adverse reactions in the patient population. Therefore, theophylline levels should be closely monitored and appropriate dosage adjustments made when LEVAQUIN<span class="Sup">®</span> is co-administered. Adverse reactions, including <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, may occur with or without an elevation in serum theophylline levels<span class="Italics"> [see<a href="#S5.6"> Warnings and Precautions (5.6)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.6"></a><a name="section-8.6"></a><p></p>
<h2>7.6 Cyclosporine</h2>
<p class="First">No significant effect of LEVAQUIN<span class="Sup">®</span> on the peak plasma concentrations, AUC, and other disposition parameters for cyclosporine was detected in a clinical study involving healthy volunteers. However, elevated serum levels of cyclosporine have been reported in the patient population when co-administered with some other fluoroquinolones. Levofloxacin C<span class="Sub">max</span> and k<span class="Sub">e</span> were slightly lower while T<span class="Sub">max</span> and t<span class="Sub">½</span> were slightly longer in the presence of cyclosporine than those observed in other studies without concomitant medication. The differences, however, are not considered to be clinically significant. Therefore, no dosage adjustment is required for LEVAQUIN<span class="Sup">®</span> or cyclosporine when administered concomitantly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.7"></a><a name="section-8.7"></a><p></p>
<h2>7.7 Digoxin</h2>
<p class="First">No significant effect of LEVAQUIN<span class="Sup">®</span> on the peak plasma concentrations, AUC, and other disposition parameters for digoxin was detected in a clinical study involving healthy volunteers. Levofloxacin absorption and disposition kinetics were similar in the presence or absence of digoxin. Therefore, no dosage adjustment for LEVAQUIN<span class="Sup">®</span> or digoxin is required when administered concomitantly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.8"></a><a name="section-8.8"></a><p></p>
<h2>7.8 Probenecid and Cimetidine</h2>
<p class="First">No significant effect of probenecid or cimetidine on the C<span class="Sub">max</span> of levofloxacin was observed in a clinical study involving healthy volunteers. The AUC and t<span class="Sub">½</span> of levofloxacin were higher while CL/F and CL<span class="Sub">R</span> were lower during concomitant treatment of LEVAQUIN<span class="Sup">®</span> with probenecid or cimetidine compared to LEVAQUIN<span class="Sup">®</span> alone. However, these changes do not warrant dosage adjustment for LEVAQUIN<span class="Sup">®</span> when probenecid or cimetidine is co-administered.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="S7.9"></a><a name="section-8.9"></a><p></p>
<h2>7.9 Interactions with Laboratory or Diagnostic Testing</h2>
<p class="First">Some fluoroquinolones, including LEVAQUIN<span class="Sup">®</span>, may produce false-positive urine screening results for opiates using commercially available immunoassay kits. Confirmation of positive opiate screens by more specific methods may be necessary.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-9"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-9.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-9.1.1"></a><p></p>
<p class="First">Pregnancy Category C. Levofloxacin was not teratogenic in rats at oral doses as high as 810 mg/kg/day which corresponds to 9.4 times the highest recommended human dose based upon relative body surface area, or at intravenous doses as high as 160 mg/kg/day corresponding to 1.9 times the highest recommended human dose based upon relative body surface area. The oral dose of 810 mg/kg/day to rats caused decreased fetal body weight and increased fetal mortality. No <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was observed when rabbits were dosed orally as high as 50 mg/kg/day which corresponds to 1.1 times the highest recommended human dose based upon relative body surface area, or when dosed intravenously as high as 25 mg/kg/day, corresponding to 0.5 times the highest recommended human dose based upon relative body surface area.</p>
<p>There are, however, no adequate and well-controlled studies in pregnant women. LEVAQUIN<span class="Sup">®</span> should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-9.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Based on data on other fluoroquinolones and very limited data on LEVAQUIN<span class="Sup">®</span>, it can be presumed that levofloxacin will be excreted in human milk. Because of the potential for serious adverse reactions from LEVAQUIN<span class="Sup">®</span> in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-9.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Quinolones, including levofloxacin, cause <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> and <span class="product-label-link" type="condition" conceptid="433565" conceptname="Juvenile osteochondrosis of spine">osteochondrosis</span> in juvenile animals of several species.<span class="Italics"> [see<a href="#S5.10"> Warnings and Precautions (5.10) </a>and<a href="#S13.2"> Animal Toxicology and/or Pharmacology (13.2)</a>].</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.3.1"></a><p></p>
<p class="First"><span class="Underline">Inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">Anthrax</span> (Post-Exposure)</span></p>
<p>Levofloxacin is indicated in pediatric patients for inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> (post-exposure). The risk-benefit assessment indicates that administration of levofloxacin to pediatric patients is appropriate. The safety of levofloxacin in pediatric patients treated for more than 14 days has not been studied. The pharmacokinetics of levofloxacin following a single intravenous dose were investigated in pediatric patients ranging in age from six months to 16 years. Pediatric patients cleared levofloxacin faster than adult patients resulting in lower plasma exposures than adults for a given mg/kg dose<span class="Italics"> [see<a href="#S1.13"> Indications and Usage (1.13)</a>,<a href="#S2.2"> Dosage and Administration (2.2)</a>,<a href="#S12.3"> Clinical Pharmacology (12.3) </a>and<a href="#S14.9"> Clinical Studies (14.9)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.3.2"></a><p></p>
<p class="First"><span class="Underline">Adverse Events</span></p>
<p>In clinical trials, 1534 children (6 months to 16 years of age) were treated with oral and intravenous LEVAQUIN<span class="Sup">®</span>. Children 6 months to 5 years of age received LEVAQUIN<span class="Sup">®</span> 10 mg/kg twice a day and children greater than 5 years of age received 10 mg/kg once a day (maximum 500 mg per day) for approximately 10 days.</p>
<p>A subset of children in the clinical trials (1340 LEVAQUIN<span class="Sup">®</span>-treated and 893 non-fluoroquinolone-treated) enrolled in a prospective, long-term surveillance study to assess the incidence of protocol-defined <span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">musculoskeletal disorders</span> (<span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, tendinopathy, gait abnormality) during 60 days and 1 year following the first dose of the study drug. Children treated with LEVAQUIN<span class="Sup">®</span> had a significantly higher incidence of <span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">musculoskeletal disorders</span> when compared to the non-fluoroquinolone-treated children as illustrated in Table 9.</p>
<a name="i66e6c8ab-319f-49e3-8672-6c81be9cec87"></a><table width="100%">
<caption><span>Table 9: Incidence of <span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">Musculoskeletal Disorders</span> in Pediatric Clinical Trial</span></caption>
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead><tr class="First Last">
<th class="Lrule" align="left">Follow-up Period</th>
<th class="Lrule" align="center">LEVAQUIN<span class="Sup">®</span><br> N = 1340</th>
<th class="Lrule" align="center">Non-Fluoroquinolone<a name="footnote-reference-16" href="#footnote-16" class="Sup">*</a><br> N = 893</th>
<th class="Lrule Rrule" align="center">p-value<a name="footnote-reference-17" href="#footnote-17" class="Sup">†</a>
</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-16" href="#footnote-reference-16">*</a></dt>
<dd>Non-Fluoroquinolone: ceftriaxone, amoxicillin/ clavulanate, clarithromycin</dd>
<dt><a name="footnote-17" href="#footnote-reference-17">†</a></dt>
<dd>2-sided Fisher's Exact Test</dd>
<dt><a name="footnote-18" href="#footnote-reference-18">‡</a></dt>
<dd>There were 1199 LEVAQUIN<span class="Sup">®</span>-treated and 804 non-fluoroquinolone-treated children who had a one-year evaluation visit. However, the incidence of <span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">musculoskeletal disorders</span> was calculated using all reported events during the specified period for all children enrolled regardless of whether they completed the 1-year evaluation visit.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="left"><span class="Bold">60 days  </span></td>
<td class="Lrule" align="center">28 (2.1%)</td>
<td class="Lrule" align="center">8 (0.9%)</td>
<td class="Lrule Rrule" align="center">p = 0.038</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left"><span class="Bold">1 year<a name="footnote-reference-18" href="#footnote-18" class="Sup">‡</a></span></td>
<td class="Lrule" align="center">46 (3.4%)</td>
<td class="Lrule" align="center">16 (1.8%)</td>
<td class="Lrule Rrule" align="center">p = 0.025</td>
</tr>
</tbody>
</table>
<p><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span> was the most frequently occurring <span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">musculoskeletal disorder</span> in both treatment groups. Most of the <span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">musculoskeletal disorders</span> in both groups involved multiple weight-bearing joints. Disorders were moderate in 8/46 (17%) children and mild in 35/46 (76%) LEVAQUIN<span class="Sup">®</span>-treated children and most were treated with analgesics. The median time to resolution was 7 days for LEVAQUIN<span class="Sup">®</span>-treated children and 9 for non-fluoroquinolone-treated children (approximately 80% resolved within 2 months in both groups). No child had a severe or serious disorder and all <span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">musculoskeletal disorders</span> resolved without sequelae. </p>
<p><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> were the most frequently reported adverse events, occurring in similar frequency in the LEVAQUIN<span class="Sup">®</span>-treated and non-fluoroquinolone-treated children.</p>
<p>In addition to the events reported in pediatric patients in clinical trials, events reported in adults during clinical trials or post-marketing experience<span class="Italics"> [see<a href="#S6"> Adverse Reactions (6)</a>] </span>may also be expected to occur in pediatric patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-9.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Geriatric patients are at increased risk for developing severe <span class="product-label-link" type="condition" conceptid="442264" conceptname="Disorder of tendon">tendon disorders</span> including <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> when being treated with a fluoroquinolone such as LEVAQUIN<span class="Sup">®</span>. This risk is further increased in patients receiving concomitant corticosteroid therapy. <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">Tendinitis</span> or <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> can involve the Achilles, hand, shoulder, or other tendon sites and can occur during or after completion of therapy; cases occurring up to several months after fluoroquinolone treatment have been reported. Caution should be used when prescribing LEVAQUIN<span class="Sup">®</span> to elderly patients especially those on corticosteroids. Patients should be informed of this potential side effect and advised to discontinue LEVAQUIN<span class="Sup">®</span> and contact their healthcare provider if any symptoms of <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span> or <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> occur<span class="Italics"> [see<a href="#BOX"> Boxed Warning</a>;<a href="#S5.1"> Warnings and Precautions (5.1)</a>; and<a href="#S6.3"> Adverse Reactions (6.3)</a>]</span>.</p>
<p>In phase 3 clinical trials, 1,945 LEVAQUIN<span class="Sup">®</span>-treated patients (26%) were ≥ 65 years of age. Of these, 1,081 patients (14%) were between the ages of 65 and 74 and 864 patients (12%) were 75 years or older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, but greater sensitivity of some older individuals cannot be ruled out.</p>
<p>Severe, and sometimes fatal, cases of hepatotoxicity have been reported post-marketing in association with LEVAQUIN<span class="Sup">®</span>. The majority of fatal hepatotoxicity reports occurred in patients 65 years of age or older and most were not associated with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>. LEVAQUIN<span class="Sup">®</span> should be discontinued immediately if the patient develops signs and symptoms of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span><span class="Italics"> [see<a href="#S5.5"> Warnings and Precautions (5.5)</a>]</span>.</p>
<p>Elderly patients may be more susceptible to drug-associated effects on the QT interval. Therefore, precaution should be taken when using LEVAQUIN<span class="Sup">®</span> with concomitant drugs that can result in prolongation of the QT interval (e.g., Class IA or Class III antiarrhythmics) or in patients with risk factors for <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span> (e.g., known QT prolongation, uncorrected <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>)<span class="Italics"> [see<a href="#S5.9"> Warnings and Precautions (5.9)</a>]</span>.</p>
<p>The pharmacokinetic properties of levofloxacin in younger adults and elderly adults do not differ significantly when creatinine clearance is taken into consideration. However, since the drug is known to be substantially excreted by the kidney, the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function<span class="Italics"> [see<a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-9.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Clearance of levofloxacin is substantially reduced and plasma elimination half-life is substantially prolonged in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (creatinine clearance &lt; 50 mL/min), requiring dosage adjustment in such patients to avoid accumulation. Neither hemodialysis nor continuous ambulatory peritoneal dialysis (CAPD) is effective in removal of levofloxacin from the body, indicating that supplemental doses of LEVAQUIN<span class="Sup">®</span> are not required following hemodialysis or CAPD<span class="Italics"> [see<a href="#S2.3"> Dosage and Administration (2.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.7"></a><a name="section-9.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Pharmacokinetic studies in hepatically impaired patients have not been conducted. Due to the limited extent of levofloxacin metabolism, the pharmacokinetics of levofloxacin are not expected to be affected by <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">In the event of an acute overdosage, the stomach should be emptied. The patient should be observed and appropriate hydration maintained. Levofloxacin is not efficiently removed by hemodialysis or peritoneal dialysis.</p>
<p>LEVAQUIN<span class="Sup">®</span> exhibits a low potential for acute toxicity. Mice, rats, dogs and monkeys exhibited the following clinical signs after receiving a single high dose of LEVAQUIN<span class="Sup">®</span>: <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span>, decreased locomotor activity, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">prostration</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. Doses in excess of 1500 mg/kg orally and 250 mg/kg IV produced significant mortality in rodents.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">LEVAQUIN<span class="Sup">®</span> is a synthetic broad-spectrum antibacterial agent for oral and intravenous administration. Chemically, levofloxacin, a chiral fluorinated carboxyquinolone, is the pure (-)-(S)-enantiomer of the racemic drug substance ofloxacin. The chemical name is (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate. </p>
<p><span class="Bold">Figure 1: The Chemical Structure of Levofloxacin</span></p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=139f86a4-75c5-4304-894c-8f8b8a396c78&amp;name=levaquin-01.jpg"></div>
<p>The empirical formula is C<span class="Sub">18</span>H<span class="Sub">20</span>FN<span class="Sub">3</span>O<span class="Sub">4</span> • ½ H<span class="Sub">2</span>O and the molecular weight is 370.38. Levofloxacin is a light yellowish-white to yellow-white crystal or crystalline powder. The molecule exists as a zwitterion at the pH conditions in the small intestine.</p>
<p>The data demonstrate that from pH 0.6 to 5.8, the solubility of levofloxacin is essentially constant (approximately 100 mg/mL). Levofloxacin is considered<span class="Italics"> soluble to freely soluble </span>in this pH range, as defined by USP nomenclature. Above pH 5.8, the solubility increases rapidly to its maximum at pH 6.7 (272 mg/mL) and is considered<span class="Italics"> freely soluble </span>in this range. Above pH 6.7, the solubility decreases and reaches a minimum value (about 50 mg/mL) at a pH of approximately 6.9.</p>
<p>Levofloxacin has the potential to form stable coordination compounds with many metal ions. This in vitro chelation potential has the following formation order: Al<span class="Sup">+3</span>&gt;Cu<span class="Sup">+2</span>&gt;Zn<span class="Sup">+2</span>&gt;Mg<span class="Sup">+2</span>&gt;Ca<span class="Sup">+2</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1"></a><p></p>
<p class="First"><span class="Bold">Excipients and Description of Dosage Forms</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1.1"></a><p></p>
<p class="First"><span class="Underline">LEVAQUIN<span class="Sup">®</span> Tablets</span></p>
<p>LEVAQUIN<span class="Sup">®</span> Tablets are available as film-coated tablets and contain the following inactive ingredients:</p>
<ul class="Disc">
<li>250 mg (as expressed in the anhydrous form): hypromellose, crospovidone, microcrystalline cellulose, magnesium stearate, polyethylene glycol, titanium dioxide, polysorbate 80 and synthetic red iron oxide.</li>
<li>500 mg (as expressed in the anhydrous form): hypromellose, crospovidone, microcrystalline cellulose, magnesium stearate, polyethylene glycol, titanium dioxide, polysorbate 80 and synthetic red and yellow iron oxides.</li>
<li>750 mg (as expressed in the anhydrous form): hypromellose, crospovidone, microcrystalline cellulose, magnesium stearate, polyethylene glycol, titanium dioxide, polysorbate 80.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1.2"></a><p></p>
<p class="First"><span class="Underline">LEVAQUIN<span class="Sup">®</span> Oral Solution</span></p>
<p>LEVAQUIN<span class="Sup">®</span> Oral Solution, 25 mg/mL, is a multi-use self-preserving aqueous solution of levofloxacin with pH ranging from 5.0 to 6.0. The appearance of LEVAQUIN<span class="Sup">®</span> Oral Solution may range from clear yellow to clear greenish-yellow. This does not adversely affect product potency.</p>
<p>LEVAQUIN<span class="Sup">®</span> Oral Solution contains the following inactive ingredients: sucrose, glycerin, sucralose, hydrochloric acid, purified water, propylene glycol, artificial and natural flavors, benzyl alcohol, ascorbic acid, and caramel color. It may also contain a solution of sodium hydroxide for pH adjustment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1.3"></a><p></p>
<p class="First"><span class="Underline">LEVAQUIN<span class="Sup">®</span> Injection</span></p>
<p>The appearance of LEVAQUIN<span class="Sup">®</span> Injection may range from a clear yellow to a clear greenish-yellow solution. This does not adversely affect product potency.</p>
<p><span class="Italics">LEVAQUIN</span><span class="Sup">®</span><span class="Italics"> Injection in Single-Use Vials </span>is a sterile, preservative-free aqueous solution of levofloxacin in Water for Injection, with pH ranging from 3.8 to 5.8.</p>
<p><span class="Italics">LEVAQUIN</span><span class="Sup">®</span><span class="Italics"> Injection Premix in Single-Use Flexible Containers </span>is a sterile, preservative-free aqueous solution of levofloxacin with pH ranging from 3.8 to 5.8. This is a dilute, non-pyrogenic, nearly isotonic premixed solution that contains levofloxacin in 5% Dextrose (D<span class="Sub">5</span>W). Solutions of hydrochloric acid and sodium hydroxide may have been added to adjust the pH.</p>
<p>The flexible container is fabricated from a specially formulated non-plasticized, thermoplastic copolyester (CR3). The amount of water that can permeate from the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the flexible container can leach out certain of the container's chemical components in very small amounts within the expiration period. The suitability of the container material has been confirmed by tests in animals according to USP biological tests for plastic containers.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Levofloxacin is a member of the fluoroquinolone class of antibacterial agents<span class="Italics"> [see<a href="#S12.4"> Clinical Pharmacology (12.4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-12.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The mean ± SD pharmacokinetic parameters of levofloxacin determined under single and steady-state conditions following oral tablet, oral solution, or intravenous (IV) doses of LEVAQUIN<span class="Sup">®</span> are summarized in Table 10.</p>
<a name="iac036099-fd3d-4c89-8379-6ee65621766c"></a><table width="100%">
<caption><span>Table 10: Mean ± SD Levofloxacin PK Parameters</span></caption>
<col align="left" valign="middle" width="23%">
<col align="center" valign="middle" width="11%">
<col align="center" valign="middle" width="11%">
<col align="center" valign="middle" width="11%">
<col align="center" valign="middle" width="11%">
<col align="center" valign="middle" width="11%">
<col align="center" valign="middle" width="11%">
<col align="center" valign="middle" width="11%">
<thead>
<tr class="First">
<th class="Lrule Toprule" align="left" rowspan="2" valign="bottom">Regimen</th>
<th class="Lrule Toprule" align="center">C<span class="Sub">max</span>
</th>
<th class="Lrule Toprule" align="center">T<span class="Sub">max</span>
</th>
<th class="Lrule Toprule" align="center">AUC</th>
<th class="Lrule Toprule" align="center">CL/F<a name="footnote-reference-19" href="#footnote-19" class="Sup">*</a>
</th>
<th class="Lrule Toprule" align="center">Vd/F<a name="footnote-reference-20" href="#footnote-20" class="Sup">†</a>
</th>
<th class="Lrule Toprule" align="center">t<span class="Sub">1/2</span>
</th>
<th class="Lrule Rrule" align="center">CL<span class="Sub">R</span>
</th>
</tr>
<tr class="Botrule Last">
<th class="Lrule" align="center">(mcg/mL)</th>
<th class="Lrule" align="center">(h)</th>
<th class="Lrule" align="center">(mcg∙h/mL)</th>
<th class="Lrule" align="center">(mL/min)</th>
<th class="Lrule" align="center">(L)</th>
<th class="Lrule" align="center">(h)</th>
<th class="Lrule Rrule" align="center">(mL/min)</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="8">ND=not determined.</td></tr>
<tr><td colspan="8" align="left"><dl class="Footnote">
<dt><a name="footnote-19" href="#footnote-reference-19">*</a></dt>
<dd>clearance/bioavailability</dd>
<dt><a name="footnote-20" href="#footnote-reference-20">†</a></dt>
<dd>volume of distribution/bioavailability</dd>
<dt><a name="footnote-21" href="#footnote-reference-21">‡</a></dt>
<dd>healthy males 18–53 years of age</dd>
<dt><a name="footnote-22" href="#footnote-reference-22">§</a></dt>
<dd>Absolute bioavailability; F=0.99 ± 0.08 from a 500 mg tablet and F=0.99 ± 0.06 from a 750 mg tablet;</dd>
<dt><a name="footnote-23" href="#footnote-reference-23">¶</a></dt>
<dd>healthy males and females 19–55 years of age.</dd>
<dt><a name="footnote-24" href="#footnote-reference-24">#</a></dt>
<dd>healthy male and female subjects 18–54 years of age</dd>
<dt><a name="footnote-25" href="#footnote-reference-25">Þ</a></dt>
<dd>60 min infusion for 250 mg and 500 mg doses, 90 min infusion for 750 mg dose</dd>
<dt><a name="footnote-26" href="#footnote-reference-26">ß</a></dt>
<dd>500 mg every 48h for patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CLCR 20–50 mL/min) and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the respiratory tract or skin</dd>
<dt><a name="footnote-27" href="#footnote-reference-27">à</a></dt>
<dd>dose-normalized values (to 500 mg dose), estimated by population pharmacokinetic modeling</dd>
<dt><a name="footnote-28" href="#footnote-reference-28">è</a></dt>
<dd>healthy males 22–75 years of age</dd>
<dt><a name="footnote-29" href="#footnote-reference-29">ð</a></dt>
<dd>healthy females 18–80 years of age</dd>
<dt><a name="footnote-30" href="#footnote-reference-30">ø</a></dt>
<dd>young healthy male and female subjects 18–36 years of age</dd>
<dt><a name="footnote-31" href="#footnote-reference-31">ý</a></dt>
<dd>healthy elderly male and female subjects 66–80 years of age</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="8"><span class="Bold">Single dose</span></td></tr>
<tr class="Botrule">
<td class="Lrule" align="left">250 mg oral tablet<a name="footnote-reference-21" href="#footnote-21" class="Sup">‡</a>
</td>
<td class="Lrule" align="center">2.8 ± 0.4</td>
<td class="Lrule" align="center">1.6 ± 1.0</td>
<td class="Lrule" align="center">27.2 ± 3.9</td>
<td class="Lrule" align="center">156 ± 20</td>
<td class="Lrule" align="center">ND</td>
<td class="Lrule" align="center">7.3 ± 0.9</td>
<td class="Lrule Rrule" align="center">142 ± 21</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">500 mg oral tablet<a href="#footnote-21" class="Sup">‡</a><a name="footnote-reference-22" href="#footnote-22" class="Sup">§</a>
</td>
<td class="Lrule" align="center">5.1 ± 0.8</td>
<td class="Lrule" align="center">1.3 ± 0.6</td>
<td class="Lrule" align="center">47.9 ± 6.8</td>
<td class="Lrule" align="center">178 ± 28</td>
<td class="Lrule" align="center">ND</td>
<td class="Lrule" align="center">6.3 ± 0.6</td>
<td class="Lrule Rrule" align="center">103 ± 30</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">500 mg oral solution<a name="footnote-reference-23" href="#footnote-23" class="Sup">¶</a>
</td>
<td class="Lrule" align="center">5.8 ± 1.8</td>
<td class="Lrule" align="center">0.8 ± 0.7</td>
<td class="Lrule" align="center">47.8 ± 10.8</td>
<td class="Lrule" align="center">183 ± 40</td>
<td class="Lrule" align="center">112 ± 37.2</td>
<td class="Lrule" align="center">7.0 ± 1.4</td>
<td class="Lrule Rrule" align="center">ND</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">500 mg IV<a href="#footnote-21" class="Sup">‡</a>
</td>
<td class="Lrule" align="center">6.2 ± 1.0</td>
<td class="Lrule" align="center">1.0 ± 0.1</td>
<td class="Lrule" align="center">48.3 ± 5.4</td>
<td class="Lrule" align="center">175 ± 20</td>
<td class="Lrule" align="center">90 ± 11</td>
<td class="Lrule" align="center">6.4 ± 0.7</td>
<td class="Lrule Rrule" align="center">112 ± 25</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">750 mg oral tablet<a name="footnote-reference-24" href="#footnote-24" class="Sup">#</a><a href="#footnote-22" class="Sup">§</a>
</td>
<td class="Lrule" align="center">9.3 ± 1.6</td>
<td class="Lrule" align="center">1.6 ± 0.8</td>
<td class="Lrule" align="center">101 ± 20</td>
<td class="Lrule" align="center">129 ± 24</td>
<td class="Lrule" align="center">83 ± 17</td>
<td class="Lrule" align="center">7.5 ± 0.9</td>
<td class="Lrule Rrule" align="center">ND</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">750 mg IV<a href="#footnote-24" class="Sup">#</a>
</td>
<td class="Lrule" align="center">11.5 ± 4.0<a name="footnote-reference-25" href="#footnote-25" class="Sup">Þ</a>
</td>
<td class="Lrule" align="center">ND</td>
<td class="Lrule" align="center">110 ± 40</td>
<td class="Lrule" align="center">126 ± 39</td>
<td class="Lrule" align="center">75 ± 13</td>
<td class="Lrule" align="center">7.5 ± 1.6</td>
<td class="Lrule Rrule" align="center">ND</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="8"><span class="Bold">Multiple dose</span></td></tr>
<tr class="Botrule">
<td class="Lrule" align="left">500 mg every 24h oral tablet<a href="#footnote-21" class="Sup">‡</a>
</td>
<td class="Lrule" align="center">5.7 ± 1.4</td>
<td class="Lrule" align="center">1.1 ± 0.4</td>
<td class="Lrule" align="center">47.5 ± 6.7</td>
<td class="Lrule" align="center">175 ± 25</td>
<td class="Lrule" align="center">102 ± 22</td>
<td class="Lrule" align="center">7.6 ± 1.6</td>
<td class="Lrule Rrule" align="center">116 ± 31</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">500 mg every 24h IV<a href="#footnote-21" class="Sup">‡</a>
</td>
<td class="Lrule" align="center">6.4 ± 0.8</td>
<td class="Lrule" align="center">ND</td>
<td class="Lrule" align="center">54.6 ± 11.1</td>
<td class="Lrule" align="center">158 ± 29</td>
<td class="Lrule" align="center">91 ± 12</td>
<td class="Lrule" align="center">7.0 ± 0.8</td>
<td class="Lrule Rrule" align="center">99 ± 28</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">500 mg or 250 mg every 24h IV, patients with <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span><a name="footnote-reference-26" href="#footnote-26" class="Sup">ß</a>
</td>
<td class="Lrule" align="center" valign="middle">8.7± 4.0<a name="footnote-reference-27" href="#footnote-27" class="Sup">à</a>
</td>
<td class="Lrule" align="center" valign="middle">ND</td>
<td class="Lrule" align="center" valign="middle">72.5 ± 51.2<a href="#footnote-27" class="Sup">à</a>
</td>
<td class="Lrule" align="center" valign="middle">154 ± 72</td>
<td class="Lrule" align="center" valign="middle">111 ± 58</td>
<td class="Lrule" align="center" valign="middle">ND</td>
<td class="Lrule Rrule" align="center" valign="middle">ND</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">750 mg every 24h oral tablet<a href="#footnote-24" class="Sup">#</a>
</td>
<td class="Lrule" align="center">8.6 ± 1.9</td>
<td class="Lrule" align="center">1.4 ± 0.5</td>
<td class="Lrule" align="center">90.7 ± 17.6</td>
<td class="Lrule" align="center">143 ± 29</td>
<td class="Lrule" align="center">100 ± 16</td>
<td class="Lrule" align="center">8.8 ± 1.5</td>
<td class="Lrule Rrule" align="center">116 ± 28</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">750 mg every 24h IV<a href="#footnote-24" class="Sup">#</a>
</td>
<td class="Lrule" align="center">12.1 ± 4.1<a href="#footnote-25" class="Sup">Þ</a>
</td>
<td class="Lrule" align="center">ND</td>
<td class="Lrule" align="center">108 ± 34</td>
<td class="Lrule" align="center">126 ± 37</td>
<td class="Lrule" align="center">80 ± 27</td>
<td class="Lrule" align="center">7.9 ± 1.9</td>
<td class="Lrule Rrule" align="center">ND</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="8"><span class="Bold">500 mg oral tablet single dose, effects of gender and age:</span></td></tr>
<tr class="Botrule">
<td class="Lrule" align="left">Male<a name="footnote-reference-28" href="#footnote-28" class="Sup">è</a>
</td>
<td class="Lrule" align="center">5.5 ± 1.1</td>
<td class="Lrule" align="center">1.2 ± 0.4</td>
<td class="Lrule" align="center">54.4 ± 18.9</td>
<td class="Lrule" align="center">166 ± 44</td>
<td class="Lrule" align="center">89 ± 13</td>
<td class="Lrule" align="center">7.5 ± 2.1</td>
<td class="Lrule Rrule" align="center">126 ± 38</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Female<a name="footnote-reference-29" href="#footnote-29" class="Sup">ð</a>
</td>
<td class="Lrule" align="center">7.0 ± 1.6</td>
<td class="Lrule" align="center">1.7 ± 0.5</td>
<td class="Lrule" align="center">67.7 ± 24.2</td>
<td class="Lrule" align="center">136 ± 44</td>
<td class="Lrule" align="center">62 ± 16</td>
<td class="Lrule" align="center">6.1 ± 0.8</td>
<td class="Lrule Rrule" align="center">106 ± 40</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Young<a name="footnote-reference-30" href="#footnote-30" class="Sup">ø</a>
</td>
<td class="Lrule" align="center">5.5 ± 1.0</td>
<td class="Lrule" align="center">1.5 ± 0.6</td>
<td class="Lrule" align="center">47.5 ± 9.8</td>
<td class="Lrule" align="center">182 ± 35</td>
<td class="Lrule" align="center">83 ± 18</td>
<td class="Lrule" align="center">6.0 ± 0.9</td>
<td class="Lrule Rrule" align="center">140 ± 33</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Elderly<a name="footnote-reference-31" href="#footnote-31" class="Sup">ý</a>
</td>
<td class="Lrule" align="center">7.0 ± 1.6</td>
<td class="Lrule" align="center">1.4 ± 0.5</td>
<td class="Lrule" align="center">74.7 ± 23.3</td>
<td class="Lrule" align="center">121 ± 33</td>
<td class="Lrule" align="center">67 ± 19</td>
<td class="Lrule" align="center">7.6 ± 2.0</td>
<td class="Lrule Rrule" align="center">91 ± 29</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="8"><span class="Bold">500 mg oral single dose tablet, patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>:</span></td></tr>
<tr class="Botrule">
<td class="Lrule" align="left">CLCR 50–80 mL/min</td>
<td class="Lrule" align="center">7.5 ± 1.8</td>
<td class="Lrule" align="center">1.5 ± 0.5</td>
<td class="Lrule" align="center">95.6 ± 11.8</td>
<td class="Lrule" align="center">88 ± 10</td>
<td class="Lrule" align="center">ND</td>
<td class="Lrule" align="center">9.1 ± 0.9</td>
<td class="Lrule Rrule" align="center">57 ± 8</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">CLCR 20–49 mL/min</td>
<td class="Lrule" align="center">7.1 ± 3.1</td>
<td class="Lrule" align="center">2.1 ± 1.3</td>
<td class="Lrule" align="center">182.1 ± 62.6</td>
<td class="Lrule" align="center">51 ± 19</td>
<td class="Lrule" align="center">ND</td>
<td class="Lrule" align="center">27 ± 10</td>
<td class="Lrule Rrule" align="center">26 ± 13</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">CLCR &lt;20 mL/min</td>
<td class="Lrule" align="center">8.2 ± 2.6</td>
<td class="Lrule" align="center">1.1 ± 1.0</td>
<td class="Lrule" align="center">263.5 ± 72.5</td>
<td class="Lrule" align="center">33 ± 8</td>
<td class="Lrule" align="center">ND</td>
<td class="Lrule" align="center">35 ± 5</td>
<td class="Lrule Rrule" align="center">13 ± 3</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Hemodialysis</td>
<td class="Lrule" align="center">5.7 ± 1.0</td>
<td class="Lrule" align="center">2.8 ± 2.2</td>
<td class="Lrule" align="center">ND</td>
<td class="Lrule" align="center">ND</td>
<td class="Lrule" align="center">ND</td>
<td class="Lrule" align="center">76 ± 42</td>
<td class="Lrule Rrule" align="center">ND</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">CAPD</td>
<td class="Lrule" align="center">6.9 ± 2.3</td>
<td class="Lrule" align="center">1.4 ± 1.1</td>
<td class="Lrule" align="center">ND</td>
<td class="Lrule" align="center">ND</td>
<td class="Lrule" align="center">ND</td>
<td class="Lrule" align="center">51 ± 24</td>
<td class="Lrule Rrule" align="center">ND</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.1"></a><p></p>
<p class="First"><span class="Bold">Absorption</span></p>
<p>Levofloxacin is rapidly and essentially completely absorbed after oral administration. Peak plasma concentrations are usually attained one to two hours after oral dosing. The absolute bioavailability of levofloxacin from a 500 mg tablet and a 750 mg tablet of LEVAQUIN<span class="Sup">®</span> are both approximately 99%, demonstrating complete oral absorption of levofloxacin. Following a single intravenous dose of LEVAQUIN<span class="Sup">®</span> to healthy volunteers, the mean ± SD peak plasma concentration attained was 6.2 ± 1.0 mcg/mL after a 500 mg dose infused over 60 minutes and 11.5 ± 4.0 mcg/mL after a 750 mg dose infused over 90 minutes. LEVAQUIN<span class="Sup">®</span> Oral Solution and Tablet formulations are bioequivalent.</p>
<p>Levofloxacin pharmacokinetics are linear and predictable after single and multiple oral or IV dosing regimens. Steady-state conditions are reached within 48 hours following a 500 mg or 750 mg once-daily dosage regimen. The mean ± SD peak and trough plasma concentrations attained following multiple once-daily oral dosage regimens were approximately 5.7 ± 1.4 and 0.5 ± 0.2 mcg/mL after the 500 mg doses, and 8.6 ± 1.9 and 1.1 ± 0.4 mcg/mL after the 750 mg doses, respectively. The mean ± SD peak and trough plasma concentrations attained following multiple once-daily IV regimens were approximately 6.4 ± 0.8 and 0.6 ± 0.2 mcg/mL after the 500 mg doses, and 12.1 ± 4.1 and 1.3 ± 0.71 mcg/mL after the 750 mg doses, respectively. Oral administration of a 500 mg dose of LEVAQUIN<span class="Sup">®</span> with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration. Therefore, LEVAQUIN<span class="Sup">®</span> Tablets can be administered without regard to food. It is recommended that LEVAQUIN<span class="Sup">®</span> Oral Solution be taken 1 hour before or 2 hours after eating.</p>
<p>The plasma concentration profile of levofloxacin after IV administration is similar and comparable in extent of exposure (AUC) to that observed for LEVAQUIN<span class="Sup">®</span> Tablets when equal doses (mg/mg) are administered. Therefore, the oral and IV routes of administration can be considered interchangeable<span class="Italics"> (see<a href="#fig2"> Figure 2 </a>and<a href="#fig3"> Figure 3</a>).</span></p>
<a name="fig2"></a><table width="100%">
<col align="center" valign="top" width="100%">
<tbody class="Headless">
<tr class="First Toprule" align="center"><td align="center"><span class="Bold">Figure 2: Mean Levofloxacin Plasma Concentration vs. Time Profile: 750 mg</span></td></tr>
<tr class="Botrule Last"><td align="center"><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=139f86a4-75c5-4304-894c-8f8b8a396c78&amp;name=image2.jpg"></td></tr>
</tbody>
</table>
<a name="fig3"></a><table width="100%">
<col align="center" valign="top" width="100%">
<tbody class="Headless">
<tr class="First Toprule" align="center"><td align="center"><span class="Bold">Figure 3: Mean Levofloxacin Plasma Concentration vs. Time Profile: 500 mg</span></td></tr>
<tr class="Botrule Last"><td align="center"><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=139f86a4-75c5-4304-894c-8f8b8a396c78&amp;name=image3.jpg"></td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.2"></a><p></p>
<p class="First"><span class="Bold">Distribution</span></p>
<p>The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues. Levofloxacin reaches its peak levels in skin tissues and in <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> fluid of healthy subjects at approximately 3 hours after dosing. The skin tissue biopsy to plasma AUC ratio is approximately 2 and the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> fluid to plasma AUC ratio is approximately 1 following multiple once-daily oral administration of 750 mg and 500 mg doses of LEVAQUIN<span class="Sup">®</span>, respectively, to healthy subjects. Levofloxacin also penetrates well into lung tissues. Lung tissue concentrations were generally 2- to 5-fold higher than plasma concentrations and ranged from approximately 2.4 to 11.3 mcg/g over a 24-hour period after a single 500 mg oral dose.</p>
<p><span class="Italics">In vitro</span>, over a clinically relevant range (1 to 10 mcg/mL) of serum/plasma levofloxacin concentrations, levofloxacin is approximately 24 to 38% bound to serum proteins across all species studied, as determined by the equilibrium dialysis method. Levofloxacin is mainly bound to serum albumin in humans. Levofloxacin binding to serum proteins is independent of the drug concentration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.3"></a><p></p>
<p class="First"><span class="Bold">Metabolism</span></p>
<p>Levofloxacin is stereochemically stable in plasma and urine and does not invert metabolically to its enantiomer, D-ofloxacin. Levofloxacin undergoes limited metabolism in humans and is primarily excreted as unchanged drug in the urine. Following oral administration, approximately 87% of an administered dose was recovered as unchanged drug in urine within 48 hours, whereas less than 4% of the dose was recovered in feces in 72 hours. Less than 5% of an administered dose was recovered in the urine as the desmethyl and N-oxide metabolites, the only metabolites identified in humans. These metabolites have little relevant pharmacological activity.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.4"></a><p></p>
<p class="First"><span class="Bold">Excretion</span></p>
<p>Levofloxacin is excreted largely as unchanged drug in the urine. The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously. The mean apparent total body clearance and renal clearance range from approximately 144 to 226 mL/min and 96 to 142 mL/min, respectively. Renal clearance in excess of the glomerular filtration rate suggests that tubular secretion of levofloxacin occurs in addition to its glomerular filtration. Concomitant administration of either cimetidine or probenecid results in approximately 24% and 35% reduction in the levofloxacin renal clearance, respectively, indicating that secretion of levofloxacin occurs in the renal proximal tubule. No levofloxacin crystals were found in any of the urine samples freshly collected from subjects receiving LEVAQUIN<span class="Sup">®</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.5"></a><p></p>
<p class="First"><span class="Bold">Geriatric</span></p>
<p>There are no significant differences in levofloxacin pharmacokinetics between young and elderly subjects when the subjects' differences in creatinine clearance are taken into consideration. Following a 500 mg oral dose of LEVAQUIN<span class="Sup">®</span> to healthy elderly subjects (66 – 80 years of age), the mean terminal plasma elimination half-life of levofloxacin was about 7.6 hours, as compared to approximately 6 hours in younger adults. The difference was attributable to the variation in renal function status of the subjects and was not believed to be clinically significant. Drug absorption appears to be unaffected by age. LEVAQUIN<span class="Sup">®</span> dose adjustment based on age alone is not necessary<span class="Italics"> [see<a href="#S8.5"> Use in Specific Populations (8.5)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.6"></a><p></p>
<p class="First"><span class="Bold">Pediatrics</span></p>
<p>The pharmacokinetics of levofloxacin following a single 7 mg/kg intravenous dose were investigated in pediatric patients ranging in age from 6 months to 16 years. Pediatric patients cleared levofloxacin faster than adult patients, resulting in lower plasma exposures than adults for a given mg/kg dose. Subsequent pharmacokinetic analyses predicted that a dosage regimen of 8 mg/kg every 12 hours (not to exceed 250 mg per dose) for pediatric patients 6 months to 17 years of age would achieve comparable steady state plasma exposures (AUC<span class="Sub">0–24</span> and C<span class="Sub">max</span>) to those observed in adult patients administered 500 mg of levofloxacin once every 24 hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.7"></a><p></p>
<p class="First"><span class="Bold">Gender</span></p>
<p>There are no significant differences in levofloxacin pharmacokinetics between male and female subjects when subjects' differences in creatinine clearance are taken into consideration. Following a 500 mg oral dose of LEVAQUIN<span class="Sup">®</span> to healthy male subjects, the mean terminal plasma elimination half-life of levofloxacin was about 7.5 hours, as compared to approximately 6.1 hours in female subjects. This difference was attributable to the variation in renal function status of the male and female subjects and was not believed to be clinically significant. Drug absorption appears to be unaffected by the gender of the subjects. Dose adjustment based on gender alone is not necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.8"></a><p></p>
<p class="First"><span class="Bold">Race</span></p>
<p>The effect of race on levofloxacin pharmacokinetics was examined through a covariate analysis performed on data from 72 subjects: 48 white and 24 non-white. The apparent total body clearance and apparent volume of distribution were not affected by the race of the subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.9"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>Clearance of levofloxacin is substantially reduced and plasma elimination half-life is substantially prolonged in adult patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (creatinine clearance &lt; 50 mL/min), requiring dosage adjustment in such patients to avoid accumulation. Neither hemodialysis nor continuous ambulatory peritoneal dialysis (CAPD) is effective in removal of levofloxacin from the body, indicating that supplemental doses of LEVAQUIN<span class="Sup">®</span> are not required following hemodialysis or CAPD<span class="Italics"> [see<a href="#S2.3"> Dosage and Administration (2.3)</a>,<a href="#S8.6"> Use in Specific Populations (8.6)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.10"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>Pharmacokinetic studies in hepatically impaired patients have not been conducted. Due to the limited extent of levofloxacin metabolism, the pharmacokinetics of levofloxacin are not expected to be affected by <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span><span class="Italics"> [see<a href="#S8.7"> Use in Specific Populations (8.7)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.11"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">Bacterial Infection</span></span></p>
<p>The pharmacokinetics of levofloxacin in patients with serious community-acquired <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span> are comparable to those observed in healthy subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.12"></a><p></p>
<p class="First"><span class="Bold">Drug-Drug Interactions</span></p>
<p>The potential for pharmacokinetic drug interactions between LEVAQUIN<span class="Sup">®</span> and antacids, warfarin, theophylline, cyclosporine, digoxin, probenecid, and cimetidine has been evaluated<span class="Italics"> [see<a href="#S7"> Drug Interactions (7)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="S12.4"></a><a name="section-12.3"></a><p></p>
<h2>12.4 Microbiology</h2>
<div class="Section" data-sectionCode="43679-0">
<a name="section-12.3.1"></a><p></p>
<p class="First"><span class="Bold">Mechanism of Action</span></p>
<p>Levofloxacin is the L-isomer of the racemate, ofloxacin, a quinolone antimicrobial agent. The antibacterial activity of ofloxacin resides primarily in the L-isomer. The mechanism of action of levofloxacin and other fluoroquinolone antimicrobials involves inhibition of bacterial topoisomerase IV and DNA gyrase (both of which are type II topoisomerases), enzymes required for DNA replication, transcription, repair and recombination.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.2"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">Drug Resistance</span></span></p>
<p>Fluoroquinolone resistance can arise through mutations in defined regions of DNA gyrase or topoisomerase IV, termed the Quinolone-Resistance Determining Regions (QRDRs), or through altered efflux.</p>
<p>Fluoroquinolones, including levofloxacin, differ in chemical structure and mode of action from aminoglycosides, macrolides and β-lactam antibiotics, including penicillins. Fluoroquinolones may, therefore, be active against bacteria resistant to these antimicrobials.</p>
<p>Resistance to levofloxacin due to spontaneous mutation<span class="Italics"> in vitro </span>is a rare occurrence (range: 10<span class="Sup">-9</span> to 10<span class="Sup">-10</span>). Although cross-resistance has been observed between levofloxacin and some other fluoroquinolones, some microorganisms resistant to other fluoroquinolones may be susceptible to levofloxacin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.3"></a><p></p>
<p class="First"><span class="Bold">Activity<span class="Italics"> in vitro </span>and<span class="Italics"> in vivo</span></span></p>
<p>Levofloxacin has<span class="Italics"> in vitro </span>activity against a wide range of Gram-negative and Gram-positive microorganisms.</p>
<p>Levofloxacin is often bactericidal at concentrations equal to or slightly greater than inhibitory concentrations.</p>
<p>Levofloxacin has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms both<span class="Italics"> in vitro </span>and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in<span class="Italics"><a href="#S1"> Indications and Usage (1)</a>:</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.3.1"></a><p></p>
<dl>
<dt> </dt>
<dd>
<span class="Bold">	Aerobic Gram-Positive Microorganisms</span><dl>
<dt> </dt>
<dd>
<span class="Italics">Enterococcus faecalis </span>(many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> are only moderately susceptible)</dd>
<dt> </dt>
<dd>
<span class="Italics">Staphylococcus aureus </span>(methicillin-susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)</dd>
<dt> </dt>
<dd>
<span class="Italics">Staphylococcus epidermidis </span>(methicillin-susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)</dd>
<dt> </dt>
<dd><span class="Italics">Staphylococcus saprophyticus</span></dd>
<dt> </dt>
<dd>
<span class="Italics">Streptococcus pneumoniae </span>(including multi-drug resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> [MDRSP]<a name="footnote-reference-32" href="#footnote-32" class="Sup">1</a>)</dd>
<dt> </dt>
<dd><span class="Italics">Streptococcus pyogenes</span></dd>
</dl>
</dd>
</dl>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-32" href="#footnote-reference-32">1</a></dt>
<dd>MDRSP (Multi-drug resistant<span class="Italics"> Streptococcus pneumoniae</span>) isolates are <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> resistant to two or more of the following antibiotics: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime; macrolides, tetracyclines and trimethoprim/sulfamethoxazole.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.3.2"></a><p></p>
<dl>
<dt> </dt>
<dd>
<span class="Bold">Aerobic Gram-Negative Microorganisms</span><dl>
<dt> </dt>
<dd><span class="Italics">Enterobacter cloacae</span></dd>
<dt> </dt>
<dd><span class="Italics">Escherichia coli</span></dd>
<dt> </dt>
<dd><span class="Italics">Haemophilus influenzae</span></dd>
<dt> </dt>
<dd><span class="Italics">Haemophilus parainfluenzae</span></dd>
<dt> </dt>
<dd><span class="Italics">Klebsiella pneumoniae</span></dd>
<dt> </dt>
<dd><span class="Italics">Legionella pneumophila</span></dd>
<dt> </dt>
<dd><span class="Italics">Moraxella catarrhalis</span></dd>
<dt> </dt>
<dd><span class="Italics">Proteus mirabilis</span></dd>
<dt> </dt>
<dd>
<span class="Italics">Pseudomonas aeruginosa</span><a name="footnote-reference-33" href="#footnote-33" class="Sup">2</a>
</dd>
<dt> </dt>
<dd><span class="Italics">Serratia marcescens</span></dd>
</dl>
</dd>
</dl>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-33" href="#footnote-reference-33">2</a></dt>
<dd>As with other drugs in this class, some <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of<span class="Italics"> Pseudomonas aeruginosa </span>may develop resistance fairly rapidly during treatment with LEVAQUIN<span class="Sup">®</span>.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.3.3"></a><p></p>
<dl>
<dt> </dt>
<dd>
<span class="Bold">Other Microorganisms</span><dl>
<dt> </dt>
<dd><span class="Italics">Chlamydophila pneumoniae</span></dd>
<dt> </dt>
<dd><span class="Italics">Mycoplasma pneumoniae</span></dd>
</dl>
</dd>
</dl>
<p class="First">Levofloxacin has been shown to be active against<span class="Italics"> Bacillus anthracis </span>both<span class="Italics"> in vitro </span>and by use of plasma levels as a surrogate marker in a rhesus monkey model for <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> (post-exposure)<span class="Italics"> [see<a href="#S1.13"> Indications and Usage (1.13)</a>,<a href="#S14.9"> Clinical Studies (14.9)</a>].</span></p>
<p>The following<span class="Italics"> in vitro </span>data are available, <span class="Underline">but their clinical significance is unknown<span class="Bold">:</span></span> Levofloxacin exhibits<span class="Italics"> in vitro </span><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MIC values) of 2 mcg/mL or less against most (≥90%) <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms; however, the safety and effectiveness of LEVAQUIN<span class="Sup">®</span> in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these microorganisms have not been established in adequate and well-controlled trials.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.3.4"></a><p></p>
<dl>
<dt> </dt>
<dd>
<span class="Bold">Aerobic Gram-Positive Microorganisms</span><dl>
<dt> </dt>
<dd><span class="Italics">Staphylococcus haemolyticus</span></dd>
<dt> </dt>
<dd>β-hemolytic<span class="Italics"> Streptococcus </span>(Group C/F)</dd>
<dt> </dt>
<dd>β-hemolytic<span class="Italics"> Streptococcus </span>(Group G)</dd>
<dt> </dt>
<dd><span class="Italics">Streptococcus agalactiae</span></dd>
<dt> </dt>
<dd><span class="Italics">Streptococcus milleri</span></dd>
<dt> </dt>
<dd>Viridans group<span class="Italics"> streptococci</span>
</dd>
</dl>
</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.3.5"></a><p></p>
<dl>
<dt> </dt>
<dd>
<span class="Bold">Aerobic Gram-Negative Microorganisms</span><dl>
<dt> </dt>
<dd><span class="Italics">Acinetobacter baumannii</span></dd>
<dt> </dt>
<dd><span class="Italics">Acinetobacter lwoffii</span></dd>
<dt> </dt>
<dd><span class="Italics">Bordetella <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span></span></dd>
<dt> </dt>
<dd><span class="Italics">Citrobacter koseri</span></dd>
<dt> </dt>
<dd><span class="Italics">Citrobacter freundii</span></dd>
<dt> </dt>
<dd><span class="Italics">Enterobacter aerogenes</span></dd>
<dt> </dt>
<dd><span class="Italics">Enterobacter sakazakii</span></dd>
<dt> </dt>
<dd><span class="Italics">Klebsiella oxytoca</span></dd>
<dt> </dt>
<dd><span class="Italics">Morganella morganii</span></dd>
<dt> </dt>
<dd><span class="Italics">Pantoea agglomerans</span></dd>
<dt> </dt>
<dd><span class="Italics">Proteus vulgaris</span></dd>
<dt> </dt>
<dd><span class="Italics">Providencia rettgeri</span></dd>
<dt> </dt>
<dd><span class="Italics">Providencia stuartii</span></dd>
<dt> </dt>
<dd><span class="Italics">Pseudomonas fluorescens</span></dd>
</dl>
</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.3.6"></a><p></p>
<dl>
<dt> </dt>
<dd>
<span class="Bold">Anaerobic Gram-Positive Microorganisms</span><dl>
<dt> </dt>
<dd><span class="Italics">Clostridium perfringens</span></dd>
</dl>
</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.4"></a><p></p>
<p class="First"><span class="Bold">Susceptibility Tests</span></p>
<p>Susceptibility testing for levofloxacin should be performed, as it is the optimal predictor of activity.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.4.1"></a><p></p>
<ul class="Disc"><li><span class="Bold">Dilution techniques:</span></li></ul>
<p class="First">Quantitative methods are used to determine antimicrobial minimal inhibitory concentrations (MIC values). These MIC values provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MIC values should be determined using a standardized procedure. Standardized procedures are based on a dilution method<span class="Sup">1</span> (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of levofloxacin powder. The MIC values should be interpreted according to the criteria outlined in Table 11.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.4.2"></a><p></p>
<ul class="Disc"><li><span class="Bold">Diffusion techniques:</span></li></ul>
<p class="First">Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure<span class="Sup">2</span> requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 5 mcg levofloxacin to test the susceptibility of microorganisms to levofloxacin.</p>
<p>Reports from the laboratory providing results of the standard single-disk susceptibility test with a 5 mcg levofloxacin disk should be interpreted according to the criteria outlined in Table 11. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for levofloxacin.</p>
<a name="if7321299-9bdb-4cd8-8b67-b4d86cd6aced"></a><table width="80%">
<caption><span>Table 11: Susceptibility Interpretive Criteria for LEVAQUIN<span class="Sup">®</span></span></caption>
<col align="left" valign="top" width="34%">
<col align="center" valign="top" width="11%">
<col align="center" valign="top" width="11%">
<col align="center" valign="top" width="11%">
<col align="center" valign="top" width="11%">
<col align="center" valign="top" width="11%">
<col align="center" valign="top" width="11%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" colspan="3">Minimum Inhibitory<br> Concentrations (mcg/mL)</th>
<th class="Rrule" align="center" colspan="3">Disk Diffusion<br> (zone diameter in mm)</th>
</tr></thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="7">S = Susceptible, I = Intermediate, R = Resistant</td></tr>
<tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-34" href="#footnote-reference-34">*</a></dt>
<dd>These interpretive standards are applicable only to broth microdilution susceptibility testing with <span class="Italics">Haemophilus influenzae</span> and <span class="Italics">Haemophilus parainfluenzae</span> using Haemophilus Test Medium.<span class="Sup">1</span><br>
</dd>
<dt><a name="footnote-35" href="#footnote-reference-35">†</a></dt>
<dd>The current absence of data on resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> precludes defining any categories other than "Susceptible." <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strains</span> yielding MIC /zone diameter results suggestive of a "nonsusceptible" category should be submitted to a reference laboratory for further testing.</dd>
<dt><a name="footnote-36" href="#footnote-reference-36">‡</a></dt>
<dd>These interpretive standards are applicable only to disk diffusion susceptibility testing with <span class="Italics">Haemophilus influenzae</span> and <span class="Italics">Haemophilus parainfluenzae</span> using Haemophilus Test Medium.<span class="Sup">2</span>
</dd>
<dt><a name="footnote-37" href="#footnote-reference-37">§</a></dt>
<dd>These interpretive standards are applicable only to broth microdilution susceptibility tests using cation-adjusted Mueller-Hinton broth with 2–5% lysed horse blood.</dd>
<dt><a name="footnote-38" href="#footnote-reference-38">¶</a></dt>
<dd>These zone diameter standards for <span class="Italics">Streptococcus</span> spp. including<span class="Italics"> S. pneumoniae</span> apply only to tests performed using Mueller-Hinton agar supplemented with 5% sheep blood and incubated in 5% CO<span class="Sub">2</span>.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">Pathogen  </span></td>
<td class="Rrule" align="center"><span class="Bold">S</span></td>
<td class="Rrule" align="center"><span class="Bold">I</span></td>
<td class="Rrule" align="center"><span class="Bold">R</span></td>
<td class="Rrule" align="center"><span class="Bold">S</span></td>
<td class="Rrule" align="center"><span class="Bold">I</span></td>
<td class="Rrule" align="center"><span class="Bold">R</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Italics">Enterobacteriaceae</span></td>
<td class="Rrule" align="center">≤2</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">≥8</td>
<td class="Rrule" align="center">≥17</td>
<td class="Rrule" align="center">14–16</td>
<td class="Rrule" align="center">≤13</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Italics">Enterococcus faecalis</span></td>
<td class="Rrule" align="center">≤2</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">≥8</td>
<td class="Rrule" align="center">≥17</td>
<td class="Rrule" align="center">14–16</td>
<td class="Rrule" align="center">≤13</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Methicillin-susceptible<br><span class="Italics">  Staphylococcus</span> species</td>
<td class="Rrule" align="center">≤2</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">≥8</td>
<td class="Rrule" align="center">≥17</td>
<td class="Rrule" align="center">14–16</td>
<td class="Rrule" align="center">≤13</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Italics">Pseudomonas aeruginosa</span></td>
<td class="Rrule" align="center">≤2</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">≥8</td>
<td class="Rrule" align="center">≥17</td>
<td class="Rrule" align="center">14–16</td>
<td class="Rrule" align="center">≤13</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Italics">Haemophilus influenzae</span></td>
<td class="Rrule" align="center">≤2<a name="footnote-reference-34" href="#footnote-34" class="Sup">*</a>
</td>
<td class="Rrule" align="center">--<a name="footnote-reference-35" href="#footnote-35" class="Sup">†</a>
</td>
<td class="Rrule" align="center">--<a href="#footnote-35" class="Sup">†</a>
</td>
<td class="Rrule" align="center">≥17<a name="footnote-reference-36" href="#footnote-36" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">--<a href="#footnote-35" class="Sup">†</a>
</td>
<td class="Rrule" align="center">--<a href="#footnote-35" class="Sup">†</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Italics">Haemophilus parainfluenzae</span></td>
<td class="Rrule" align="center">≤2<a href="#footnote-34" class="Sup">*</a>
</td>
<td class="Rrule" align="center">--<a href="#footnote-35" class="Sup">†</a>
</td>
<td class="Rrule" align="center">--<a href="#footnote-35" class="Sup">†</a>
</td>
<td class="Rrule" align="center">≥17<a href="#footnote-36" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">--<a href="#footnote-35" class="Sup">†</a>
</td>
<td class="Rrule" align="center">--<a href="#footnote-35" class="Sup">†</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Italics">Streptococcus pneumoniae</span></td>
<td class="Rrule" align="center">≤2<a name="footnote-reference-37" href="#footnote-37" class="Sup">§</a>
</td>
<td class="Rrule" align="center">4<a href="#footnote-37" class="Sup">§</a>
</td>
<td class="Rrule" align="center">≥8<a href="#footnote-37" class="Sup">§</a>
</td>
<td class="Rrule" align="center">≥17<a name="footnote-reference-38" href="#footnote-38" class="Sup">¶</a>
</td>
<td class="Rrule" align="center">14–16<a href="#footnote-38" class="Sup">¶</a>
</td>
<td class="Rrule" align="center">≤13<a href="#footnote-38" class="Sup">¶</a>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="Italics">Streptococcus pyogenes</span></td>
<td class="Rrule" align="center">≤2</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">≥8</td>
<td class="Rrule" align="center">≥17</td>
<td class="Rrule" align="center">14–16</td>
<td class="Rrule" align="center">≤13</td>
</tr>
</tbody>
</table>
<p>A report of<span class="Italics"> Susceptible </span>indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of<span class="Italics"> Intermediate </span>indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where a high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of<span class="Italics"> Resistant </span>indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.4.3"></a><p></p>
<ul class="Disc"><li><span class="Bold">Quality Control:</span></li></ul>
<p class="First">Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures. For dilution technique, standard levofloxacin powder should give the MIC values provided in Table 12. For diffusion technique, the 5 mcg levofloxacin disk should provide zone diameters provided in Table 12. </p>
<a name="i3b2850a4-7e74-478a-8768-d51fdd55e25c"></a><table width="90%">
<caption><span>Table 12: Quality Control for Susceptibility Testing</span></caption>
<col align="left" valign="top" width="30%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="23%">
<col align="center" valign="top" width="27%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Microorganism</th>
<th class="Rrule" align="center">Microorganism<br> QC Number</th>
<th class="Rrule" align="center">MIC (mcg/mL)</th>
<th class="Rrule" align="center">Disk Diffusion<br> (zone diameter in mm)</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-39" href="#footnote-reference-39">*</a></dt>
<dd>Careful maintenance of this organism is required as the <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> may lose its plasmid.</dd>
<dt><a name="footnote-40" href="#footnote-reference-40">†</a></dt>
<dd>This quality control range is applicable to only<span class="Italics"> H. influenzae</span> ATCC 49247 tested by a broth microdilution procedure using Haemophilus Test Medium (HTM).<span class="Sup">1</span>
</dd>
<dt><a name="footnote-41" href="#footnote-reference-41">‡</a></dt>
<dd>This quality control range is applicable to only <span class="Italics">H. influenzae</span> ATCC 49247 tested by a disk diffusion procedure using Haemophilus Test Medium (HTM).<span class="Sup">2</span>
</dd>
<dt><a name="footnote-42" href="#footnote-reference-42">§</a></dt>
<dd>This quality control range is applicable to only<span class="Italics"> S. pneumoniae</span> ATCC 49619 tested by a broth microdilution procedure using cation-adjusted Mueller-Hinton broth with 2–5% lysed horse blood.</dd>
<dt><a name="footnote-43" href="#footnote-reference-43">¶</a></dt>
<dd>This quality control range is applicable to only<span class="Italics"> S. pneumoniae</span> ATCC 49619 tested by a disk diffusion procedure using Mueller-Hinton agar supplemented with 5% sheep blood and incubated in 5% CO<span class="Sub">2</span>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Italics">Enterococcus faecalis</span></td>
<td class="Rrule" align="center">ATCC 29212</td>
<td class="Rrule" align="center">0.25 – 2</td>
<td class="Rrule" align="center">--</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Italics">Escherichia coli</span></td>
<td class="Rrule" align="center">ATCC 25922</td>
<td class="Rrule" align="center">0.008 – 0.06</td>
<td class="Rrule" align="center">29 – 37</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Italics">Escherichia coli</span><a name="footnote-reference-39" href="#footnote-39" class="Sup">*</a>
</td>
<td class="Rrule" align="center">ATCC 35218</td>
<td class="Rrule" align="center">0.015 – 0.06</td>
<td class="Rrule" align="center">--</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Italics">Haemophilus influenzae</span></td>
<td class="Rrule" align="center">ATCC 49247</td>
<td class="Rrule" align="center">0.008 – 0.03<a name="footnote-reference-40" href="#footnote-40" class="Sup">†</a>
</td>
<td class="Rrule" align="center">32 – 40<a name="footnote-reference-41" href="#footnote-41" class="Sup">‡</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Italics">Pseudomonas aeruginosa</span></td>
<td class="Rrule" align="center">ATCC 27853</td>
<td class="Rrule" align="center">0.5 – 4</td>
<td class="Rrule" align="center">19 – 26</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Italics">Staphylococcus aureus</span></td>
<td class="Rrule" align="center">ATCC 29213</td>
<td class="Rrule" align="center">0.06 – 0.5</td>
<td class="Rrule" align="center">--</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Italics">Staphylococcus aureus</span></td>
<td class="Rrule" align="center">ATCC 25923</td>
<td class="Rrule" align="center">--</td>
<td class="Rrule" align="center">25 – 30</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="Italics">Streptococcus pneumoniae</span></td>
<td class="Rrule" align="center">ATCC 49619</td>
<td class="Rrule" align="center">0.5 – 2<a name="footnote-reference-42" href="#footnote-42" class="Sup">§</a>
</td>
<td class="Rrule" align="center">20 – 25<a name="footnote-reference-43" href="#footnote-43" class="Sup">¶</a>
</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In a lifetime bioassay in rats, levofloxacin exhibited no carcinogenic potential following daily dietary administration for 2 years; the highest dose (100 mg/kg/day) was 1.4 times the highest recommended human dose (750 mg) based upon relative body surface area. Levofloxacin did not shorten the time to tumor development of UV-induced <span class="product-label-link" type="condition" conceptid="135777" conceptname="Neoplasm of uncertain behavior of skin">skin tumors</span> in hairless albino (Skh-1) mice at any levofloxacin dose level and was therefore not photo-carcinogenic under conditions of this study. Dermal levofloxacin concentrations in the hairless mice ranged from 25 to 42 mcg/g at the highest levofloxacin dose level (300 mg/kg/day) used in the photo-carcinogenicity study. By comparison, dermal levofloxacin concentrations in human subjects receiving 750 mg of LEVAQUIN<span class="Sup">®</span> averaged approximately 11.8 mcg/g at C<span class="Sub">max</span>.</p>
<p>Levofloxacin was not mutagenic in the following assays: Ames bacterial mutation assay (<span class="Italics">S. typhimurium </span>and<span class="Italics"> E. coli)</span>, CHO/HGPRT forward mutation assay, mouse micronucleus test, mouse dominant lethal test, rat unscheduled DNA synthesis assay, and the mouse sister chromatid exchange assay. It was positive in the in vitro chromosomal aberration (CHL cell line) and sister chromatid exchange (CHL/IU cell line) assays.</p>
<p>Levofloxacin caused no impairment of fertility or reproductive performance in rats at oral doses as high as 360 mg/kg/day, corresponding to 4.2 times the highest recommended human dose based upon relative body surface area and intravenous doses as high as 100 mg/kg/day, corresponding to 1.2 times the highest recommended human dose based upon relative body surface area.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="S13.2"></a><a name="section-13.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First">Levofloxacin and other quinolones have been shown to cause <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> in immature animals of most species tested<span class="Italics"> [see<a href="#S5.10"> Warnings and Precautions (5.10)</a>]. </span>In immature dogs (4–5 months old), oral doses of 10 mg/kg/day for 7 days and intravenous doses of 4 mg/kg/day for 14 days of levofloxacin resulted in arthropathic lesions. Administration at oral doses of 300 mg/kg/day for 7 days and intravenous doses of 60 mg/kg/day for 4 weeks produced <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> in juvenile rats. Three-month old beagle dogs dosed orally with levofloxacin at 40 mg/kg/day exhibited clinically severe arthrotoxicity resulting in the termination of dosing at Day 8 of a 14-day dosing routine. Slight musculoskeletal clinical effects, in the absence of gross pathological or histopathological effects, resulted from the lowest dose level of 2.5 mg/kg/day (approximately 0.2-fold the pediatric dose based upon AUC comparisons). <span class="product-label-link" type="condition" conceptid="4168183" conceptname="Synovitis">Synovitis</span> and articular cartilage lesions were observed at the 10 and 40 mg/kg dose levels (approximately 0.7-fold and 2.4-fold the pediatric dose, respectively, based on AUC comparisons). Articular cartilage gross pathology and histopathology persisted to the end of the 18-week recovery period for those dogs from the 10 and 40 mg/kg/day dose levels.</p>
<p>When tested in a mouse ear <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> bioassay, levofloxacin exhibited <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">phototoxicity</span> similar in magnitude to ofloxacin, but less <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">phototoxicity</span> than other quinolones.</p>
<p>While <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span> has been observed in some intravenous rat studies, urinary crystals are not formed in the bladder, being present only after micturition and are not associated with <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>.</p>
<p>In mice, the CNS stimulatory effect of quinolones is enhanced by concomitant administration of non-steroidal anti-inflammatory drugs.</p>
<p>In dogs, levofloxacin administered at 6 mg/kg or higher by rapid intravenous injection produced hypotensive effects. These effects were considered to be related to histamine release.</p>
<p><span class="Italics">In vitro </span>and<span class="Italics"> in vivo </span>studies in animals indicate that levofloxacin is neither an enzyme inducer nor inhibitor in the human therapeutic plasma concentration range; therefore, no drug metabolizing enzyme-related interactions with other drugs or agents are anticipated.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-14.1"></a><p></p>
<h2>14.1 <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Nosocomial Pneumonia</span></h2>
<p class="First">Adult patients with clinically and radiologically documented <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">nosocomial pneumonia</span> were enrolled in a multicenter, randomized, open-label study comparing intravenous LEVAQUIN<span class="Sup">®</span> (750 mg once daily) followed by oral LEVAQUIN<span class="Sup">®</span> (750 mg once daily) for a total of 7–15 days to intravenous imipenem/cilastatin (500–1000 mg every 6–8 hours daily) followed by oral ciprofloxacin (750 mg every 12 hours daily) for a total of 7–15 days. LEVAQUIN<span class="Sup">®</span>-treated patients received an average of 7 days of intravenous therapy (range: 1–16 days); comparator-treated patients received an average of 8 days of intravenous therapy (range: 1–19 days).</p>
<p>Overall, in the clinically and microbiologically evaluable population, adjunctive therapy was empirically initiated at study entry in 56 of 93 (60.2%) patients in the LEVAQUIN<span class="Sup">®</span> arm and 53 of 94 (56.4%) patients in the comparator arm. The average duration of adjunctive therapy was 7 days in the LEVAQUIN<span class="Sup">®</span> arm and 7 days in the comparator. In clinically and microbiologically evaluable patients with documented<span class="Italics"> Pseudomonas aeruginosa </span><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, 15 of 17 (88.2%) received ceftazidime (N=11) or piperacillin/tazobactam (N=4) in the LEVAQUIN<span class="Sup">®</span> arm and 16 of 17 (94.1%) received an aminoglycoside in the comparator arm. Overall, in clinically and microbiologically evaluable patients, vancomycin was added to the treatment regimen of 37 of 93 (39.8%) patients in the LEVAQUIN<span class="Sup">®</span> arm and 28 of 94 (29.8%) patients in the comparator arm for suspected methicillin-resistant<span class="Italics"> S. aureus </span><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p>Clinical success rates in clinically and microbiologically evaluable patients at the posttherapy visit (primary study endpoint assessed on day 3–15 after completing therapy) were 58.1% for LEVAQUIN<span class="Sup">®</span> and 60.6% for comparator. The 95% CI for the difference of response rates (LEVAQUIN<span class="Sup">®</span> minus comparator) was [-17.2, 12.0]. The microbiological eradication rates at the posttherapy visit were 66.7% for LEVAQUIN<span class="Sup">®</span> and 60.6% for comparator. The 95% CI for the difference of eradication rates (LEVAQUIN<span class="Sup">®</span> minus comparator) was [-8.3, 20.3]. Clinical success and microbiological eradication rates by pathogen are detailed in Table 13.</p>
<a name="idb3bda29-b24e-4303-8987-78108bf36a30"></a><table width="100%">
<caption><span>Table 13: Clinical Success Rates and Microbiological Eradication Rates (<span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Nosocomial Pneumonia</span>)</span></caption>
<col align="left" valign="top" width="20%">
<col align="center" valign="top" width="5%">
<col align="center" valign="top" width="35%">
<col align="center" valign="top" width="5%">
<col align="center" valign="top" width="35%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Pathogen</th>
<th class="Rrule" align="center">N</th>
<th class="Rrule" align="center">LEVAQUIN<span class="Sup">®</span> No. (%) of <br> Patients Microbiologic/Clinical Outcomes</th>
<th class="Rrule" align="center">N</th>
<th class="Rrule" align="center">Imipenem/Cilastatin No. (%)<br> of Patients Microbiologic/Clinical Outcomes</th>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-44" href="#footnote-reference-44">*</a></dt>
<dd>Methicillin-susceptible <span class="Italics">S. aureus</span>
</dd>
<dt><a name="footnote-45" href="#footnote-reference-45">†</a></dt>
<dd>See above text for use of combination therapy</dd>
<dt><a name="footnote-46" href="#footnote-reference-46">‡</a></dt>
<dd>The observed differences in rates for the clinical and microbiological outcomes may reflect other factors that were not accounted for in the study</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">MSSA<a name="footnote-reference-44" href="#footnote-44" class="Sup">*</a>
</td>
<td class="Rrule" align="center">21</td>
<td class="Rrule" align="center">14 (66.7)/13 (61.9)</td>
<td class="Rrule" align="center">19</td>
<td class="Rrule" align="center">13 (68.4)/15 (78.9)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Italics">P. aeruginosa</span><a name="footnote-reference-45" href="#footnote-45" class="Sup">†</a>
</td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center">10 (58.8)/11 (64.7)</td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center">5 (29.4)/7 (41.2)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Italics">S. marcescens  </span></td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">9 (81.8)/7 (63.6)</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">2 (28.6)/3 (42.9)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Italics">E. coli  </span></td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">10 (83.3)/7 (58.3)</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">7 (63.6 )/8 (72.7)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Italics">K. pneumoniae</span><a name="footnote-reference-46" href="#footnote-46" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">9 (81.8)/5 (45.5)</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">6 (85.7)/3 (42.9)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Italics">H. influenzae  </span></td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">13 (81.3)/10 (62.5)</td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">14 (93.3)/11 (73.3)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="Italics">S. pneumoniae  </span></td>
<td class="Rrule" align="center">4 </td>
<td class="Rrule" align="center">3 (75.0)/3 (75.0)</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">5 (71.4)/4 (57.1)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.2"></a><a name="section-14.2"></a><p></p>
<h2>14.2 Community-Acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span>: 7–14 day Treatment Regimen</h2>
<p class="First">Adult inpatients and outpatients with a diagnosis of community-acquired bacterial <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> were evaluated in 2 pivotal clinical studies. In the first study, 590 patients were enrolled in a prospective, multi-center, unblinded randomized trial comparing LEVAQUIN<span class="Sup">®</span> 500 mg once daily orally or intravenously for 7 to 14 days to ceftriaxone 1 to 2 grams intravenously once or in equally divided doses twice daily followed by cefuroxime axetil 500 mg orally twice daily for a total of 7 to 14 days. Patients assigned to treatment with the control regimen were allowed to receive erythromycin (or doxycycline if intolerant of erythromycin) if an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> due to atypical pathogens was suspected or proven. Clinical and microbiologic evaluations were performed during treatment, 5 to 7 days posttherapy, and 3 to 4 weeks posttherapy. Clinical success (cure plus improvement) with LEVAQUIN<span class="Sup">®</span> at 5 to 7 days posttherapy, the primary efficacy variable in this study, was superior (95%) to the control group (83%). The 95% CI for the difference of response rates (LEVAQUIN<span class="Sup">®</span> minus comparator) was [-6, 19]. In the second study, 264 patients were enrolled in a prospective, multi-center, non-comparative trial of 500 mg LEVAQUIN<span class="Sup">®</span> administered orally or intravenously once daily for 7 to 14 days. Clinical success for clinically evaluable patients was 93%. For both studies, the clinical success rate in patients with <span class="product-label-link" type="condition" conceptid="4050869" conceptname="Atypical pneumonia">atypical pneumonia</span> due to<span class="Italics"> Chlamydophila pneumoniae, Mycoplasma pneumoniae</span>, and<span class="Italics"> Legionella pneumophila </span>were 96%, 96%, and 70%, respectively. Microbiologic eradication rates across both studies are presented in Table 14.</p>
<a name="i71ff5b24-e562-4212-89e5-608a72fa430c"></a><table width="75%">
<caption><span>Table 14: Microbiologic Eradication Rates Across 2 <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Community Acquired Pneumonia</span> Clinical Studies</span></caption>
<col align="left" valign="middle" width="30%">
<col align="center" valign="middle" width="23%">
<col align="center" valign="middle" width="47%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Pathogen</th>
<th class="Rrule" align="left">No. Pathogens</th>
<th class="Rrule" align="left">Microbiologic Eradication Rate (%)</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Italics">H. influenzae</span></td>
<td class="Rrule" align="center">55</td>
<td class="Rrule" align="center">98</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Italics">S. pneumoniae</span></td>
<td class="Rrule" align="center">83</td>
<td class="Rrule" align="center">95</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Italics">S. aureus</span></td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center">88</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Italics">M. catarrhalis</span></td>
<td class="Rrule" align="center">18</td>
<td class="Rrule" align="center">94</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Italics">H. parainfluenzae</span></td>
<td class="Rrule" align="center">19</td>
<td class="Rrule" align="center">95</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="Italics">K. pneumoniae</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">100.0</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.2.1"></a><p></p>
<p class="First"><span class="Bold">Community-Acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span> Due to Multi-Drug Resistant<span class="Italics"> Streptococcus pneumoniae</span></span></p>
<p>LEVAQUIN<span class="Sup">®</span> was effective for the treatment of community-acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> caused by multi-drug resistant<span class="Italics"> Streptococcus pneumoniae </span>(MDRSP). MDRSP isolates are <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2<span class="Sup">nd</span> generation cephalosporins (e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole). Of 40 microbiologically evaluable patients with MDRSP isolates, 38 patients (95.0%) achieved clinical and bacteriologic success at post-therapy. The clinical and bacterial success rates are shown in Table 15.</p>
<a name="i1a645983-289b-4613-877d-c02f69c291b2"></a><table width="100%">
<caption><span>Table 15: Clinical and Bacterial Success Rates for LEVAQUIN<span class="Sup">®</span>-Treated MDRSP in <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Community Acquired Pneumonia</span> Patients (Population Valid for Efficacy)</span></caption>
<col align="left" valign="middle" width="48%">
<col align="center" valign="middle" width="13%">
<col align="center" valign="middle" width="13%">
<col align="center" valign="middle" width="13%">
<col align="center" valign="middle" width="13%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left">Screening Susceptibility</th>
<th class="Rrule" align="center" colspan="2">Clinical Success</th>
<th class="Rrule" align="center" colspan="2">Bacteriological Success<a name="footnote-reference-47" href="#footnote-47" class="Sup">*</a>
</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">n/N<a name="footnote-reference-48" href="#footnote-48" class="Sup">†</a>
</th>
<th class="Rrule" align="center">%</th>
<th class="Rrule" align="center">n/N<a name="footnote-reference-49" href="#footnote-49" class="Sup">‡</a>
</th>
<th class="Rrule" align="center">%</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-47" href="#footnote-reference-47">*</a></dt>
<dd>One patient had a respiratory isolate that was resistant to tetracycline, cefuroxime, macrolides and TMP/SMX and intermediate to penicillin and a blood isolate that was intermediate to penicillin and cefuroxime and resistant to the other classes. The patient is included in the database based on respiratory isolate.</dd>
<dt><a name="footnote-48" href="#footnote-reference-48">†</a></dt>
<dd>n=the number of microbiologically evaluable patients who were clinical successes; N=number of microbiologically evaluable patients in the designated resistance group.</dd>
<dt><a name="footnote-49" href="#footnote-reference-49">‡</a></dt>
<dd>n=the number of MDRSP isolates eradicated or presumed eradicated in microbiologically evaluable patients; N=number of MDRSP isolates in a designated resistance group.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">Penicillin-resistant  </span></td>
<td class="Rrule" align="center">16/17</td>
<td class="Rrule" align="center">94.1</td>
<td class="Rrule" align="center">16/17</td>
<td class="Rrule" align="center">94.1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">2nd generation Cephalosporin resistant</span></td>
<td class="Rrule" align="center">31/32</td>
<td class="Rrule" align="center">96.9</td>
<td class="Rrule" align="center">31/32</td>
<td class="Rrule" align="center">96.9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Macrolide-resistant  </span></td>
<td class="Rrule" align="center">28/29</td>
<td class="Rrule" align="center">96.6</td>
<td class="Rrule" align="center">28/29</td>
<td class="Rrule" align="center">96.6</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Trimethoprim/ Sulfamethoxazole resistant</span></td>
<td class="Rrule" align="center">17/19</td>
<td class="Rrule" align="center">89.5</td>
<td class="Rrule" align="center">17/19</td>
<td class="Rrule" align="center">89.5</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="Bold">Tetracycline-resistant  </span></td>
<td class="Rrule" align="center">12/12</td>
<td class="Rrule" align="center">100</td>
<td class="Rrule" align="center">12/12</td>
<td class="Rrule" align="center">100</td>
</tr>
</tbody>
</table>
<p>Not all isolates were resistant to all antimicrobial classes tested. Success and eradication rates are summarized in Table 16.</p>
<a name="ie8bc75af-0dcb-414a-856b-df43f92ceb3e"></a><table width="100%">
<caption><span>Table 16: Clinical Success and Bacteriologic Eradication Rates for Resistant Streptococcus pneumoniae (<span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Community Acquired Pneumonia</span>)</span></caption>
<col align="left" valign="middle" width="36%">
<col align="center" valign="middle" width="30%">
<col align="center" valign="middle" width="34%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Type of Resistance</th>
<th class="Rrule" align="left">Clinical Success</th>
<th class="Rrule" align="left">Bacteriologic Eradication</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Resistant to 2 antibacterials</td>
<td class="Rrule" align="center">17/18 (94.4%) </td>
<td class="Rrule" align="center">17/18 (94.4%) </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Resistant to 3 antibacterials</td>
<td class="Rrule" align="center">14/15 (93.3%)</td>
<td class="Rrule" align="center">14/15 (93.3%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Resistant to 4 antibacterials</td>
<td class="Rrule" align="center">7/7 (100%) </td>
<td class="Rrule" align="center">7/7 (100%) </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Resistant to 5 antibacterials</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">Bacteremia</span> with MDRSP </td>
<td class="Rrule" align="center">8/9 (89%)</td>
<td class="Rrule" align="center">8/9 (89%)</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.3"></a><a name="section-14.3"></a><p></p>
<h2>14.3 Community-Acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span>: 5-Day Treatment Regimen</h2>
<p class="First">To evaluate the safety and efficacy of the higher dose and shorter course of LEVAQUIN<span class="Sup">®</span>, 528 outpatient and hospitalized adults with clinically and radiologically determined mild to severe community-acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> were evaluated in a double-blind, randomized, prospective, multicenter study comparing LEVAQUIN<span class="Sup">®</span> 750 mg, IV or orally, every day for five days or LEVAQUIN<span class="Sup">®</span> 500 mg IV or orally, every day for 10 days.</p>
<p>Clinical success rates (cure plus improvement) in the clinically evaluable population were 90.9% in the LEVAQUIN<span class="Sup">®</span> 750 mg group and 91.1% in the LEVAQUIN<span class="Sup">®</span> 500 mg group. The 95% CI for the difference of response rates (LEVAQUIN<span class="Sup">®</span> 750 minus LEVAQUIN<span class="Sup">®</span> 500) was [-5.9, 5.4]. In the clinically evaluable population (31–38 days after enrollment) <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> was observed in 7 out of 151 patients in the LEVAQUIN<span class="Sup">®</span> 750 mg group and 2 out of 147 patients in the LEVAQUIN<span class="Sup">®</span> 500 mg group. Given the small numbers observed, the significance of this finding cannot be determined statistically. The microbiological efficacy of the 5-day regimen was documented for <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> listed in Table 17.</p>
<a name="id233f554-d27c-4a07-82f0-139c974c6f55"></a><table width="60%">
<caption><span>Table 17: Microbiological Eradication Rates (Community-Acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span>)</span></caption>
<col align="left" valign="middle" width="60%">
<col align="center" valign="middle" width="40%">
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Penicillin susceptible <span class="Italics">S. pneumoniae</span>
</td>
<td class="Rrule" align="center">19/20</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Italics">Haemophilus influenzae</span></td>
<td class="Rrule" align="center">12/12</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Italics">Haemophilus parainfluenzae</span></td>
<td class="Rrule" align="center">10/10</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Italics">Mycoplasma pneumoniae</span></td>
<td class="Rrule" align="center">26/27</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="Italics">Chlamydophila pneumoniae</span></td>
<td class="Rrule" align="center">13/15</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.4"></a><a name="section-14.4"></a><p></p>
<h2>14.4 Acute Bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span>: 5-day and 10–14 day Treatment Regimens</h2>
<p class="First">LEVAQUIN<span class="Sup">®</span> is approved for the treatment of acute bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span> (ABS) using either 750 mg by mouth × 5 days or 500 mg by mouth once daily × 10–14 days. To evaluate the safety and efficacy of a high dose short course of LEVAQUIN<span class="Sup">®</span>, 780 outpatient adults with clinically and radiologically determined acute bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span> were evaluated in a double-blind, randomized, prospective, multicenter study comparing LEVAQUIN<span class="Sup">®</span> 750 mg by mouth once daily for five days to LEVAQUIN<span class="Sup">®</span> 500 mg by mouth once daily for 10 days.</p>
<p>Clinical success rates (defined as complete or partial resolution of the pre-treatment signs and symptoms of ABS to such an extent that no further antibiotic treatment was deemed necessary) in the microbiologically evaluable population were 91.4% (139/152) in the LEVAQUIN<span class="Sup">®</span> 750 mg group and 88.6% (132/149) in the LEVAQUIN<span class="Sup">®</span> 500 mg group at the test-of-cure (TOC) visit (95% CI [-4.2, 10.0] for LEVAQUIN<span class="Sup">®</span> 750 mg minus LEVAQUIN<span class="Sup">®</span> 500 mg).</p>
<p>Rates of clinical success by pathogen in the microbiologically evaluable population who had specimens obtained by antral tap at study entry showed comparable results for the five- and ten-day regimens at the test-of-cure visit 22 days post treatment.</p>
<a name="iba9fa69c-8415-4d4d-89ad-05285349b430"></a><table width="100%">
<caption><span>Table 18: Clinical Success Rate by Pathogen at the TOC in Microbiologically Evaluable Subjects Who Underwent Antral Puncture (Acute Bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span>)</span></caption>
<col align="left" valign="middle" width="33%">
<col align="center" valign="middle" width="33%">
<col align="center" valign="middle" width="34%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Pathogen</th>
<th class="Rrule" align="left">LEVAQUIN<span class="Sup">®</span> 750 mg × 5 days</th>
<th class="Rrule" align="left">LEVAQUIN<span class="Sup">®</span> 500 mg × 10 days</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-50" href="#footnote-reference-50">*</a></dt>
<dd>Note: Forty percent of the subjects in this trial had specimens obtained by sinus endoscopy. The efficacy data for subjects whose specimen was obtained endoscopically were comparable to those presented in the above table.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">
<span class="Italics">Streptococcus pneumoniae</span><a name="footnote-reference-50" href="#footnote-50" class="Sup">*</a>
</td>
<td class="Rrule" align="center">25/27 (92.6%)</td>
<td class="Rrule" align="center">26/27 (96.3%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Italics">Haemophilus influenzae<a href="#footnote-50" class="Sup">*</a></span></td>
<td class="Rrule" align="center">19/21 (90.5%)</td>
<td class="Rrule" align="center">25/27 (92.6%)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="Italics">Moraxella catarrhalis<a href="#footnote-50" class="Sup">*</a></span></td>
<td class="Rrule" align="center">10/11 (90.9%)</td>
<td class="Rrule" align="center">13/13 (100%)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.5"></a><a name="section-14.5"></a><p></p>
<h2>14.5 Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">Three hundred ninety-nine patients were enrolled in an open-label, randomized, comparative study for complicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. The patients were randomized to receive either LEVAQUIN<span class="Sup">®</span> 750 mg once daily (IV followed by oral), or an approved comparator for a median of 10 ± 4.7 days. As is expected in complicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, surgical procedures were performed in the LEVAQUIN<span class="Sup">®</span> and comparator groups. Surgery (incision and drainage or debridement) was performed on 45% of the LEVAQUIN<span class="Sup">®</span>-treated patients and 44% of the comparator-treated patients, either shortly before or during antibiotic treatment and formed an integral part of therapy for this indication.</p>
<p>Among those who could be evaluated clinically 2–5 days after completion of study drug, overall success rates (improved or cured) were 116/138 (84.1%) for patients treated with LEVAQUIN<span class="Sup">®</span> and 106/132 (80.3%) for patients treated with the comparator.</p>
<p>Success rates varied with the type of diagnosis ranging from 68% in patients with infected <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> to 90% in patients with infected <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span> and <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscesses</span>. These rates were equivalent to those seen with comparator drugs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.6"></a><a name="section-14.6"></a><p></p>
<h2>14.6 Chronic Bacterial <span class="product-label-link" type="condition" conceptid="194997" conceptname="Prostatitis">Prostatitis</span></h2>
<p class="First">Adult patients with a clinical diagnosis of <span class="product-label-link" type="condition" conceptid="194997" conceptname="Prostatitis">prostatitis</span> and microbiological culture results from urine sample collected after prostatic massage (VB<span class="Sub">3</span>) or expressed prostatic secretion (EPS) specimens obtained via the Meares-Stamey procedure were enrolled in a multicenter, randomized, double-blind study comparing oral LEVAQUIN<span class="Sup">®</span> 500 mg, once daily for a total of 28 days to oral ciprofloxacin 500 mg, twice daily for a total of 28 days. The primary efficacy endpoint was microbiologic efficacy in microbiologically evaluable patients. A total of 136 and 125 microbiologically evaluable patients were enrolled in the LEVAQUIN<span class="Sup">®</span> and ciprofloxacin groups, respectively. The microbiologic eradication rate by patient <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> at 5–18 days after completion of therapy was 75.0% in the LEVAQUIN<span class="Sup">®</span> group and 76.8% in the ciprofloxacin group (95% CI [-12.58, 8.98] for LEVAQUIN<span class="Sup">®</span> minus ciprofloxacin). The overall eradication rates for pathogens of interest are presented in Table 19.</p>
<a name="ic1b80aa9-6cf0-4f9f-82d7-466c51c87eb0"></a><table width="100%">
<caption><span>Table 19: Microbiological Eradication Rates (Chronic Bacterial <span class="product-label-link" type="condition" conceptid="194997" conceptname="Prostatitis">Prostatitis</span>)</span></caption>
<col align="left" valign="middle" width="25%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="27%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="28%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="left" colspan="2">LEVAQUIN<span class="Sup">®</span> (N=136)</th>
<th class="Rrule" align="left" colspan="2">Ciprofloxacin (N=125)</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left">Pathogen</th>
<th class="Rrule" align="center">N</th>
<th class="Rrule" align="center">Eradication</th>
<th class="Rrule" align="center">N</th>
<th class="Rrule" align="center">Eradication</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-51" href="#footnote-reference-51">*</a></dt>
<dd>Eradication rates shown are for patients who had a sole pathogen only; mixed cultures were excluded.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Italics">E. coli  </span></td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">14 (93.3%)</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">9 (81.8%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Italics">E. faecalis  </span></td>
<td class="Rrule" align="center">54</td>
<td class="Rrule" align="center">39 (72.2%)</td>
<td class="Rrule" align="center">44</td>
<td class="Rrule" align="center">33 (75.0%)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">
<span class="Italics">S. epidermidis</span><a name="footnote-reference-51" href="#footnote-51" class="Sup">*</a>
</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">9 (81.8%)</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">11 (78.6%)</td>
</tr>
</tbody>
</table>
<p>Eradication rates for<span class="Italics"> S. epidermidis </span>when found with other co-pathogens are consistent with rates seen in pure isolates.</p>
<p>Clinical success (cure + improvement with no need for further antibiotic therapy) rates in microbiologically evaluable population 5–18 days after completion of therapy were 75.0% for LEVAQUIN<span class="Sup">®</span>-treated patients and 72.8% for ciprofloxacin-treated patients (95% CI [-8.87, 13.27] for LEVAQUIN<span class="Sup">®</span> minus ciprofloxacin). Clinical long-term success (24–45 days after completion of therapy) rates were 66.7% for the LEVAQUIN<span class="Sup">®</span>-treated patients and 76.9% for the ciprofloxacin-treated patients (95% CI [-23.40, 2.89] for LEVAQUIN<span class="Sup">®</span> minus ciprofloxacin).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.7"></a><a name="section-14.7"></a><p></p>
<h2>14.7 Complicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span> and <span class="product-label-link" type="condition" conceptid="4139915" conceptname="Acute pyelitis">Acute Pyelonephritis</span>: 5-day Treatment Regimen</h2>
<p class="First">To evaluate the safety and efficacy of the higher dose and shorter course of LEVAQUIN<span class="Sup">®</span>, 1109 patients with cUTI and AP were enrolled in a randomized, double-blind, multicenter clinical trial conducted in the US from November 2004 to April 2006 comparing LEVAQUIN<span class="Sup">®</span> 750 mg IV or orally once daily for 5 days (546 patients) with ciprofloxacin 400 mg IV or 500 mg orally twice daily for 10 days (563 patients). Patients with AP complicated by underlying <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal diseases</span> or conditions such as complete obstruction, surgery, transplantation, concurrent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or congenital malformation were excluded. Efficacy was measured by bacteriologic eradication of the baseline organism(s) at the post-therapy visit in patients with a pathogen identified at baseline. The post-therapy (test-of-cure) visit occurred 10 to 14 days after the last active dose of LEVAQUIN<span class="Sup">®</span> and 5 to 9 days after the last dose of active ciprofloxacin. </p>
<p>The bacteriologic cure rates overall for LEVAQUIN<span class="Sup">®</span> and control at the test-of-cure (TOC) visit for the group of all patients with a documented pathogen at baseline (modified intent to treat or mITT) and the group of patients in the mITT population who closely followed the protocol (Microbiologically Evaluable) are summarized in Table 20.</p>
<a name="i321bd600-a550-41d3-8151-3a7a795a4edd"></a><table width="100%">
<caption><span>Table 20: Bacteriologic Eradication at Test-of-Cure</span></caption>
<col align="left" valign="top" width="22%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="left" valign="top" width="30%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left"> </th>
<th class="Rrule" align="center" colspan="2">LEVAQUIN<span class="Sup">®</span> 750 mg orally or IV once daily for 5 days</th>
<th class="Rrule" align="center" colspan="2">Ciprofloxacin 400 mg IV/500 mg orally twice daily for 10 days</th>
<th class="Rrule" align="center">Overall Difference [95% CI]</th>
</tr>
<tr class="Botrule Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">n/N</th>
<th class="Rrule" align="center">%</th>
<th class="Rrule" align="center">n/N</th>
<th class="Rrule" align="center">%</th>
<th class="Rrule" align="center">LEVAQUIN<span class="Sup">®</span>-Ciprofloxacin</th>
</tr>
</thead>
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-52" href="#footnote-reference-52">*</a></dt>
<dd>The mITT population included patients who received study medication and who had a positive (≥10<span class="Sup">5</span> CFU/mL) urine culture with no more than 2 uropathogens at baseline. Patients with missing response were counted as failures in this analysis.</dd>
<dt><a name="footnote-53" href="#footnote-reference-53">†</a></dt>
<dd>The Microbiologically Evaluable population included patients with a confirmed diagnosis of cUTI or AP, a causative organism(s) at baseline present at ≥ 10<span class="Sup">5</span> CFU/mL, a valid test-of-cure urine culture, no pathogen isolated from blood resistant to study drug, no premature discontinuation or loss to follow-up, and compliance with treatment (among other criteria).</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="center" colspan="6">
<span class="Bold">mITT Population</span><a name="footnote-reference-52" href="#footnote-52" class="Sup">*</a>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Overall (cUTI or AP)</td>
<td class="Rrule" align="center">252/333</td>
<td class="Rrule" align="center">75.7</td>
<td class="Rrule" align="center">239/318</td>
<td class="Rrule" align="center">75.2</td>
<td class="Rrule" align="left">0.5 (-6.1, 7.1)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">cUTI</td>
<td class="Rrule" align="center">168/230</td>
<td class="Rrule" align="center">73.0</td>
<td class="Rrule" align="center">157/213</td>
<td class="Rrule" align="center">73.7</td>
<td class="Rrule" align="left"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">AP</td>
<td class="Rrule" align="center">84/103</td>
<td class="Rrule" align="center">81.6</td>
<td class="Rrule" align="center">82/105</td>
<td class="Rrule" align="center">78.1</td>
<td class="Rrule" align="left"></td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="6">
<span class="Bold">Microbiologically Evaluable Population</span><a name="footnote-reference-53" href="#footnote-53" class="Sup">†</a>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Overall (cUTI or AP)</td>
<td class="Rrule" align="center">228/265</td>
<td class="Rrule" align="center">86.0</td>
<td class="Rrule" align="center">215/241</td>
<td class="Rrule" align="center">89.2</td>
<td class="Rrule" align="left">-3.2 [-8.9, 2.5]</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">cUTI</td>
<td class="Rrule" align="center">154/185</td>
<td class="Rrule" align="center">83.2</td>
<td class="Rrule" align="center">144/165</td>
<td class="Rrule" align="center">87.3</td>
<td class="Rrule" align="left"></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">AP</td>
<td class="Rrule" align="center">74/80</td>
<td class="Rrule" align="center">92.5</td>
<td class="Rrule" align="center">71/76</td>
<td class="Rrule" align="center">93.4</td>
<td class="Rrule" align="left"></td>
</tr>
</tbody>
</table>
<p>Microbiologic eradication rates in the Microbiologically Evaluable population at TOC for individual pathogens recovered from patients randomized to LEVAQUIN<span class="Sup">®</span> treatment are presented in Table 21.</p>
<a name="ia5b3bfa7-5663-41c4-83ed-4a1155c7b9f1"></a><table width="75%">
<caption><span>Table 21: Microbiological Eradication Rates for Individual Pathogens Recovered From Patients Randomized to LEVAQUIN<span class="Sup">®</span> 750 mg QD for 5 Days Treatment</span></caption>
<col align="left" valign="top" width="30%">
<col align="center" valign="top" width="45%">
<col align="center" valign="top" width="25%">
<thead><tr class="Botrule First Last">
<th class="Lrule Rrule Toprule" align="left" valign="middle">Pathogen</th>
<th class="Rrule Toprule" align="center">Microbiologic Eradication Rate<br>(n/N)</th>
<th class="Rrule Toprule" align="center" valign="middle">%</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-54" href="#footnote-reference-54">*</a></dt>
<dd>The predominant organism isolated from patients with AP was <span class="Italics">E. coli</span>: 91% (63/69) eradication in AP and 89% (92/103) in patients with cUTI.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">
<span class="Italics">Escherichia coli</span><a name="footnote-reference-54" href="#footnote-54" class="Sup">*</a>
</td>
<td class="Rrule" align="center">155/172</td>
<td class="Rrule" align="center">90</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Italics">Klebsiella pneumoniae</span></td>
<td class="Rrule" align="center">20/23</td>
<td class="Rrule" align="center">87</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="Italics">Proteus mirabilis</span></td>
<td class="Rrule" align="center">12/12</td>
<td class="Rrule" align="center">100</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.8"></a><a name="section-14.8"></a><p></p>
<h2>14.8 Complicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span> and <span class="product-label-link" type="condition" conceptid="4139915" conceptname="Acute pyelitis">Acute Pyelonephritis</span>: 10-day Treatment Regimen</h2>
<p class="First">To evaluate the safety and efficacy of the 250 mg dose, 10 day regimen of LEVAQUIN<span class="Sup">®</span>, 567 patients with uncomplicated UTI, mild-to-moderate cUTI, and mild-to-moderate AP were enrolled in a randomized, double-blind, multicenter clinical trial conducted in the US from June 1993 to January 1995 comparing LEVAQUIN<span class="Sup">®</span> 250 mg orally once daily for 10 days (285 patients) with ciprofloxacin 500 mg orally twice daily for 10 days (282 patients). Patients with a resistant pathogen, recurrent UTI, women over age 55 years, and with an indwelling catheter were initially excluded, prior to protocol amendment which took place after 30% of enrollment. Microbiological efficacy was measured by bacteriologic eradication of the baseline organism(s) at 1–12 days post-therapy in patients with a pathogen identified at baseline.</p>
<p>The bacteriologic cure rates overall for LEVAQUIN<span class="Sup">®</span> and control at the test-of-cure (TOC) visit for the group of all patients with a documented pathogen at baseline (modified intent to treat or mITT) and the group of patients in the mITT population who closely followed the protocol (Microbiologically Evaluable) are summarized in Table 22.</p>
<a name="i0c519d23-18b5-4e1e-8050-6cf8883a93c9"></a><table>
<caption><span>Table 22: Bacteriologic Eradication Overall (cUTI or AP) at Test-Of-Cure<a name="footnote-reference-55" href="#footnote-55" class="Sup">*</a></span></caption>
<col align="left" valign="top" width="39%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="16%">
<thead>
<tr class="Botrule First">
<th class="Lrule Toprule" align="left"> </th>
<th class="Lrule Toprule" align="center" colspan="2">LEVAQUIN<span class="Sup">®</span><br>250 mg once daily for 10 days</th>
<th class="Lrule Rrule Toprule" align="center" colspan="2">Ciprofloxacin<br>500 mg twice daily for 10 days</th>
</tr>
<tr class="Last">
<th class="Lrule" align="left"> </th>
<th class="Lrule" align="center">n/N</th>
<th class="Lrule" align="center">%</th>
<th class="Lrule" align="center">n/N</th>
<th class="Lrule Rrule" align="center">%</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-55" href="#footnote-reference-55">*</a></dt>
<dd>1–9 days posttherapy for 30% of subjects enrolled prior to a protocol amendment; 5–12 days posttherapy for 70% of subjects.</dd>
<dt><a name="footnote-56" href="#footnote-reference-56">†</a></dt>
<dd>The mITT population included patients who had a pathogen isolated at baseline. Patients with missing response were counted as failures in this analysis.</dd>
<dt><a name="footnote-57" href="#footnote-reference-57">‡</a></dt>
<dd>The Microbiologically Evaluable population included mITT patients who met protocol-specified evaluability criteria.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="left"><span class="Bold">mITT Population<a name="footnote-reference-56" href="#footnote-56" class="Sup">†</a></span></td>
<td class="Lrule" align="center">174/209</td>
<td class="Lrule" align="center">83.3</td>
<td class="Lrule" align="center">184/219</td>
<td class="Lrule Rrule" align="center">84.0</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left"><span class="Bold">Microbiologically Evaluable Population<a name="footnote-reference-57" href="#footnote-57" class="Sup">‡</a></span></td>
<td class="Lrule" align="center" valign="middle">164/177</td>
<td class="Lrule" align="center" valign="middle">92.7</td>
<td class="Lrule" align="center" valign="middle">159/171</td>
<td class="Lrule Rrule" align="center" valign="middle">93.0</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.9"></a><a name="section-14.9"></a><p></p>
<h2>14.9 Inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">Anthrax</span> (Post-Exposure)</h2>
<p class="First">The effectiveness of LEVAQUIN<span class="Sup">®</span> for this indication is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. LEVAQUIN<span class="Sup">®</span> has not been tested in humans for the post-exposure prevention of inhalation <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span>. The mean plasma concentrations of LEVAQUIN<span class="Sup">®</span> associated with a statistically significant improvement in survival over placebo in the rhesus monkey model of inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> are reached or exceeded in adult and pediatric patients receiving the recommended oral and intravenous dosage regimens<span class="Italics"> [see<a href="#S1.13"> Indications and Usage (1.13)</a>;<a href="#S2.1"> Dosage and Administration (2.1</a>,<a href="#S2.2"> 2.2)</a>].</span></p>
<p>Levofloxacin pharmacokinetics have been evaluated in adult and pediatric patients. The mean (± SD) steady state peak plasma concentration in human adults receiving 500 mg orally or intravenously once daily is 5.7 ± 1.4 and 6.4 ± 0.8 mcg/mL, respectively; and the corresponding total plasma exposure (AUC<span class="Sub">0–24</span>) is 47.5 ± 6.7 and 54.6 ± 11.1 mcg.h/mL, respectively. The predicted steady-state pharmacokinetic parameters in pediatric patients ranging in age from 6 months to 17 years receiving 8 mg/kg orally every 12 hours (not to exceed 250 mg per dose) were calculated to be comparable to those observed in adults receiving 500 mg orally once daily<span class="Italics"> [see<a href="#S12.3"> Clinical Pharmacology (12.3)</a>].</span></p>
<p>In adults, the safety of LEVAQUIN<span class="Sup">®</span> for treatment durations of up to 28 days is well characterized. However, information pertaining to extended use at 500 mg daily up to 60 days is limited. Prolonged LEVAQUIN<span class="Sup">®</span> therapy in adults should only be used when the benefit outweighs the risk.</p>
<p>In pediatric patients, the safety of levofloxacin for treatment durations of more than 14 days has not been studied. An increased incidence of musculoskeletal adverse events (<span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, tendinopathy, gait abnormality) compared to controls has been observed in clinical studies with treatment duration of up to 14 days. Long-term safety data, including effects on cartilage, following the administration of levofloxacin to pediatric patients is limited<span class="Italics"> [see<a href="#S5.10"> Warnings and Precautions (5.10)</a>,<a href="#S8.4"> Use in Specific Populations (8.4)</a>]</span>.</p>
<p>A placebo-controlled animal study in rhesus monkeys exposed to an inhaled mean dose of 49 LD<span class="Sub">50</span> (~2.7 × 10<span class="Sup">6</span>) spores (range 17 – 118 LD<span class="Sub">50</span>) of<span class="Italics"> B. anthracis </span>(Ames <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span>) was conducted. The minimal inhibitory concentration (MIC) of levofloxacin for the <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> used in this study was 0.125 mcg/mL. In the animals studied, mean plasma concentrations of levofloxacin achieved at expected T<span class="Sub">max</span> (1 hour post-dose) following oral dosing to steady state ranged from 2.79 to 4.87 mcg/mL. Steady state trough concentrations at 24 hours post-dose ranged from 0.107 to 0.164 mcg/mL. Mean (SD) steady state AUC<span class="Sub">0–24</span> was 33.4 ± 3.2 mcg.h/mL (range 30.4 to 36.0 mcg.h/mL). Mortality due to <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> for animals that received a 30 day regimen of oral LEVAQUIN<span class="Sup">®</span> beginning 24 hrs post exposure was significantly lower (1/10), compared to the placebo group (9/10) [P=0.0011, 2-sided Fisher's Exact Test]. The one levofloxacin treated animal that died of <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> did so following the 30-day drug administration period.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="S15"></a><a name="section-15"></a><p></p>
<h1>15 REFERENCES</h1>
<ol class="Arabic">
<li>Clinical and Laboratory Standards Institute. <span class="Underline">Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically</span>. Approved Standard – Eighth Edition. Clinical and Laboratory Standards Institute document M7-A8, Vol. 29, No. 2, CLSI, Wayne, PA, January 2009.</li>
<li>Clinical and Laboratory Standards Institute. <span class="Underline">Performance Standards for Antimicrobial Disk Susceptibility Tests</span>. Approved Standard – Tenth Edition. Clinical and Laboratory Standards Institute document M2-A10, Vol. 29, No. 1, CLSI, Wayne, PA, January 2009. </li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-16"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S16.1"></a><a name="section-16.1"></a><p></p>
<h2>16.1 LEVAQUIN<span class="Sup">®</span> Tablets</h2>
<p class="First">LEVAQUIN<span class="Sup">®</span> Tablets are supplied as 250, 500, and 750 mg capsule-shaped, coated tablets. LEVAQUIN<span class="Sup">®</span> Tablets are packaged in bottles and in unit-dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> strips in the following configurations:</p>
<ul class="Disc"><li>500 mg tablets are terra cotta pink and are imprinted: "LEVAQUIN" on one side and "250" on the other side <dl>
<dt>–</dt>
<dd>bottles of 5 (NDC 67296-0586-1)</dd>
</dl>
</li></ul>
<p>LEVAQUIN<span class="Sup">®</span> Tablets should be stored at 15° to 30°C (59° to 86°F) in well-closed containers.</p>
<p>LEVAQUIN<span class="Sup">®</span> Tablets are manufactured for PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., Raritan, NJ 08869 by Janssen Ortho LLC, Gurabo, Puerto Rico 00778.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S16.2"></a><a name="section-16.2"></a><p></p>
<h2>16.2 LEVAQUIN® Oral Solution</h2>
<p class="First">LEVAQUIN<span class="Sup">®</span> Oral Solution is supplied in a 16 oz. multi-use bottle (NDC 50458-170-01). Each bottle contains 480 mL of the 25 mg/mL levofloxacin oral solution.</p>
<p>LEVAQUIN<span class="Sup">®</span> Oral Solution should be stored at 25°C (77°F); excursions permitted to 15° – 30°C (59° to 86°F) [refer to USP controlled room temperature].</p>
<p>LEVAQUIN<span class="Sup">®</span> Oral Solution is manufactured for PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., Raritan, NJ 08869 by Janssen Pharmaceutica N.V., Beerse, Belgium.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S16.3"></a><a name="section-16.3"></a><p></p>
<h2>16.3 LEVAQUIN® Injection, Single-Use Vials</h2>
<p class="First">LEVAQUIN<span class="Sup">®</span> Injection is supplied in single-use vials. Each vial contains a concentrated solution with the equivalent of 500 mg of levofloxacin in 20 mL vials and 750 mg of levofloxacin in 30 mL vials.</p>
<ul class="Disc">
<li>25 mg/mL, 20 mL vials (NDC 50458-164-20)</li>
<li>25 mg/mL, 30 mL vials (NDC 50458-165-30)</li>
</ul>
<p>LEVAQUIN<span class="Sup">®</span> Injection in Single-Use Vials should be stored at controlled room temperature and protected from light.</p>
<p>LEVAQUIN<span class="Sup">®</span> Injection in Single-Use Vials is manufactured for Ortho-McNeil, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., Raritan, NJ 08869 by Janssen Pharmaceutica N.V., Beerse, Belgium.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S16.4"></a><a name="section-16.4"></a><p></p>
<h2>16.4 LEVAQUIN® Injection Pre-Mixed Solution, Single-Use in Flexible Container</h2>
<p class="First">LEVAQUIN<span class="Sup">®</span> (levofloxacin in 5% dextrose) Injection is supplied as a single-use, premixed solution in flexible containers. Each bag contains a dilute solution with the equivalent of 250, 500, or 750 mg of levofloxacin, respectively, in 5% Dextrose (D5W).</p>
<ul class="Disc">
<li>5 mg/mL (250 mg), 100 mL flexible container, 50 mL fill (NDC 50458-167-01)</li>
<li>5 mg/mL (500 mg), 100 mL flexible container, 100 mL fill (NDC 50458-168-01)</li>
<li>5 mg/mL (750 mg), 150 mL flexible container, 150 mL fill (NDC 50458-166-01)</li>
</ul>
<p>LEVAQUIN<span class="Sup">®</span> Injection Premix in Flexible Containers should be stored at or below 25°C (77°F); however, brief exposure up to 40°C (104°F) does not adversely affect the product. Avoid excessive heat and protect from freezing and light. LEVAQUIN<span class="Sup">®</span> Injection Premix in Flexible Containers is manufactured for Ortho-McNeil, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., Raritan, NJ 08869 by Hospira, Inc., Austin, TX 78728.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-17"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See<span class="Italics"><a href="#S17.5"> FDA-Approved Medication Guide (17.5)</a></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.1"></a><a name="section-17.1"></a><p></p>
<h2>17.1 Antibacterial Resistance</h2>
<p class="First">Antibacterial drugs including LEVAQUIN<span class="Sup">®</span> should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When LEVAQUIN<span class="Sup">®</span> is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by LEVAQUIN<span class="Sup">®</span> or other antibacterial drugs in the future.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.2"></a><a name="section-17.2"></a><p></p>
<h2>17.2 Administration with Food, Fluids, and Concomitant Medications</h2>
<p class="First">Patients should be informed that LEVAQUIN<span class="Sup">®</span> Tablets may be taken with or without food. LEVAQUIN<span class="Sup">®</span> Oral Solution should be taken 1 hour before or 2 hours after eating. The tablet and oral solution should be taken at the same time each day.</p>
<p>Patients should drink fluids liberally while taking LEVAQUIN<span class="Sup">®</span> to avoid formation of a highly concentrated urine and crystal formation in the urine.</p>
<p>Antacids containing magnesium, or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc or didanosine should be taken at least two hours before or two hours after oral LEVAQUIN<span class="Sup">®</span> administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.3"></a><a name="section-17.3"></a><p></p>
<h2>17.3 Serious and Potentially Serious Adverse Reactions</h2>
<p class="First">Patients should be informed of the following serious adverse reactions that have been associated with LEVAQUIN<span class="Sup">®</span> or other fluoroquinolone use:</p>
<ul class="Disc">
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="442264" conceptname="Disorder of tendon">Tendon Disorders</span>: </span>Patients should contact their healthcare provider if they experience <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, or <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of a tendon, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or inability to use one of their joints; rest and refrain from exercise; and discontinue LEVAQUIN<span class="Sup">®</span> treatment. The risk of severe <span class="product-label-link" type="condition" conceptid="442264" conceptname="Disorder of tendon">tendon disorders</span> with fluoroquinolones is higher in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants.</li>
<li>
<span class="Bold">Exacerbation of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">Myasthenia Gravis</span>: </span>Patients should inform their physician of any history of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. Patients should notify their physician if they experience any symptoms of <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, including respiratory difficulties. </li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>: </span>Patients should be informed that LEVAQUIN<span class="Sup">®</span> can cause <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, even following the first dose. Patients should discontinue the drug at the first sign of a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span> or other <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, a rapid heartbeat, difficulty in swallowing or breathing, any <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> suggesting <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> (e.g., <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the lips, tongue, face, tightness of the throat, <span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">hoarseness</span>), or other symptoms of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>.</li>
<li>
<span class="Bold">Hepatotoxicity: </span>Severe hepatotoxicity (including acute <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and fatal events) has been reported in patients taking LEVAQUIN<span class="Sup">®</span>. Patients should inform their physician and be instructed to discontinue LEVAQUIN<span class="Sup">®</span> treatment immediately if they experience any signs or symptoms of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> including: loss of appetite, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, right upper quadrant <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, yellowing of the skin and eyes, light colored bowel movements or dark colored urine.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span>: </span><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> have been reported in patients taking fluoroquinolones, including LEVAQUIN<span class="Sup">®</span>. Patients should notify their physician before taking this drug if they have a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>.</li>
<li>
<span class="Bold">Neurologic Adverse Effects (e.g., <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>): </span>Patients should know how they react to LEVAQUIN<span class="Sup">®</span> before they operate an automobile or machinery or engage in other activities requiring mental alertness and coordination.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>: </span><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.</li>
<li>
<span class="Bold">Peripheral Neuropathies: </span>If symptoms of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> including <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, burning, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, and/or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> develop, patients should discontinue treatment and contact their physician.</li>
<li>
<span class="Bold">Prolongation of the QT Interval: </span>Patients should inform their physician of any personal or family history of QT prolongation or proarrhythmic conditions such as <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, or recent <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>; if they are taking any Class IA (quinidine, procainamide), or Class III (amiodarone, sotalol) antiarrhythmic agents. Patients should notify their physicians if they have any symptoms of prolongation of the QT interval, including prolonged heart <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span> or a <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">Musculoskeletal Disorders</span> in Pediatric Patients:</span> Parents should inform their child's physician if their child has a history of joint-related problems before taking this drug. Parents of pediatric patients should also notify their child's physician of any tendon or joint-related problems that occur during or following LEVAQUIN<span class="Sup">®</span> therapy<span class="Italics"> [see<a href="#S5.10"> Warnings and Precautions (5.10) </a>and<a href="#S8.4"> Use in Specific Populations (8.4)</a>].</span>
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span>/<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Phototoxicity</span>: </span>Patients should be advised that <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>/<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">phototoxicity</span> has been reported in patients receiving fluoroquinolone antibiotics. Patients should minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment) while taking fluoroquinolones. If patients need to be outdoors when taking fluoroquinolones, they should wear loose-fitting clothes that protect skin from sun exposure and discuss other sun protection measures with their physician. If a sunburn like reaction or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin eruption</span> occurs, patients should contact their physician.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.4"></a><a name="section-17.4"></a><p></p>
<h2>17.4 Drug Interactions with Insulin, Oral Hypoglycemic Agents, and Warfarin</h2>
<p class="First">Patients should be informed that if they are diabetic and are being treated with insulin or an oral hypoglycemic agent and a <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemic reaction</span> occurs, they should discontinue LEVAQUIN<span class="Sup">®</span> and consult a physician.</p>
<p>Patients should be informed that concurrent administration of warfarin and LEVAQUIN<span class="Sup">®</span> has been associated with increases of the International Normalized Ratio (INR) or <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time and clinical episodes of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Patients should notify their physician if they are taking warfarin, be monitored for evidence of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and also have their anticoagulation tests closely monitored while taking warfarin concomitantly.</p>
<p>Manufactured by:</p>
<ul class="Disc">
<li>Janssen Ortho LLC, Gurabo, Puerto Rico 00778 (for the Tablets).</li>
<li>Janssen Pharmaceutica N.V., Beerse, Belgium (for the Oral Solution and Injection, Single-Use Vials).</li>
<li>Hospira, Inc., Austin, TX 78728 (for the Injection Pre-Mixed Solution Single-Use in Flexible Container).</li>
</ul>
<p>Manufactured for:</p>
<ul class="Disc">
<li>PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., Raritan, NJ 08869 (for the Tablets and Oral Solution)</li>
<li>Ortho-McNeil, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., Raritan, NJ 08869 (for the Injection, Single-Use Vials and Injection Pre-Mixed Solution Single-Use in Flexible Container)</li>
</ul>
<p>©Ortho-McNeil-Janssen Pharmaceuticals, Inc.</p>
<p>Issued June 2011</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.5"></a><a name="section-17.5"></a><p></p>
<h2>17.5 FDA-Approved Medication Guide</h2>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="section-18"></a><p></p>
<p class="First"><span class="Bold">MEDICATION GUIDE<br>LEVAQUIN<span class="Sup">®</span> [Leave ah kwin]<br>(levofloxacin)<br>250 mg Tablets, 500 mg Tablets, and 750 mg Tablets<br>And<br>LEVAQUIN<span class="Sup">®</span> (levofloxacin) Oral Solution, 25 mg/mL<br>And<br>LEVAQUIN<span class="Sup">®</span> (levofloxacin) Injection, for Intravenous Use<br>And<br>LEVAQUIN<span class="Sup">®</span> (levofloxacin in 5% dextrose) Injection, for Intravenous Use</span></p>
<p>Read the Medication Guide that comes with LEVAQUIN<span class="Sup">®</span> before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or your treatment.</p>
<p><span class="Bold">What is the most important information I should know about LEVAQUIN<span class="Sup">®</span>?</span></p>
<p>LEVAQUIN<span class="Sup">®</span> belongs to a class of antibiotics called fluoroquinolones. LEVAQUIN<span class="Sup">®</span> can cause side effects that may be serious or even cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. If you get any of the following serious side effects, get medical help right away. Talk with your healthcare provider about whether you should continue to take LEVAQUIN<span class="Sup">®</span>.</p>
<ul>
<li>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">Tendon rupture</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the tendon (<span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span>).</span></p>
<ul class="Disc">
<li>Tendons are tough cords of tissue that connect muscles to bones.</li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, tears, and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of tendons including the back of the ankle (Achilles), shoulder, hand, or other tendon sites can happen in people of all ages who take fluoroquinolone antibiotics, including LEVAQUIN<span class="Sup">®</span>. The risk of getting tendon problems is higher if you:<ul class="Disc">
<li>are over 60 years of age</li>
<li>are taking steroids (corticosteroids)</li>
<li>have had a kidney, heart or lung transplant.</li>
</ul>
</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">Swelling</span> of the tendon (<span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span>) and <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> (breakage) have also happened in patients who take fluoroquinolones who do not have the above risk factors.</li>
<li>Other reasons for <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon ruptures</span> can include:<ul class="Disc">
<li>physical activity or exercise</li>
<li><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span></li>
<li>tendon problems in the past, such as in people with <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> (RA).</li>
</ul>
</li>
<li>Call your healthcare provider right away at the first sign of <span class="product-label-link" type="condition" conceptid="4068332" conceptname="Tenalgia">tendon pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>. Stop taking LEVAQUIN<span class="Sup">®</span> until <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span> or <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> has been ruled out by your healthcare provider. Avoid exercise and using the affected area. The most common area of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> is the Achilles tendon at the back of your ankle. This can also happen with other tendons. Talk to your healthcare provider about the risk of <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> with continued use of LEVAQUIN<span class="Sup">®</span>. You may need a different antibiotic that is not a fluoroquinolone to treat your <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</li>
<li><span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">Tendon rupture</span> can happen while you are taking or after you have finished taking LEVAQUIN<span class="Sup">®</span>. <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">Tendon ruptures</span> have happened up to several months after patients have finished taking their fluoroquinolone.</li>
<li>Get medical help right away if you get any of the following signs or symptoms of a <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span>:<ul class="Disc">
<li>hear or feel a snap or pop in a tendon area</li>
<li><span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> right after an injury in a tendon area</li>
<li>unable to move the affected area or bear weight</li>
</ul>
</li>
</ul>
</li>
<li>
<span class="Bold">Worsening of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> (a disease that causes <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>). </span>Fluoroquinolones like LEVAQUIN<span class="Sup">®</span> may cause worsening of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> symptoms, including <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> and breathing problems. Call your healthcare provider right away if you have any worsening <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> or breathing problems.</li>
</ul>
<p>See the section <span class="Bold">"<a href="#sideeffect">What are the possible side effects of LEVAQUIN</a><span class="Sup">®</span>?"</span> for more information about side effects.</p>
<p><span class="Bold">What is LEVAQUIN<span class="Sup">®</span>?</span></p>
<p>LEVAQUIN<span class="Sup">®</span> is a fluoroquinolone antibiotic medicine used in adults, 18 years or older, to treat certain <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by certain germs called bacteria.</p>
<p>Children have a higher chance of getting bone, joint, or tendon (musculoskeletal) problems such as <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> while taking LEVAQUIN<span class="Sup">®</span>.</p>
<p>In children 6 months and older who have breathed the <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> bacteria germ:</p>
<ul>
<li>LEVAQUIN<span class="Sup">®</span> is used to prevent <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> disease (inhalation <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span>).</li>
<li>It is not known if it is safe to use LEVAQUIN<span class="Sup">®</span> in children for more than 14 days.</li>
</ul>
<p>It is not known if LEVAQUIN<span class="Sup">®</span> is safe and works in children under the age of 6 months.</p>
<p>Sometimes <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> are caused by viruses rather than by bacteria. Examples include <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> in the sinuses and lungs, such as the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span> or flu. Antibiotics, including LEVAQUIN<span class="Sup">®</span>, do not kill viruses.</p>
<p>Call your healthcare provider if you think your condition is not getting better while you are taking LEVAQUIN<span class="Sup">®</span>.</p>
<p><span class="Bold">Who should not take LEVAQUIN<span class="Sup">®</span>?</span></p>
<p>Do not take LEVAQUIN<span class="Sup">®</span> if you have ever had a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to an antibiotic known as a fluoroquinolone, or if you are allergic to any of the ingredients in LEVAQUIN<span class="Sup">®</span>. Ask your healthcare provider if you are not sure. See the list of the ingredients in LEVAQUIN<span class="Sup">®</span> at the end of this Medication Guide.</p>
<p><span class="Bold">What should I tell my healthcare provider before taking LEVAQUIN<span class="Sup">®</span>?</span></p>
<p>See <span class="Bold">"<a href="#important">What is the most important information I should know about LEVAQUIN</a><span class="Sup">®</span>?"  </span></p>
<p><span class="Bold">Tell your healthcare provider about all your medical conditions, including if you:  </span></p>
<ul>
<li>have tendon problems</li>
<li>have a disease that causes <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> (<span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>)</li>
<li>have central nervous system problems (such as <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>)</li>
<li>have nerve problems</li>
<li>have or anyone in your family has an irregular heartbeat, especially a condition called "QT prolongation."</li>
<li>have low <span class="product-label-link" type="condition" conceptid="4107462" conceptname="k">blood potassium</span> (<span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>)</li>
<li>have a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span></li>
<li>have bone and joint problems</li>
<li>have kidney problems. You may need a lower dose of LEVAQUIN<span class="Sup">®</span> if your kidneys do not work well.</li>
<li>have liver problems</li>
<li>have <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> (RA) or other history of joint problems</li>
<li>are pregnant or planning to become pregnant. It is not known if LEVAQUIN<span class="Sup">®</span> will harm your unborn child.</li>
<li>are breast-feeding or planning to breast-feed. LEVAQUIN<span class="Sup">®</span> is thought to pass into breast milk. You and your healthcare provider should decide whether you will take LEVAQUIN<span class="Sup">®</span> or breast-feed.</li>
</ul>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take,</span> including prescription and non-prescription medicines, vitamins, herbal and dietary supplements. LEVAQUIN<span class="Sup">®</span> and other medicines can affect each other causing side effects. Especially tell your healthcare provider if you take: 						</p>
<ul>
<li>an NSAID (Non-Steroidal Anti-Inflammatory Drug). Many common medicines for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief are NSAIDs. Taking an NSAID while you take LEVAQUIN<span class="Sup">®</span> or other fluoroquinolones may increase your risk of central nervous system effects and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. See <span class="Bold">"<a href="#sideeffect">What are the possible side effects of LEVAQUIN</a><span class="Sup">®</span>?"</span>
</li>
<li>an oral anti-<span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicine or insulin</li>
<li>a blood thinner (warfarin, Coumadin, Jantoven)</li>
<li>a medicine to control your heart rate or rhythm (antiarrhythmics). See <span class="Bold">"<a href="#sideeffect">What are the possible side effects of LEVAQUIN</a><span class="Sup">®</span>?"</span>.</li>
<li>an anti-<span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> medicine</li>
<li>a tricyclic antidepressant</li>
<li>a water pill (diuretic)</li>
<li>a steroid medicine. Corticosteroids taken by mouth or by injection may increase the chance of <span class="product-label-link" type="condition" conceptid="4344040" conceptname="Tendon injury">tendon injury</span>. See  <span class="Bold">"<a href="#important">What is the most important information I should know about LEVAQUIN</a><span class="Sup">®</span>?"</span>.</li>
<li>theophylline (Theo-24<span class="Sup">®</span>, Elixophyllin<span class="Sup">®</span>, Theochron<span class="Sup">®</span>, Uniphyl<span class="Sup">®</span>, Theolair<span class="Sup">®</span>)</li>
<li>Certain medicines may keep LEVAQUIN<span class="Sup">®</span> from working correctly.  Take LEVAQUIN<span class="Sup">®</span> Tablets or Oral Solution either 2 hours before or 2 hours after taking these products:<ul class="Disc">
<li>an antacid, multivitamin, or other product that has magnesium, aluminum, iron, or zinc.</li>
<li>sucralfate (Carafate<span class="Sup">®</span>) </li>
<li>didanosine (Videx<span class="Sup">®</span>,Videx<span class="Sup">®</span> EC)</li>
</ul>
</li>
</ul>
<p><span class="Bold">Ask your healthcare provider if you are not sure if any of your medicines are listed above.</span></p>
<p>Know the medicines you take. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take LEVAQUIN<span class="Sup">®</span>?</span></p>
<ul>
<li>Take LEVAQUIN<span class="Sup">®</span> exactly as prescribed by your healthcare provider.</li>
<li>Take LEVAQUIN<span class="Sup">®</span> at about the same time each day.</li>
<li>Drink plenty of fluids while taking LEVAQUIN<span class="Sup">®</span>.</li>
<li>LEVAQUIN<span class="Sup">®</span> Tablets can be taken with or without food.</li>
<li>Take LEVAQUIN<span class="Sup">®</span> Oral Solution 1 hour before or 2 hours after eating.</li>
<li>If you miss a dose of LEVAQUIN<span class="Sup">®</span>, take it as soon as you remember. Do not take more than one dose in one day.</li>
<li>LEVAQUIN<span class="Sup">®</span> for Injection is given to you by intravenous (I.V.) infusion into your vein, slowly, over 60 or 90 minutes, as prescribed by your healthcare provider. See "<a href="#sideeffect">What are the possible side effects of LEVAQUIN</a><span class="Sup">®</span>?"</li>
<li>Do not skip any doses, or stop taking LEVAQUIN<span class="Sup">®</span> even if you begin to feel better, until you finish your prescribed treatment, unless: 								<ul class="Disc">
<li>you have tendon effects (see "<a href="#important">What is the most important information I should know about LEVAQUIN</a><span class="Sup">®</span>?"),</li>
<li>you have a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> (see "<a href="#sideeffect">What are the possible side effects of LEVAQUIN</a><span class="Sup">®</span>?"), or</li>
<li>your healthcare provider tells you to stop.</li>
</ul>
</li>
<li>This will help make sure that all of the bacteria are killed and lower the chance that the bacteria will become resistant to LEVAQUIN<span class="Sup">®</span>. If this happens, LEVAQUIN<span class="Sup">®</span> and other antibiotic medicines may not work in the future.</li>
</ul>
<p>If you take too much, call your healthcare provider or get medical help immediately.</p>
<p><span class="Bold">If you have been prescribed LEVAQUIN<span class="Sup">®</span> after being exposed to <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span>:</span></p>
<ul>
<li>LEVAQUIN<span class="Sup">®</span> has been approved to lessen the chance of getting <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> disease or worsening of the disease after you are exposed to the <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> bacteria germ.</li>
<li>Take LEVAQUIN<span class="Sup">®</span> exactly as prescribed by your healthcare provider. Do not stop taking LEVAQUIN<span class="Sup">®</span> without talking with your healthcare provider. If you stop taking LEVAQUIN<span class="Sup">®</span> too soon, it may not keep you from getting the <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> disease.</li>
<li>Side effects may happen while you are taking LEVAQUIN<span class="Sup">®</span>. When taking LEVAQUIN<span class="Sup">®</span> to prevent <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, you and your healthcare provider should talk about whether the risks of stopping your medicine too soon are more important than the risks of side effects with LEVAQUIN<span class="Sup">®</span>. It is not known if it is safe to use LEVAQUIN<span class="Sup">®</span> for more than 28 days in adults and for more than 14 days in children 6 months of age and older.</li>
<li>If you are pregnant, or plan to become pregnant while taking LEVAQUIN<span class="Sup">®</span>, you and your healthcare provider should decide whether the benefits of taking LEVAQUIN<span class="Sup">®</span> for <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> are more important than the risks.</li>
</ul>
<p><span class="Bold">What should I avoid while taking LEVAQUIN<span class="Sup">®</span>?</span></p>
<ul><li>LEVAQUIN<span class="Sup">®</span> can make you feel dizzy and lightheaded. Do not drive, operate machinery, or do other activities that require mental alertness or coordination until you know how LEVAQUIN<span class="Sup">®</span> affects you.</li></ul>
<ul><li>Avoid sunlamps, tanning beds, and try to limit your time in the sun. LEVAQUIN<span class="Sup">®</span> can make your skin sensitive to the sun (<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>) and the light from sunlamps and tanning beds. You could get severe sunburn, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your skin. If you get any of these symptoms while taking LEVAQUIN<span class="Sup">®</span>, call your healthcare provider right away. You should use a sunscreen and wear a hat and clothes that cover your skin if you have to be in sunlight.</li></ul>
<p><span class="Bold">What are the possible side effects of LEVAQUIN<span class="Sup">®</span>?</span></p>
<p>LEVAQUIN<span class="Sup">®</span>can cause side effects that may be serious or even cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. See <span class="Bold">"<a href="#important">What is the most important information I should know about LEVAQUIN</a><span class="Sup">®</span>?"</span></p>
<p>Other serious side effects of LEVAQUIN<span class="Sup">®</span> include:</p>
<ul><li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">Liver damage</span> (hepatotoxicity):</span> <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">Liver damage</span> (hepatotoxicity) can happen in people who take LEVAQUIN<span class="Sup">®</span>. Call your healthcare provider right away if you have unexplained symptoms such as:<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>,</li>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>,</li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>,</li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>,</li>
<li><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> or <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>,</li>
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>,</li>
<li>unusual <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>,</li>
<li>loss of appetite,</li>
<li>light colored bowel movements,</li>
<li>dark colored urine or yellowing of your skin or the whites of your eyes.</li>
</ul>
</li></ul>
<ul class="Disc"><li>
<span class="Bold">Central Nervous System Effects.</span> <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> have been reported in people who take fluoroquinolone antibiotics including LEVAQUIN<span class="Sup">®</span>. Tell your healthcare provider if you have a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. Ask your healthcare provider whether taking LEVAQUIN<span class="Sup">®</span> will change your risk of having a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>. 								<br> <br><p class="First">Central Nervous System (CNS) side effects may happen as soon as after taking the first dose of LEVAQUIN<span class="Sup">®</span>. Talk to your healthcare provider right away if you get any of these side effects, or other changes in mood or behavior:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> </li>
<li>hear voices, see things, or sense things that are not there (<span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>)</li>
<li>feel <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restless</span></li>
<li><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span></li>
<li>feel anxious or nervous</li>
<li><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span></li>
<li><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></li>
<li>trouble sleeping</li>
<li><span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span></li>
<li>feel lightheaded</li>
<li>feel more suspicious (<span class="product-label-link" type="condition" conceptid="432590" conceptname="Delusional disorder">paranoia</span>)</li>
<li>suicidal thoughts or acts</li>
</ul>
</li></ul>
<ul class="Disc"><li>
<span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.</span><br> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> can happen in people taking fluoroquinolones, including LEVAQUIN<span class="Sup">®</span>, even after only one dose. Stop taking LEVAQUIN<span class="Sup">®</span> and get emergency medical help right away if you get any of the following symptoms of a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>: 								<ul class="Disc">
<li>										<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span> 									</li>
<li>										trouble breathing or swallowing 									</li>
<li>										<span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the lips, tongue, face 									</li>
<li>										<span class="product-label-link" type="condition" conceptid="4194507" conceptname="Feeling of throat tightness">throat tightness</span>, <span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">hoarseness</span> 									</li>
<li>										rapid heartbeat 									</li>
<li>										<span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span> 									</li>
<li>										Yellowing of the skin or eyes. Stop taking LEVAQUIN<span class="Sup">®</span> and tell your healthcare provider right away if you get yellowing of your skin or white part of your eyes, or if you have dark urine. These can be signs of a serious reaction to LEVAQUIN<span class="Sup">®</span> (a liver problem). 									</li>
</ul>
</li></ul>
<ul><li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rash</span></span><br>								<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rash</span> may happen in people taking LEVAQUIN<span class="Sup">®</span>, even after only one dose. Stop taking LEVAQUIN<span class="Sup">®</span> at the first sign of a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> and call your healthcare provider. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rash</span> may be a sign of a more serious reaction to LEVAQUIN<span class="Sup">®</span>. 							</li></ul>
<ul><li>
<span class="Bold">Intestine <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (<span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span>)</span><br>								<span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span> can happen with most antibiotics, including LEVAQUIN<span class="Sup">®</span>. Call your healthcare provider right away if you get <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">watery diarrhea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> that does not go away, or <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span>. You may have <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span> can happen 2 or more months after you have finished your antibiotic. 							</li></ul>
<ul><li>
<span class="Bold">Changes in sensation and possible <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span> (<span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral Neuropathy</span>)</span><br>								Damage to the nerves in arms, hands, legs, or feet can happen in people taking fluoroquinolones, including LEVAQUIN<span class="Sup">®</span>. Talk with your healthcare provider right away if you get any of the following symptoms of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> in your arms, hands, legs, or feet: 								<ul class="Disc">
<li>										<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> 									</li>
<li>										burning 									</li>
<li>										<span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> 									</li>
<li>										<span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span></li>
<li>										<span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> 									</li>
</ul>
</li></ul>
<p>LEVAQUIN<span class="Sup">®</span> may need to be stopped to prevent permanent <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span>.</p>
<ul><li>
<span class="Bold">Serious heart rhythm changes</span> (QT prolongation and <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span>) 								<br>Tell your healthcare provider right away if you have a change in your heart beat (a fast or irregular heartbeat), or if you <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>. LEVAQUIN<span class="Sup">®</span> may cause a rare heart problem known as prolongation of the QT interval. This condition can cause an abnormal heartbeat and can be very dangerous. The chances of this happening are higher in people: 								<ul class="Disc">
<li>										who are elderly 									</li>
<li>										with a family history of prolonged QT interval 									</li>
<li>										with low <span class="product-label-link" type="condition" conceptid="4107462" conceptname="k">blood potassium</span> (<span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>) 									</li>
<li>										who take certain medicines to control heart rhythm (antiarrhythmics) 									</li>
</ul>
</li></ul>
<ul><li>
<span class="Bold">Changes in blood sugar [low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>) and high blood sugar (<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>)]</span><br>People who take LEVAQUIN<span class="Sup">®</span> and other fluoroquinolone medicines with oral anti-<span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicines or with insulin can get low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>) and high blood sugar (<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>). Follow your healthcare provider's instructions for how often to check your blood sugar. If you have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and you get low blood sugar while taking LEVAQUIN<span class="Sup">®</span>, stop taking LEVAQUIN<span class="Sup">®</span> and call your healthcare provider right away. Your antibiotic medicine may need to be changed. 							</li></ul>
<ul><li>
<span class="Bold">Sensitivity to sunlight (<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>)</span><br>								See <span class="Bold">"<a href="#avoid">What should I avoid while taking LEVAQUIN</a><span class="Sup">®</span>?"</span>
</li></ul>
<ul><li>
<span class="Bold">Joint Problems</span><br>								Increased chance of problems with joints and tissues around joints in children. Tell your child's healthcare provider if your child has any joint problems during or after treatment with LEVAQUIN<span class="Sup">®</span>. 							</li></ul>
<p>							The most common side effects of LEVAQUIN<span class="Sup">®</span> include: 						</p>
<ul>
<li>								<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> 							</li>
<li>								<span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> 							</li>
<li>								<span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> 							</li>
<li>								<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> 							</li>
<li>								<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> 							</li>
</ul>
<p>							In children 6 months and older who take LEVAQUIN<span class="Sup">®</span> to prevent <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> disease, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> is also common. 						</p>
<p>							<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Low blood pressure</span> can happen with LEVAQUIN<span class="Sup">®</span> given by IV injection if it is given too fast. Tell your healthcare provider if you feel dizzy, or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span> during a treatment with LEVAQUIN<span class="Sup">®</span>. 						</p>
<p>							LEVAQUIN<span class="Sup">®</span> may cause false-positive urine screening results for opiates when testing is done with some commercially available kits. A positive result should be confirmed using a more specific test. 						</p>
<p>							These are not all the possible side effects of LEVAQUIN<span class="Sup">®</span>. Tell your healthcare provider about any side effect that bothers you or that does not go away. 						</p>
<p>							Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. 						</p>
<p><span class="Bold">How should I store LEVAQUIN<span class="Sup">®</span></span>?   						</p>
<p>							Store LEVAQUIN<span class="Sup">®</span> Film-Coated Tablets at 59° to 86° F (15°C to 30°C). Keep the container closed tightly. 						</p>
<p>Store LEVAQUIN<span class="Sup">®</span> Oral Solution at 59° to 86° F (15°C to 30°C).</p>
<p><span class="Bold">Keep LEVAQUIN<span class="Sup">®</span> and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General Information about LEVAQUIN<span class="Sup">®</span></span></p>
<p>							Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use LEVAQUIN<span class="Sup">®</span> for a condition for which it is not prescribed. Do not give LEVAQUIN<span class="Sup">®</span> to other people, even if they have the same symptoms that you have. It may harm them. 						</p>
<p>							This Medication Guide summarizes the most important information about LEVAQUIN<span class="Sup">®</span>. If you would like more information about LEVAQUIN<span class="Sup">®</span>, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about LEVAQUIN<span class="Sup">®</span> that is written for healthcare professionals. For more information go to www.levaquin.com or call 1-800-526-7736. 						</p>
<p><span class="Bold">What are the ingredients in LEVAQUIN<span class="Sup">®</span>?  </span></p>
<ul>
<li>								250 mg LEVAQUIN<span class="Sup">®</span> Film-Coated Tablets: 								<ul class="Disc">
<li>										Active ingredient: levofloxacin. 									</li>
<li>										Inactive ingredients: hypromellose, crospovidone, microcrystalline cellulose, magnesium stearate, polyethylene glycol, titanium dioxide, polysorbate 80 and synthetic red iron oxide. 									</li>
</ul>
</li>
<li>								500 mg LEVAQUIN<span class="Sup">®</span> Film-Coated Tablets: 								<ul class="Disc">
<li>										Active ingredient: levofloxacin. 									</li>
<li>										Inactive ingredients: hypromellose, crospovidone, microcrystalline cellulose, magnesium stearate, polyethylene glycol, titanium dioxide, polysorbate 80 and synthetic red and yellow iron oxides. 									</li>
</ul>
</li>
<li>								750 mg LEVAQUIN<span class="Sup">®</span> Film-Coated Tablets: 								<ul class="Disc">
<li>									Active ingredient: levofloxacin. 									</li>
<li>									Inactive ingredients: hypromellose, crospovidone, microcrystalline cellulose, magnesium stearate, polyethylene glycol, titanium dioxide, polysorbate 80. 									</li>
</ul>
</li>
<li>								LEVAQUIN<span class="Sup">®</span> Oral Solution (25 mg/mL): 								<ul class="Disc">
<li>										Active ingredient: levofloxacin. 									</li>
<li>										Inactive ingredients: sucrose, glycerin, sucralose, hydrochloric acid, purified water, propylene glycol, artificial and natural flavors, benzyl alcohol, ascorbic acid, and caramel color. It may also contain a solution of sodium hydroxide for pH adjustment. 										<ul class="Disc"><li>											LEVAQUIN<span class="Sup">®</span> Oral Solution may look clear yellow to clear greenish-yellow in color. 											</li></ul>
</li>
</ul>
</li>
<li>							LEVAQUIN<span class="Sup">®</span> Injection in Single-Use Vials: 								<ul class="Disc">
<li>									Active ingredient: levofloxacin. 									</li>
<li>									Inactive ingredients: water for injection. LEVAQUIN<span class="Sup">®</span> for Injection Single Use Vials do not contain any preservatives. 									</li>
</ul>
</li>
<li>LEVAQUIN<span class="Sup">®</span> Injection Premix in Single-Use Flexible Containers:<ul class="Disc">
<li>Active ingredient: levofloxacin.</li>
<li>Inactive ingredients: Dextrose (D<span class="Sub">5</span>W). Solutions of hydrochloric acid and sodium hydroxide may have been added to adjust the pH.</li>
</ul>
</li>
</ul>
<p>Revised June 2011</p>
<p>Manufactured by:<br>Janssen Ortho LLC, Gurabo, Puerto Rico 00778 (Tablets).<br>Janssen Pharmaceutica N.V., Beerse, Belgium (Oral Solution, Injection Single-Use Vials).<br> Hospira, Inc., Austin, TX 78728 (Injection Premix).</p>
<p>Manufactured for:<br> PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., Raritan, NJ 08869 (Tablets, Oral Solution)<br>Ortho-McNeil, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., Raritan, NJ 08869 (Injection Single-Use Vials, Injection Premix)</p>
<p>							©Ortho-McNeil-Janssen Pharmaceuticals, Inc.</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>copy of label<div class="Figure"><img alt="copy of label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=139f86a4-75c5-4304-894c-8f8b8a396c78&amp;name=6729603721.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LEVAQUIN 		
					</strong><br><span class="contentTableReg">levofloxacin tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67296-0586(NDC:50458-920)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>levofloxacin</strong> (levofloxacin) </td>
<td class="formItem">levofloxacin</td>
<td class="formItem">250 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>crospovidone</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polyethylene glycols</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polysorbate 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ferric oxide red</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">pink (terra cotta pink) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">15mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">LEVAQUIN;250</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67296-0586-1</td>
<td class="formItem">3  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020634</td>
<td class="formItem">12/20/1996</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>RedPharm Drug Inc.
							(008039641)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Janssen Pharmaceutica, N.V.</td>
<td class="formItem"></td>
<td class="formItem">370005019</td>
<td class="formItem">MANUFACTURE, ANALYSIS</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Janssen Ortho, LLC</td>
<td class="formItem"></td>
<td class="formItem">062191882</td>
<td class="formItem">MANUFACTURE, ANALYSIS</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Hospira, Inc.</td>
<td class="formItem"></td>
<td class="formItem">012660999</td>
<td class="formItem">MANUFACTURE, ANALYSIS</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Hospira, Inc.</td>
<td class="formItem"></td>
<td class="formItem">093132819</td>
<td class="formItem">MANUFACTURE, ANALYSIS</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Ortho-McNeil-Janssen Pharmaceuticals Inc.</td>
<td class="formItem"></td>
<td class="formItem">010779978</td>
<td class="formItem">ANALYSIS</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Lancaster Laboratories</td>
<td class="formItem"></td>
<td class="formItem">069777290</td>
<td class="formItem">ANALYSIS</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f988da15-db11-448a-b10b-e06ed3dbb758</div>
<div>Set id: 139f86a4-75c5-4304-894c-8f8b8a396c78</div>
<div>Version: 2</div>
<div>Effective Time: 20110727</div>
</div>
</div> <div class="DistributorName">RedPharm Drug Inc.</div></p>
</body></html>
